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ABSTRACT 
 
It has been 30 years since HIV was first discovered, yet the molecular mechanisms 
whereby the virus mediates its pathogenic effects have not yet been completely 
elucidated. The glucocorticoid receptor (GR) is a ligand-activated host transcription 
factor, which mediates anti-inflammatory effects in response to stimulation with 
glucocorticoids (GC). One of the HIV-1 accessory proteins, Vpr, is highly 
immunosuppressive and contributes to suppression of the immune system thereby 
creating an environment favourable for viral proliferation. Vpr has been previously 
reported to act as a GR co-activator on glucocorticoid response element (GRE) 
containing promoters. Thus, the GR appears likely to play a role in HIV-1 
pathogenesis. Contraceptive usage is also likely to affect HIV-1 pathogenesis as 
some hormonal contraceptives can bind to and activate the GR. Progesterone (P4) 
regulates the female reproductive system and the synthetic progestins 
medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A) are 
extensively used as injectable contraceptives. MPA has been shown to act as a 
partial or full GR agonist and recent evidence indicates that injectable MPA 
increases HIV-1 acquisition and transmission. The molecular mechanisms of this 
remain unclear, but may involve decreasing the thickness of the vaginal epithelium 
as well as actions via the GR that affect gene expression in the cervo-vaginal 
environment and/or elsewhere. This study aims to investigate the actions of GC’s, 
P4, MPA and NET-A via the GR in the absence and presence of Vpr protein  
towards gaining some insight into the potential interplay between the host GR, 
contraceptive use, HIV-1 pathogenesis, and the mechanisms thereof.  
 
Using promoter-reporter assays it was found that Vpr greatly increased 
dexamethasone, cortisol, and MPA-mediated, but not NET-A or progesterone-
mediated transactivation via overexpressed GR in COS1 monkey kidney cells but did 
not change the biocharacter of any of the tested ligands at this promoter. The extent 
of the Vpr-mediated increase in GR-dependent transcription of the reporter gene was 
found to depend on both the concentration and efficacy of the activating GR ligand, 
with higher concentrations and more efficacious ligands resulting in the highest level 
of reporter gene activity. Vpr enhanced the efficacy of dexamethasone but did not 
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affect either potency for transactivation or change the Hill co-efficient and thereby 
affect the co-operation of ligand binding to the GR. Vpr did not enhance ligand-
dependent transactivation of two endogenous GRE-containing genes, MKP-1 and 
IκBα in COS1 and human endocervical END cells. However, Vpr appeared to 
increase the partial agonist activities of some ligands in a gene-specific manner, 
causing them to act like full agonists. These discrepancies regarding the effect of Vpr 
on transactivation of the reporter gene and two endogenous genes suggest that the 
ligand-dependent effects of Vpr on the GR may be highly promoter-specific, depend 
on the absence of native chromatin, and/or be sensitive to the relative concentrations 
of Vpr, GR, and DNA target sites. Interestingly Vpr induced a marginal but 
statistically significant increase in basal GR-mediated transactivation of the reporter 
gene. Investigating various steps in the pathway of GR function showed that Vpr did 
not significantly increase ligand-dependent GR phosphorylation or nuclear 
translocation, but did significantly increase GR turnover and may have exerted a 
moderate effect on the basal level of S226 phosphorylation and GR nuclear 
translocation. Taken together these data suggest Vpr could potentially be a weak, 
non-classical GR-activator. However, data from this study could not firmly establish 
whether Vpr was a classical GR co-activator, acted as a non-classical GR agonist, or 
reflected the actions of both.  
 
Of great potential significance for disease and choice of contraceptive, high levels of 
reporter gene transactivation were obtained by MPA, but not NET-A or progesterone, 
in the presence of Vpr, which are greater than those observed with the full agonist 
dexamethasone in the absence of Vpr. This suggests that MPA may have very 
different effects on HIV-1 pathogenesis as compared to NET-A and progesterone, 
via GR-mediated transcriptional effects, and likely exerts deleterious GC like effects. 
It remains to be determined if the observed effects of Vpr at the reporter gene are 
physiologically relevant by investigation of further GRE containing endogenous 
genes. The results on reporter genes however do suggest that Vpr may lead to 
enhanced GR signalling on select target promoters which could be a possible 
mechanism leading to increased susceptibility to HIV-1 acquisition and transmission 
or even disease progression. 
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1. LITERATURE REVIEW 
 
Cortisol (CORT) is the natural glucocorticoid (GC) in humans and mediates its 
effects via binding to the ligand-activated transcription factor (TF), the glucocorticoid 
receptor (GR). The GR is a member of the nuclear receptor superfamily type III, 
which includes the Androgen (AR), Oestrogen (ER), Mineralocorticoid (MR) and 
Progesterone (PR) receptors (Nuclear Receptors Nomenclature, 1999), each of 
which has a cognate ligand and specialised function. Dexamethasone (DEX) is a 
synthetic derivative of cortisol, which is more potent but has similar effects via the 
GR (Meikle and Tyler, 1977). The GR has profound anti-inflammatory and 
immunosuppressive effects (Ashwell et al., 2000; Galon et al., 2002) which are 
widely exploited in medicine (Boumpas et al., 1993). It is also involved in a diverse 
array of physiological processes including homeostasis, growth, reproduction, 
metabolism, neuroendocrine and cardiovascular functions (Chrousos, 2004; 
Chrousos et al., 2004; Sapolsky et al., 2000). 
 
 
1.1. The hypothalamic-pituitary-adrenal axis 
 
The hypothalamic-pituitary-adrenal-axis (HPA) is a stress regulated pathway 
responsible for activation of the GR (Tsigos and Chrousos, 2002). When the body 
senses stress, corticotropin releasing hormone (CRH) is released from the 
hypothalamus (Bloom et al., 1982). This stimulates the pituitary gland to produce 
adrenocorticotropic hormone (ACTH), which in turn activates the synthesis of GC’s in 
the adrenal cortex, leading to the release of cortisol (Chrousos, 1995; Webster et al., 
2002). Cortisol is a homeostatic mediator which plays a pivotal role in the 
maintenance of blood glucose levels, carbohydrate metabolism and most notably 
suppression of inflammation and the immune response (Ashwell et al., 2000; Herold 
et al., 2006; Tait et al., 2008). Once released into the blood, 90% of the cortisol will 
associate with corticosteroid binding globulins (CBG), distributing the steroid around 
the body (Breuner and Orchinik, 2002).  
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Figure 1.1: Regulation of the hypothalamic-pituitary-adrenal (HPA) and -gonadal (HGA) axis. 
Stress leads to activation of the HPA axis through hypothalamic release of corticotropin releasing 
hormone (CRH) and associated pituitary release of adrenocorticotropic hormone (ACTH). This results 
in adrenal gland synthesis of cortisol. The release of the sex hormone, progesterone (P4), is under 
control of the hypothalamic-pituitary-gonadal (HPG) axis, where gonadotropin-releasing hormone 
(GnRH) synthesis in the hypothalamus causes anterior pituitary release of follicle-stimulating 
hormone (FSH) and luteinising hormone (LH) thereby inducing the gonads to synthesise P4 (Adapted 
from Backstrom et al., 1982; Reichardt and Schutz, 1998; Tait et al., 2008).  
 
 
1.2. The Glucocorticoid Receptor 
1.2.1. The GR gene and expression 
 
The GR gene is comprised of ten exons spanning 110 kb, encoded on the fifth 
chromosome at region 5q31p (Encio and Detera-Wadleigh, 1991). GR mRNA is 
highly expressed in lung, spleen, brain, and liver tissue (Kalinyak et al., 1987). 
Ligand activation of the GR causes a decrease in mRNA expression in a negative-
feedback manner (Burnstein et al., 1994; Okret et al., 1986). Alternative splicing of 
the 9α or 9β exon in the pre-mRNA yields either the GRα or the GRβ, two highly 
homologous receptor isoforms with molecular weights of 97 and 94 kDa, 
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respectively. Both are identical between amino acids (aa) 1-727, with the α-isoform 
containing an additional 50 residues at the carboxyl terminal, harbouring an 
activation function (AF), whereas the β-isoform has only 15 non-homologous 
residues (Hollenberg et al., 1985). Three further GC resistant splice variants have 
also been discovered (GR-γ, GR-A, and GR-P) which have much lower expression 
than the α-isoform, but are not yet fully characterised. These may be related to 
aberrant GR signalling and diseases (Beger et al., 2003; Krett et al., 1995; Moalli et 
al., 1993). 
 
The physiological role of GRβ is unclear, but is thought to be involved in 
transcriptional repression by recruiting histone deacetylase (HDAC) (Kelly et al., 
2008) and regulating the selective recruitment of co-factors (Charmandari et al., 
2005). It is expressed at much lower levels than GRα (Oakley et al., 1997) and 
resides primarily in the nucleus (Oakley et al., 1996). The GRβ lacks the ligand 
binding domain of the GRα (de Castro et al., 1996), and has been reported to 
function as a dominant negative regulator of GRα, by forming transcriptionally 
inactive heterodimers with the ligand-activated GRα (Bamberger et al., 1995; Oakley 
et al., 1999). The GRβ has been reported to also repress transcription independently 
of GRα (Kino et al., 2009). 
 
Alternate translation of GRα mRNA may yield eight further isoforms truncated at the 
amino terminal. In descending order of size these are termed GRα-A, -B, -C1, -C2, -
C3, -D1, -D2, or -D3, and result from translational initiation at alternate start codons 
(Lu and Cidlowski, 2004; Lu and Cidlowski, 2005). These eight isoforms are 
transcriptionally active and exhibit differential expression according to tissue type (Lu 
and Cidlowski, 2005) and exert different magnitudes of transcriptional responses (Lu 
and Cidlowski, 2006). This is thought to contribute to the cell-specific manner of 
GRα-mediated transcription (Revollo and Cidlowski, 2009). 
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1.2.2. Structure of the GR protein 
 
The full length (GRα-A) protein consists of 777 aa comprising three functional 
domains; the amino terminal domain (NTD), the DNA binding domain (DBD) which 
encompasses a hinge region (HR), and the ligand binding domain (LBD) (Figure 1.2) 
(reviewed in Nicolaides et al., 2010; Revollo and Cidlowski, 2009; Zhou and 
Cidlowski, 2005). 
 
 
 
 
Figure 1.2: Structural organisation of the full length GRα protein. The GR consists of three 
functional domains, each harbouring regions which mediate discrete functions of GR signalling. NTD- 
Amino terminal domain, DBD- DNA binding domain, HR- Hinge Region, LBD- Ligand Binding Domain 
(adapted from Beck et al., 2011; Nicolaides et al., 2010). 
 
 
The NTD is the least well conserved amongst both the different isoforms of the GRα 
(Lu and Cidlowski, 2005) and other steroid receptors (SR’s) (Griekspoor et al., 
2007). It resides between amino acids 1-419 and harbours a constitutive activation 
function (AF-1) between residues 77-262 (Godowski et al., 1987; Kumar et al., 
2001). The AF-1 physically interacts with the basal transcriptional machinery (BTM) 
(Kumar and Thompson, 2003), and the NTD regulates GR association with 
chromatin remodelers, co-activators, RNA polymerase-II, TATA binding protein 
(TBP) and the general transcription factor IID (TFIID) complex (Ford et al., 1997; 
Heitzer et al., 2007; Henriksson et al., 1997; Hittelman et al., 1999). Many of the 
residues which undergo post-translational modifications reside in the NTD (reviewed 
in Duma et al., 2006; Faus and Haendler, 2006). 
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The receptor makes direct DNA contact through the DBD (residues 420-480). Two 
highly conserved zinc finger motifs containing four cysteine residues co-ordinate a 
zinc atom in a tetrahedral fashion to make direct contact with DNA (Freedman et al., 
1988) in the promoters of target genes at the major groove of the double helix (La 
Baer and Yamamoto, 1994). GR homodimerisation has been shown to be dependent 
on an intact DBD (Dahlman-Wright et al., 1991; Luisi et al., 1991). The DBD contains 
a flexible, hinge region (HR) around which the NTD and carboxyl terminal may 
rotate. The amino part of the HR overlaps with a nuclear localisation signal (NLS) 
which is required for GR nuclear translocation upon agonist binding (Jewell et al., 
1995; Picard and Yamamoto, 1987).  
 
The carboxyl terminus (residues 527-777) is termed the ligand binding domain (LBD) 
and contains the second, ligand-dependent, activation function (AF-2) (reviewed in 
Duma et al., 2006; Nicolaides et al., 2010) and other NLS (Cadepond et al., 1992; 
Picard and Yamamoto, 1987). Two key residues in the LBD have also been 
demonstrated to be critical for GR homodimerisation (Bledsoe et al., 2002). The LBD 
is responsible for the recognition and association with steroids, which bind the 
receptor at a hydrophobic pocket created by twelve α-helices and four β-sheets 
resulting in a conformational change of the receptor thereby determining the nature 
of co-factor interaction with the GR and ultimately the transcriptional response 
elicited by the GR (Bledsoe et al., 2004; Kauppi et al., 2003; Leers et al., 1998). 
 
 
1.3. GR mechanism of action 
 
In the absence of ligand, the monomeric and inactive GR is held in a heteromeric 
chaperone complex that is predominantly cytoplasmic (Jewell et al., 1995) but does 
cycle in and out of the nucleus (Hache et al., 1999). The components of this complex 
include the Heat Shock Proteins (HSP) 90, 70, 40, and 23, HSP organising Protein 
(HOP), immunophilins such as FK506 binding protein 51 (FKBP51), and 
phosphatases such as Protein Phosphatase 5 (PP5), as well as p23 (Figure 1.3) 
(Dalman et al., 1989; Echeverria et al., 2009; Echeverria and Picard, 2010; 
Galigniana et al., 2010). HSP90 and the associated chaperones hold the receptor in 
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a conformation essential for allowing ligand binding (Bohen, 1995; Bohen et al., 
1995; Dittmar et al., 1997). 
 
 
 
 
Figure 1.3: Mechanism of GR transcriptional signalling. Ligand binding causes chaperone 
complex dissociation, nuclear translocation, receptor dimerisation, and binding to DNA response 
elements resulting in GR-mediated modulation of transcription (Adapted from Revollo and Cidlowski, 
2009). 
 
 
1.3.1. Ligand binding to the GR 
 
Due to their lipophilic nature, cortisol and other GC’s passively diffuse from the blood 
across the plasma membrane after their release from CBG’s. Ligands bind the GR 
directly at a hydrophobic pocket in the LBD (Bledsoe et al., 2004). Several lines of 
evidence suggest that electrostatic interactions between ligands and the residues in 
this pocket are specific to the ligand and cause a conformational change to the 
tertiary structure of the LBD according to the nature of the bound ligand (Gass et al., 
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1998; Lind et al., 2000; Ray et al., 1999). This is critical for the induction of 
transcription because it dictates co-factor association and DNA binding of the GR 
(Figure 1.4) (Kauppi et al., 2003). 
 
 
 
 
Figure 1.4: Ribbon diagram showing DEX vs. RU486 binding to the LBD hydrophobic pocket in 
the human GR α isoform (hGRα). Agonist binding to the GR shifts the position of helix-12 (red) 
allowing a co-factor, in this case, Steroids Receptor Co-activator 2 (SRC-2) to associate with the GR 
through LXXLL co-activator motifs (Voegel et al., 1998). Antagonist binding causes helix-12 to block 
this site and prevents co-factor interaction (taken from Kauppi et al., 2003). 
 
 
Electrostatic and hydrophobic interactions between the receptor and bound ligand 
compact the helices around this pocket, changing the conformation of the receptor. 
Agonist binding causes the twelfth α-helix to close over the steroid which allows co-
factors to bind (Kauppi et al., 2003) at the AF-2 domain through LXXLL co-activator 
(Heery et al., 1997), or LXX I/H I XXX I/L co-repressor motifs (Perissi et al., 1999). It 
is generally accepted that the specific conformation the helices adopt, and thus the 
extent of co-factor interaction varies according to whether an agonist, partial agonist, 
or antagonist is bound. Antagonist binding blocks exposure of the AF-2 domain on 
helix-12 and prevents co-factor association (Figure 1.4) (Wang et al., 2004c). A GR 
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partial agonist is a steroid which displays less than the maximal transactivation 
efficacy of an agonist such as cortisol or dexamethasone, and an antagonist is able 
to inhibit the transactivation induced by a full agonist (Figure 1.5). 
 
 
 
 
Figure 1.5: Structures of select GR ligands, indicated as full or partial agonists, dissociated, or 
antagonists by GR-mediated transactivation efficacies. Dexamethasone, Cortisol and 
Prednisolone are full GR agonists and induce the highest extent of GR-mediated transactivation. 
Aldosterone, Fludrocortisone, and Medroxyprogesterone Acetate (MPA) may act as either full 
agonists or partial agonists, and Abbott Ligand AL438 and Progesterone are partial GR agonists as 
their relative efficacies are much lower than that of dexamethasone. Mifepristone (RU486) and 
CompoundA are dissociated GC’s, as they may selectively act as an agonist or antagonise GR-
mediated transcription in a cell type and promoter-specific manner. Norethisterone Acetate (NET-A 
exerts nearly no effect on GR-mediated transactivation and Abbott Ligand 082D06 is able to 
antagonise GR-mediated transactivation. It should be noted that the biocharacter of these ligands 
varies in a cell type and promoter-specific manner (Avenant et al., 2010b; Koubovec et al., 2005; 
Ronacher et al., 2009).  
 
 
Apart from conformational changes in the LBD, it is generally accepted that upon 
association with ligand, the whole GR protein undergoes a conformational change, 
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causing much of the chaperone complex to dissociate and exposing the NLS’s 
(reviewed in Nicolaides et al., 2010). The unliganded GR associates with FKBP51 
through a direct interaction with HSP90, which upon ligand binding is switched for 
the nucleophilic FKBP52 (Banerjee et al., 2008; Davies et al., 2002; Galigniana et 
al., 1998; Galigniana et al., 2010; Silverstein et al., 1999). Recent evidence indicates 
that HSP90 translocates into the nucleus along with the GR and can be found in 
association with DNA, acting as a regulator of GR function and modulating GR 
mobility within the nucleus (Echeverria et al., 2009; Echeverria and Picard, 2010; 
Elbi et al., 2004). 
 
 
1.3.2. Dimerisation 
 
Chaperone complex dissociation exposes hydrophobic residues in the LBD and DBD 
which cause GR homodimerisation (Bledsoe et al., 2002; Luisi et al., 1991). This 
occurs prior to (Savory et al., 1999; Savory et al., 2001), but is not strictly required 
for nuclear translocation or DNA binding (Adams et al., 2003). Certain mutations in 
the LBD and DBD prevent homodimerisation and abrogate transactivation, but do 
not affect nuclear translocation or transrepression (Reichardt and Schutz, 1998; 
Reichardt et al., 2001). CompoundA is a dissociated GC which causes nuclear 
localisation and GR-mediated transrepression, but not homodimerisation or 
transactivation (De Bosscher et al., 2005; Robertson et al., 2010). Thus several lines 
of evidence suggest that dimerisation is important for GRE-mediated 
transactivation/DNA binding but not for transrepression or nuclear translocation, 
although transactivation has been reported to also occur via a monomeric GR 
(Segard-Maurel et al., 1996). 
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1.3.3. Nuclear translocation 
 
The two GR NLS’s are exposed upon chaperone complex dissociation (Urda et al., 
1989). NLS-1 is found at the DBD, with the less well defined NLS-2 at the LBD 
(Picard and Yamamoto, 1987; Wan et al., 2001). The exposure of these motifs 
causes a direct interaction between the GR and nucleophilins (importin-α, -7, and -8) 
responsible for translocation through nuclear pores (Figure 1.3) (Echeverria et al., 
2009; Elbi et al., 2004; Freedman and Yamamoto, 2004). The switch between 
FKBP51 and FKBP52 is also responsible for GR nuclear translocation. The 
unliganded GR is associated with FKBP51, which is switched for the nucleophilic 
FKBP52 upon ligand stimulation (Banerjee et al., 2008; Davies et al., 2002). FKBP52 
associates with dynein and translocates the HSP90/GR complex into the nucleus 
along the microtubule network (Czar et al., 1994; Galigniana et al., 1998; Silverstein 
et al., 1999). Knockout mouse models have shown that the absence of FKBP52 
does not cause defects in GR physiology, indicating a degree of redundancy in GR 
nuclear import (Wolf et al., 2009). DEX stimulation causes GR nuclear translocation 
in 10 minutes (Picard and Yamamoto, 1987) and the proportion of nuclear GR 
correlates well with the transactivation efficacy of the stimulating ligand (Hadley et 
al., 2011). 
 
 
1.3.4. Post-translational modifications 
 
The GR is expressed in nearly all mammalian cells, but regulates transcription in a 
cell type- and promoter-specific manner. One mechanism that explains some of 
these variable effects of the GR is covalent modifications that occur on the receptor 
after translation (Figure 1.6). These include acetylation (A) (Kino and Chrousos, 
2011), nitrosylation (N) (Galigniana et al., 1999), phosphorylation (P) (Orti et al., 
1993), sumoylation (S) (Tian et al., 2002), and ubiquitination (U) (Kinyamu et al., 
2005). GR post-translational modifications may have a positive or negative effect on 
GR-mediated transcription (reviewed in Duma et al., 2006; Faus and Haendler, 
2006). 
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Figure 1.6: Structure of the GR protein showing residues that may undergo covalent post-
translational modifications. Serine (S) and threonine (T) residues may be phosphorylated (P) and 
specific lysine (K) residues may be sumoylated (S), ubiquitinated (U) or acetylated (A) under 
appropriate stimuli (Adapted from Beck et al., 2011; Faus and Haendler, 2006; Galliher-Beckley and 
Cidlowski, 2009; Ismaili and Garabedian, 2004). 
 
 
1.3.4.1. Phosphorylation 
 
GR phosphorylation has been reported to regulate many aspects of GR signalling, 
including nuclear localisation (Wang et al., 2002), cofactor association (Avenant et 
al., 2010a; Krstic et al., 1997), promoter association (Blind and Garabedian, 2008), 
GR protein stability (Webster et al., 1997), and gene expression (Lynch et al., 2010). 
The unliganded GR is partially phosphorylated, and hyperphosphorylation occurs at 
specific residues in response to agonist (Avenant et al., 2010a; Avenant et al., 
2010b; Chen et al., 2008; Orti et al., 1993; Wang et al., 2002) but not antagonist 
binding (Hoeck and Groner, 1990; Orti et al., 1989; Wang et al., 2002). Most GR 
phosphorylation sites reside in the AF-1 domain (Figure 1.6), with three serine (S) 
residues; S203, S211, and S226 being the best characterised (reviewed in Beck et 
al., 2011; Galliher-Beckley and Cidlowski, 2009; Ismaili and Garabedian, 2004).  
 
S211 is not phosphorylated in the absence of ligand and becomes 
hyperphosphorylated upon agonist binding (Wang et al., 2007) in a manner that 
correlates with ligand efficacy (Avenant et al., 2010b; Wang et al., 2002). S211 
phosphorylation has been implicated in GR promoter association (Blind and 
Garabedian, 2008) and to increase GR-mediated transactivation, as an S211A 
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mutation causes lower transactivation efficacy of reporter (Avenant et al., 2010b) and 
endogenous genes (Chen et al., 2008) in a variety of mammalian cells. This 
phosphorylation mutant also fails to induce apoptosis to the same extent as the wild 
type (wt) GR does (Almlof et al., 1995; Miller et al., 2005), and taken together this 
indicates that S211 phosphorylation is likely required for maximal GR-mediated 
transactivation. The p38 mitogen-activated protein kinase (MAPK) (Miller et al., 
2005) and cyclin-dependent kinases (CDK’s) 5 and 2 (Kino et al., 2007; Krstic et al., 
1997) have both been implicated in S211 phosphorylation indicating some 
redundancy or cell specificity in the kinases responsible for S211 phosphorylation 
(Chen et al., 2008; Lynch et al., 2010). 
 
The GR may be phosphorylated simultaneously at S211 and S226 (Wang et al., 
2007) with transcriptional activation being greatest when the ratio of S211/S226 
phosphorylation is highest (Chen et al., 2008). S226 is partially phosphorylated in the 
absence of ligand, but is hyperphosphorylated by ligand stimulation (Blind and 
Garabedian, 2008). S226 phosphorylation is kept at a low level through the actions 
of PP5 in the chaperone complex (Wang et al., 2007). The pro-inflammatory c-Jun 
N-terminal kinase (JNK) ligand-dependently increases phosphorylation of S226, 
which inhibits GR-mediated transcription (Lynch et al., 2010) and enhances nuclear 
export (Itoh et al., 2002). In support of this, an S226A mutation increases GR-
mediated reporter (Avenant et al., 2010b) and endogenous gene transactivation 
(Chen et al., 2008). 
 
Recent evidence has indicated S226 phosphorylation to be a marker for ligand-
independent GR activation, as GnRH (Kotitschke et al., 2009) and TNF-α (Verhoog 
et al., 2011) have both been shown to increase S226 phosphorylation and ligand-
independently activate the GR. GnRH induced phosphorylation of S226 causes 
enhanced SRC-1 association with the GR and increases transactivation of the GnRH 
gene (Kotitschke et al., 2009), whereas TNF-α further suppresses GR-mediated 
repression of IL-6 (Verhoog et al., 2011).  
 
In contrast to S211 and S226, a significant proportion of the GR is phosphorylated at 
S203 in the absence of ligand, and S203 phosphorylation is only slightly increased 
upon treatment with DEX (Blind and Garabedian, 2008; Wang et al., 2002). S203 
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phosphorylation occurs through either CDK2 or 5 (Chen et al., 2008; Kino et al., 
2007). The GR phosphorylated at S203 alone is not recruited to the promoters of the 
TAT, SULT, or GILZ genes, whereas receptors phosphorylated at S211 and/or S226 
are (Blind and Garabedian, 2008; Wang et al., 2002). S203 phosphorylation causes 
peri-nuclear (Chen et al., 2008) cytoplasmic retention of the GR (Blind and 
Garabedian, 2008), and its dephosphorylation may be related to nuclear import. 
 
 
1.3.4.2. Acetylation 
 
Acetylation is the covalent attachment of an acetyl group to a protein. Upon ligand 
stimulation all SR’s, except the ER become acetylated in the hinge region (Faus and 
Haendler, 2006) at a lysine rich motif which appears to be phylogenetically 
conserved (Fu et al., 2003a; Fu et al., 2003b; Wang et al., 2011a; Wang et al., 
2011b). The GR contains an acetylation motif (KXKK/RXKK) between amino acids 
492-495 with lysine residues K494 and K495 becoming acetylated in the presence of 
DEX (Ito et al., 2006). Acetylation of the GR by p300 has been shown to decrease 
transactivation of the 2XGRE-TATA and SV40-luc reporter promoter constructs 
(Fonte et al., 2007), but increase transactivation of the MMTV promoter (Li and 
Verma, 2002), indicating the effects of acetylation on GR transactivation are 
promoter-specific. It has been eported that histone deacetylase 2 (HDAC2) can also 
deacetylate the GR, allowing  GR association with the p65 subunit of NFκB. 
Deacetylation therefore allows GR-mediated transrepression to occur through a 
tethering mechanism (Ito et al., 2006). 
 
 
1.3.4.3. Nitrosylation 
 
Nitrosylation is thought to occur at several GR cysteine residues (Galigniana et al., 
1999). Increased Nitric Oxide (NO) synthase activity leads to increased covalent NO 
attachment to thiol groups, resulting in a decreased affinity for GC’s without affecting 
the HSP90 interaction (Galigniana et al., 1999). 
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1.3.4.4. Sumoylation 
 
Sumoylation is the covalent attachment of the small-ubiquitin-related modifier-1 
(SUMO-1) peptide to three lysine residues in the GR (K277, K293, and K703), 
through the actions of the SUMO conjugase Ubc9. Whilst this is not ligand-
dependent, it is enhanced in the presence of steroids (Tian et al., 2002) and 
increases GR-mediated transactivation. Sumoylation also decreases stability of the 
receptor by targeting it for proteasomal degradation (Le Drean et al., 2002). 
 
 
1.3.4.5. Ubiquitination 
 
Ubiquitination is the covalent attachment of a 76 aa peptide through the actions of 
three ubiquitinating enzymes: an E1 activator, E2 conjugase, and E3 ligase (Rogers 
et al., 1986), which may be reversed by de-ubiquitinating enzymes (Nijman et al., 
2005). Ubiquitination occurs at “PEST” (Pro-Glu-Ser-Thr) motifs (Rechsteiner and 
Rogers, 1996), specifically on the GR at lysine residue K419 (Wallace et al., 2010). 
Ligand binding to the GR leads to poly-ubiquitination and increases proteasomal 
degradation (Kinyamu et al., 2005), thereby abrogating the transcriptional response 
(Deroo et al., 2002; Wallace and Cidlowski, 2001). Ubiquitination acts as a measure 
of control to decrease excess GR-mediated transcription (Wallace and Cidlowski, 
2001). 
 
 
1.3.5. Transcriptional Regulation 
 
Ligand binding, chaperone complex dissociation, dimerisation, post-translational 
modifications and nuclear import are all steps which are required for and precede 
activation of the GR as a transcription factor. Once inside the nucleus, the GR can 
begin to modulate transcription, in a positive (transactivation) or negative 
(transrepression) manner, either by binding directly to DNA, or by associating with 
other transcription factors (TF) (Figure 1.7). The GR recruits the BTM, co-activators 
or co-repressors, and chromatin remodelling proteins to the promoter which 
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culminates in a change in the rate of RNA synthesis by RNA polymerase II (RNA pol 
II) (reviewed in Nicolaides et al., 2010). 
 
 
 
 
Figure 1.7 (A-G): Mechanisms of GR gene regulation by interaction directly with DNA, or 
protein regulatory elements. The GR (show in pink) may associate directly with DNA at a 
glucocorticoid response element (GRE) or negative GRE (nGRE) as a ligand bound dimer to increase 
(A) or repress (E) gene expression, or a liganded monomer may associate with other DNA bound 
transcription factors (TF) to increase (D) or repress (G) gene expression. DNA bound and liganded 
GR monomers (C) or dimers (B) are also capable of increasing gene expression by acting in concert 
with other DNA bound TF’s when bound to GRE half sites (1/2GRE). DNA binding of a liganded GR 
dimer may also block the DNA binding of other TF’s, preventing gene transactivation (F) (adapted 
from Schoneveld et al., 2004b). 
 
 
1.3.5.1. Direct DNA binding 
 
Glucocorticoid response elements (GRE’s) are palindromic DNA sequences 
comprised of two hexameric halves separated by three random nucleotides (Beato et 
al., 1989; Strahle et al., 1987). In humans a consensus GRE has the sequence 
GGTACAnnnTGTTCT (Nordeen et al., 1990). The exact sequence of each half of 
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the GRE is not tightly constrained and allows for variability in GR signalling exerted 
through variances at the GR/DNA binding interface (Kumar et al., 1999; Meijsing et 
al., 2009; So et al., 2007). GR/DNA binding causes the unstructured AF-1 region to 
adopt a specific conformation (Kumar and Thompson, 2003) leading to differential 
recruitment or exclusion of ancillary TF’s, thereby regulating transcriptional specificity 
(Hard et al., 1990; La Baer and Yamamoto, 1994). An interesting feature of GRE’s is 
that their position in DNA is not tightly constrained (Bulger and Groudine, 1999) and 
may be found in equal frequencies up- or down-stream from the transcription start 
site (TSS). Up to 63% of GRE’s were shown to be greater than 10 kb from the TSS 
with others having been found in intronic regions of the genes they regulate (So et 
al., 2007; Wang et al., 2004b).  
 
Many anti-inflammatory genes are upregulated through the liganded GR binding 
GRE’s in their promoters (Figure 1.7A). DEX activation of the GR rapidly induces 
expression of MAP Kinase Phosphatase-1 (MKP-1) (Lasa et al., 2002; Wu et al., 
2005) by acting on at least two consensus GRE’s (Shipp et al., 2010; Tchen et al., 
2010). MKP-1 is a component of the inflammatory Mitogen Activated Protein Kinase 
(MAPK) cascade which prevents activation of the ERK and p38 MAPK’s (Lang et al., 
2006). The GR can also mediate repression of cytokine genes by inhibiting NFκB 
signalling through enhancing expression of an inhibitor, IκBα (Auphan et al., 1995),  
which sequesters the RelA subunit of NFκB in the cytoplasm (Li and Verma, 2002). 
Several GRE half sites exist in the IκBα promoter (Deroo and Archer, 2001; Deroo 
and Archer, 2002) and two full length GRE’s reside within the first intron (Reddy et 
al., 2009), both of which have been observed to bind the liganded GR and cause 
transactivation.  
 
A GRE may form part of a larger regulatory complex termed a glucocorticoid 
response unit (GRU) (Figure 1.7B), where the GR functions in conjunction with other 
TF’s to achieve more dynamic control of transcription. A GRU is variable in its spatial 
organisation and constituents, and the inclusion of tissue-specific TF’s in certain 
GRU’s contributes an additional measure of specificity in GR signalling. The 
compilation of GRE’s into a GRU allows a superior level of transcriptional induction 
as the GR co-operates with other TF’s bound at adjacent sites (Kassel and Herrlich, 
2007; Schoneveld et al., 2004a). Genes regulated in this manner include the 
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carbamoylphosphate synthase gene (Schoneveld et al., 2004a) and the 
Phosphoenol Pyruvate Carboxy Kinase gene (Scott et al., 1998). 
 
The GR may also function as a monomer when directly binding DNA (Figure 1.7C). 
A GRE half-site is composed of only one of the two hexameric halves of a GRE 
(GGTACA or TGTTCT). A liganded monomer may bind directly and induce 
transactivation, although DNA association of the GR monomer alone is insufficient 
for induction of transcription (Adams et al., 2003). Half-sites do not function alone as 
a classical GRE might, but rather are regulated in conjunction with other TF’s 
(Dschietzig et al., 2009a; Dschietzig et al., 2009b; Tseng et al., 2001). Genes 
regulated by the monomeric receptor include relaxin (Dschietzig et al., 2009a; 
Dschietzig et al., 2009b) and the β1 adrenergic receptor (Tseng et al., 2001). 
 
The GR can repress transcription when binding directly to DNA through negative 
GRE’s (nGRE) (Figures 1.7E and F). These have similar sequences to consensus 
GRE’s, albeit with more variation. No consensus nGRE has yet been found, but 
transrepression is mediated through GR binding to DNA (Dostert and Heinzel, 2004; 
Surjit et al., 2011). An nGRE may function as full length 15 bp element or as nGRE 
half-sites, as seen in the CRH (Malkoski et al., 1997; Malkoski and Dorin, 1999), 
prolactin (Sakai et al., 1988) and osteocalcin promoters (Meyer et al., 1997a; Meyer 
et al., 1997b) (Figure 1.7 E). At the prolactin and osteocalcin promoters the activated 
GR binds directly to DNA, which overlaps other TF binding sites, preventing their 
DNA binding and thus transcriptional induction (Figure 1.7F). In the case of CRH, the 
GRE overlaps an AP-1 site, preventing TNF-α induced c-Jun/Fos signalling and in 
the osteocalcin promoter the nGRE incorporates the genes TATA box, which is 
where RNA-pol II would otherwise bind. An unusual mechanism of GR-mediated 
transrepression occurs at the pro-opiomelanocortin (POMC) gene. The GR first 
binds DNA as a homodimer at a consensus GRE. This alone is insufficient to 
mediate transrepression, but allows the association of a further GR monomer at the 
opposite side of the DNA, resulting in repression of POMC expression. It is unclear 
whether the GR monomer associates with the GR homodimer, or whether a 
conformational change to the DNA induced by GR dimer binding allows association 
of the monomer with DNA directly (Drouin et al., 1993). 
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1.3.5.2. Interactions with chromatin 
 
For a long time it has been thought that the GR acts as a “pioneer” factor which, 
upon ligand activation enters the nucleus and associates with GRE’s at otherwise 
inaccessible chromatin. Thereafter, the GR recruits chromatin remodelling TF’s, 
forming stable promoter bound complexes and increasing promoter accessibility for 
RNA pol II association, which then begins transcription at the nearby TSS and gene 
expression (Lemon and Freedman, 1999; Urnov and Wolffe, 2001). 
 
This paradigm of stable one-dimensional GR gene regulation is overly simplistic and 
appears to be changing. Studies have indicated that the “spreading model”, which 
stipulates that GR signalling is transmitted directly downstream via a cis element 
bound GR may be overly simple and slightly incorrect. GRE’s have been found many 
kilobases away from the TSS and within intronic regions of GR regulated genes (So 
et al., 2007; Wang et al., 2004b). A “looping model” appears more favourable; in 
which distal response elements, which occur on separate chromosomes, may 
regulate gene expression by looping the DNA bound GR into contact with the TSS 
(Hakim et al., 2010). DNA is flexible and many regions of a gene may make fleeting 
contact with many millions of other regions of promoters and other genes, simply by 
random movement within the nucleus. For the NR family, looping is mediated by a 
greater than random association frequency (Gothard et al., 1996; Hakim et al., 
2009). Indeed many NR regulated genes do not display any familiar response 
elements near the promoter (John et al., 2008; Wang et al., 2004b). It is not known 
whether the DNA loop is a cause, or consequence of this distal method of gene 
regulation (Hakim et al., 2009). 
 
The concept of promoters being inaccessible prior to ligand activation of the GR has 
also been disputed, as it has been found that many of the GRE’s in classically 
regulated genes are already in a constitutively DNase hypersensitive state and do 
not require actions of the Switch/Sucrose Non Fermentable (SWI/SNF) chromatin 
remodelling complex (John et al., 2008). Chromatin-remodelling is involved with 
rapid association and disassociation of the GR with a chromatin template, in a far 
more dynamic mode than postulated with the spreading model (Fletcher et al., 2002; 
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Nagaich and Hager, 2004). Numerous GR molecules rapidly associate and 
disassociate with the promoter (McNally et al., 2000; Nagaich et al., 2004). The 
association is dependent on the nature of the chromatin (Turner et al., 2008), with 
greater frequency of association when the DNA encompassing the GRE is in a 
hypersensitive state. It also appears that the structure of the chromatin at the 
promoter itself is a regulator of GR-mediated gene expression, through selective TF 
association (John et al., 2011). Chromatin architecture is cell type-specific, and it is 
becoming increasingly apparent that this pre-determines GR association, and by 
inference may account for specificity in GR signalling (George et al., 2009). Many 
genes highly expressed by the GR in 3134 mammary cells are refractive to GR-
mediated expression in otherwise identically treated AtT20 cells owing to the 
absence of a promoter in a hypersensitive site (John et al., 2008). GR/DNA 
association is a stochastic process owing to Brownian motion; however the 
frequency of a productive association is greater than that of non-productive 
associations (George et al., 2009; Hager, 2002; Hager et al., 2004; Hager et al., 
2006). 
 
 
1.3.5.3. Protein-protein interactions 
1.3.5.3.1. Tethering 
 
The GR may regulate transcription independently of DNA binding, as part of the 
transcriptional initiation complex (TIC). In this sense the GR acts as co-regulator of 
other TF’s. Whilst this predominantly occurs in a transrepressive manner (Figure 
1.7G) (Reichardt et al., 2001) it may increase the expression of some genes (Figure 
1.7D) (Lerner et al., 2003). This process is termed tethering and occurs when a 
liganded GR monomer modulates transcription by forming heterocomplexes with 
DNA bound TF’s (Doppler et al., 2001; Kassel and Herrlich, 2007). This process is 
independent of dimerisation and DNA binding (Ray and Prefontaine, 1994; Reichardt 
et al., 2001) but does require key residues in the DBD and LBD of the GR (De 
Bosscher et al., 1997; Heck et al., 1994; Liden et al., 1997). 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
20 
 
Transactivation of α2-Macroglobulin occurs through the signal transducer and 
activator of transcription pathway-3 (STAT-3), a transcription factor activated by IL-6 
induction of the Janus Kinase (JAK). However, stimulation of cells with both IL-6 and 
DEX leads to a much higher level of expression than IL-6 stimulation alone does. 
The α2-Macroglobulin promoter lacks GRE’s, and ligand activation of the GR alone is 
insufficient to induce transactivation (Lerner et al., 2003). Furthermore if STAT-3 is 
absent the GR is not recruited to this promoter (Stoecklin et al., 1997; Takeda et al., 
1998). It is likely that the GR increases transactivation by associating with the 
promoter bound STAT-3 and recruiting further co-factors to the promoter (Figure 
1.7F) (Lerner et al., 2003; Takeda et al., 1998). 
 
Tethering is predominantly a transrepressive mechanism of gene regulation (Figure 
1.7G). The majority of GR anti-inflammatory effects are mediated in this manner and 
it is the mechanism of gene regulation targeted by therapeutic use of GC’s for the 
beneficial effects of anti-inflammation (De Bosscher and Haegeman, 2009; Herrlich, 
2001; Reichardt et al., 2001). Transrepression occurs at a much lower GC 
concentration than transactivation through DNA binding does (Adcock and Ito, 2000; 
Ito et al., 2000; Reddy et al., 2009; Ronacher et al., 2009). The best characterised 
mechanisms of the GR tethering to other TF’s and resulting in transrepression is 
through interactions with AP-1 (fos-jun) or NFκB (p65/RelA-p50) (Kassel and 
Herrlich, 2007). Many cytokines, such as IL-1β, IL-2, IL-6, IL-8, and TNF-α contain 
AP-1 and/or NFκB sites in their respective promoters (De Bosscher et al., 2003). 
Under agonist, but not antagonist stimulation (Fryer et al., 2000) the GR attenuates 
transcription of these genes by associating with NFκB and/or AP-1 which are bound 
at their response elements in the promoters (Brostjan et al., 1997; Kassel and 
Herrlich, 2007). The effects of GR-mediated transrepression are well documented at 
the collagenase-3 (Col-3) promoter. Expression of this gene is regulated by AP-1, 
and GC stimulation causes the GR to associate with the promoter by tethering to the 
DNA bound AP-1 without altering the composition of the AP-1 subunits (c-Jun and c-
Fos). GR association thereby serves to repress transactivation of the Col-3 promoter 
(Kassel et al., 2004; Rogatsky et al., 2001; Rogatsky et al., 2002). Ligand-
independent GR-mediated transrepression through tethering has also been reported 
for expression of IL-6 and IL-8 (Verhoog et al., 2011).  
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1.3.5.3.2. Co-factor recruitment 
 
Co-factors are required for the induction or repression of transcription and are 
accordingly classed as co-activators or co-repressors (van der Laan et al., 2008). 
Generally these associate with the GR at the AF-2 region at the 12th α-helix (Figure 
1.3) (Bledsoe et al., 2002; Bledsoe et al., 2004; Kauppi et al., 2003) but have also 
been reported to bind the AF-1 region in the NTD (Kumar et al., 2001; Warnmark et 
al., 2000). The conformation the GR adopts upon DNA binding is dependent on the 
sequence and nature of the promoter (Deroo and Archer, 2002; Kumar et al., 2001; 
Meijsing et al., 2009) and allows for the selective recruitment of co-factors (Korzus et 
al., 1998; Lefstin and Yamamoto, 1998; Rogatsky et al., 2003) thereby contributing 
to highly specific gene regulation.  
 
The interaction of the GR with co-activators is associated with a change in the nature 
of chromatin (John et al., 2008). Co-activators associate with the GR through penta-
peptide LXXLL motifs (L- leucine, X- any aa), termed nuclear receptor interacting 
domains (NRID) (Heery et al., 1997; Voegel et al., 1998). The p160 family of steroid 
receptor co-activators (SRC) is particularly well characterised and includes SRC1 
(NcoA-1), SRC-2 (GRIP-1 or TIF2), and SRC3 (pCIP, RAC3, ACTR or AIB1) (Anzick 
et al., 1997; Carapeti et al., 1998; Ning et al., 1999), all of which exert a low level of 
histone acetyltransferase (HAT) activity. Histone acetylation diminishes the 
electrostatic interaction between nucleosomes and DNA, resulting in chromatin 
becoming transcriptionally permissive (Eberharter and Becker, 2002; Hsiao et al., 
2002). This increases accessibility of the promoter and allows association of co-
factors including p/CAF, p300, CREB Binding Protein (CBP), the arginine 
methyltransferase CARM1, and coiled co-activator (Kim et al., 2003; Lee et al., 2005; 
Vo et al., 2001; Vo and Goodman, 2001) and affords a platform for the BTM to 
assemble on (Archer et al., 1992; Hebbar and Archer, 2003). A multi-protein complex 
forms at the promoter, bending DNA so as to bring the GR/GRE associated TFIID 
and the TATA binding protein (TBP) into proximity with the TATA box (Ford et al., 
1997; Horikoshi et al., 1992). 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
22 
 
The chromatin remodelling protein, brahma-related gene 1 component of the 
switch/sucrose non-fermentable (SWI/SNF) complex (Fryer and Archer, 1998) 
results in ATP-dependent nucleosomal rearrangement at the transcription start site 
TSS (Logie and Peterson, 1997; Owen-Hughes et al., 1996; Whitehouse et al., 1999) 
thereby resulting in greater chromatin accessibility (Fletcher et al., 2000; Owen-
Hughes et al., 1996; Owen-Hughes and Workman, 1996). Thereafter RNA pol II 
associates so as to initiate transcription (Beato and Sanchez-Pacheco, 1996). 
 
SRC-2 is a well documented co-activator which associates directly with the liganded 
GR (Kauppi et al., 2003) and enhances GR-mediated transactivation from GRE 
driven promoters by associating with the promoter bound GR (Avenant et al., 2010a; 
Cho et al., 2005). The association of SRC-2 is ligand-dependent and correlates well 
with the efficacy of the bound ligand (Ronacher et al., 2009). Although SRC-2 has 
been reported to simultaneously increase ligand potency and efficacy (Cho et al., 
2005; Gehin et al., 2002; Hong et al., 1997; Onate et al., 1995), these functions are 
separable and mediated independently of each other (Awasthi and Simons, 2012; 
Lee and Simons, 2010; Luo and Simons, 2009). 
 
Transrepression is mediated through chromatin condensation by histone 
deacetyltransferases (HDAC’s) and methyltransferases which include the GR co-
repressors: nuclear receptor co-repressor (NCoR) and silencing mediator for retinoic 
acid and thyroid hormone receptors (SMRT) (Ordentlich et al., 1999; Seol et al., 
1996; Zamir et al., 1996). In a manner similar to the LXXLL co-activator motif, these 
associate with the GR though a co-repressor NRID (LXX I/H I XXX I/L) (Nagy et al., 
1999; Perissi et al., 1999; Wang et al., 2004c), but may associate in the absence of 
ligand (Horlein et al., 1995). NCoR and SMRT can recruit the HDAC’s 1, 2 (Jones et 
al., 2001; Li et al., 2000b; Wen et al., 2000), 4 and 5 (Hu and Lazar, 1999; Huang et 
al., 2000) which further condense DNA and prevent TF recruitment to promoter 
elements (Li et al., 2001). 
 
Interestingly, SRC-2 may also further repress expression of genes regulated by GR-
mediated transrepression (Verhoog et al., 2011). As indicated, GR represses AP-1 
mediated activation of the Col-3 gene. In the presence of DEX, SRC-2 is recruited to 
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the AP-1 bound GR and serves to enhance transrepression. Similar effects of SRC-2 
co-repression have also been observed for NFκB-induced transcription of IL-8 and 
IL-6, and of the osteocalcin gene, to which the GR mediates transrepression through 
binding to an nGRE (Rogatsky et al., 2001; Rogatsky et al., 2002; Verhoog et al., 
2011). These alternate co-activator/co-repressor modes of SRC-2 are mediated by 
separate domains (Rogatsky et al., 2002). GR allosteric interactions with other 
proteins or DNA probably dictates which of the surfaces of SRC-2 are activated and 
able to modulate transcription (Lonard and O'Malley, 2007). 
 
 
1.3.6. Ligand-dependent turnover 
 
As a measure to control against excessive GR signalling, the GR is degraded 
through the ubiquitin-proteasome pathway (Dong et al., 1988; Webster et al., 1997) 
after periods of activation (Wallace and Cidlowski, 2001). Degradation may occur 
either in the nucleus or the cytoplasm after export of the receptor (Liu and DeFranco, 
2000), with ligand dissociation accelerating the recruitment of the proteasome to the 
GR complex (Stavreva et al., 2004). Proteasomal inhibition increases the extent of 
GR-mediated transactivation, indicating the importance of this process in attenuation 
of GR signalling (Deroo et al., 2002; Garside et al., 2006). 
 
The GR is continually turned over, although the turnover rate of the unliganded 
receptor is slow if compared to the turnover rate under agonist stimulation (Dong et 
al., 1988). The half-life of the unliganded GR is roughly 44 hours in COS1 cells and 
DEX stimulation decreases this to 10 hours (Avenant et al., 2010b). In COS1 cells 
the rate of GR degradation or turnover also correlates with efficacy of the bound 
steroid. DEX causes greatest reduction in GR half life, followed respectively by 
stimulations with prednisolone, CORT, aldosterone, MPA and RU486. Stimulation of 
cells with P4, CompoundA and NET did not result in a significantly reduced GR half-
life. In the same study, after 24 hours DEX, CORT, prednisolone, aldosterone and 
MPA had significantly reduced GR levels, whereas stimulation with RU486, P4, NET, 
Ursadiol and CompoundA did not (Avenant et al., 2010b). A previous study has 
indicated that stimulation with RU486 resulted in a moderate decrease in GR levels 
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(Hoeck et al., 1989). In HeLa cells saturating concentrations of DEX and CORT lead 
to the greatest extent of turnover, with a much lower extent induced by P4. 
Oestradiol and dihydrotestosterone, which do not function as GR agonists, have no 
effect on GR protein levels (Cidlowski and Cidlowski, 1981).  
 
 
1.4. Progesterone and synthetic progestins 
 
Cortisol is not the only steroid able to activate the GR. To exploit the therapeutic 
benefits of anti-inflammatory signalling for use in immune related disorders, many 
synthetic GC’s have been developed (Figure 1.5) to act via the GR (Coghlan et al., 
2003). Apart from these artificial hormones, a degree of cross-talk between members 
of the SR family exists owing to their related structures and function (Thornton, 
2001), and conserved ligand binding domains (Griekspoor et al., 2007). Aldosterone 
and progesterone, two endogenous hormones which exert effects via the MR 
(Messaoudi and Jaisser, 2011) and PR (Gadkar-Sable et al., 2005), respectively, 
can also can act via the GR. Progesterone is a weak GR agonist (Avenant et al., 
2010b) and has been reported before as an antagonist (Rupprecht et al., 1993b), 
whilst aldosterone is a relatively potent GR partial agonist (Avenant et al., 2010b). As 
synthetic analogues to cortisol have been developed for anti-inflammatory therapy, 
so too have synthetic progestins been developed for use in contraception (Draper et 
al., 2006; Erkkola and Landgren, 2005). An interesting feature of these hormones is 
that they have long term stability, circulate at high concentrations and certain 
progestins have GR agonist or partial agonist properties (Koubovec et al., 2005; 
Ronacher et al., 2009). Progesterone itself (and by inference, its synthetic 
derivatives) also acts via the PR on the HPA/G axis which regulates GR function and 
immune responses (Figure 1.1).  
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1.4.1. Physiological function 
 
The menstrual cycle is divided into two phases; the follicular phase, in which the 
maturing follicle produces oestrogen (predominantly oestradiol - E2) leading to 
proliferation of the endometrium, and the luteal phase in which the corpus luteum in 
the ovaries produces P4 (Figure 1.8) (Graham and Clarke, 1997). Where E2 is an 
immune activator (Salem et al., 2000), P4 is anti-oestrous (Gellersen et al., 2009; 
Tait et al., 2008) and antagonises the proliferative effects of E2 (Beagley and 
Gockel, 2003; Selgrade et al., 2009) by stabilising the lining of the endometrium in 
preparation for embryo implantation (Graziano et al., 2005; Wood et al., 2007). P4 
also suppresses immune activation through negative feedback inhibition of the 
HPA/G axis (Figure 1.1). This is essential for embryo implantation and the 
maintenance of pregnancy (Lydon et al., 1995), as an immune response triggered by 
foetal antigens would otherwise be detrimental to development (Huddleston and 
Schust, 2004). 
 
 
 
Figure 1.8: Relative concentrations of oestradiol (E2), progesterone (P4), Luteinising Hormone 
(LH), and Follicle Stimulating Hormone (FSH) during the menstrual cycle. The first two weeks of 
the menstrual cycle are termed the follicular phase and are characterised by low levels of P4 and 
higher levels of E2, as produced from the maturing follicle. Around the two week mark, an LH surge is 
observed and hormonal concentrations begin to change as the corpus luteum secretes P4, having an 
anti-oestrous and anti-proliferative effect (adapted from Backstrom et al., 1982; Hel et al., 2010). 
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1.4.2. Contraception 
1.4.2.1. Mechanism of action 
 
The short half life, limited bioavailability and rapid metabolism of P4 led to the 
development of synthetic P4 mimicking analogues which are more stable and also 
prevent ovulation (Whitehead et al., 1980). MPA and NET are two such synthetic 
progestin contraceptives (Bray et al., 2005) which function by decreasing the 
pulsatile frequency of GnRH secretion from the hypothalamus, thereby preventing 
synthesis of the gonadotropins luteinising hormone (LH) and follicle stimulating 
hormone (FSH). The absence of these gonadotropins prevents follicle development 
and ovulation, which in turn prevents an increase in E2 levels, and thus menstruation 
(Jeppsson et al., 1982; Kaunitz, 2000a; Mishell, 1996). In addition, progestins cause 
endometrial thinning and increase cervical mucus thickness. This reduces sperm 
mobility, increases sperm atrophy and hinders implantation of fertilised eggs 
(Ildgruben et al., 2003). Due to the lack of pulsatile hormone synthesis, women on 
progestin-only injectable contraceptives often experience amenorrhea (Kaunitz, 
2000b; Mainwaring et al., 1995). MPA and NET elicit similar progestogenic 
responses via the PR (Bergink et al., 1983; Deckers et al., 2000; Kontula et al., 
1975; MacLaughlin and Richardson, 1979) and both have higher relative binding 
affinities for the PRthan P4 (Africander et al 2011b). However, the physiological 
effects of these steroids differ markedly not only from each other but also from that of 
P4 when acting through other SR’s (Africander et al., 2011a; Africander et al., 2011b; 
Hadley et al., 2011; Koubovec et al., 2005; Sitruk-Ware, 2004). 
 
 
1.4.2.2. Non-progestogenic MPA and NET effects 
 
Progestin based contraception may inhibit the immune system and ovary function 
through activation of the HPA/G axis (Figure 1.1) according to the dose and type of 
steroid used (Erkkola and Landgren, 2005). Newer generation progestins attempt to 
mimic as closely as possible the effects (or otherwise) P4 has on other members of 
the SR family so as to reduce side effects, and undesirable non-progestogenic 
activity. MPA and NET-EN are first generation progestins and do exert some side 
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effects (Draper et al., 2006; Haider and Darney, 2007). Both steroids interact with the 
MR, AR and GR (Africander et al., 2011a; Africander et al., 2011b; Africander, 2010; 
Bentel et al., 1999; Ghatge et al., 2005; Koubovec et al., 2005; Winneker et al., 
2003) leading to cross-reactivity and non-progestogenic activity. 
 
 
Table 1.1: P4, MPA and NET relative binding affinities and efficacies for the PR, MR and GR  
(adapted from Africander et al., 2011b). Relative binding affinities are indicated as a percentage of 
the total specific binding of the endogenous ligand (progesterone, cortisol, or aldosterone 
respectively) and determined from in vitro recombinant human steroid receptor binding studies 
(Philibert et al., 1999). 
 
 
 
 
P4 and some progestin contraceptives have been found to act as potent MR 
antagonists and inactivate this receptor by competitive inhibition with its ligand, 
aldosterone. MPA and NET-A have relatively low MR affinities, and do not 
significantly moderate transcription form the SR (Table 1.1). This lack of MR 
antagonism may result in increases in weight, cardiovascular risk and blood pressure 
during progestin-only contraception (Rupprecht et al., 1993a; Sitruk-Ware, 2004). In 
terms of transactivation efficacy via the GR, P4 is a weak agonist (Avenant et al., 
2010b; Fuhrmann et al., 1996; Koubovec et al., 2005; Ronacher et al., 2009). Due to 
their stability and affinity for the GR, synthetic progestins may exert GC like 
transcriptional effects. MPA has a much higher relative binding affinity for the GR 
(79.1%) compared to NET-A (0.88%), NET (0.1%) or P4 (5.57%), and exerts 
numerous GC like effects (Koubovec et al., 2005; Schoonen et al., 2000). MPA is a 
GR partial agonist for transactivation (Avenant et al., 2010b; Ronacher et al., 2009), 
but may become a full agonist at high GR concentrations (Zhao et al., 2003). Indeed 
MPA binds the GR with a greater affinity than does the endogenous ligand cortisol 
(Kontula et al., 1983). MPA mediates GR transrepression to a greater extent than it 
does transactivation, in a manner resembling a dissociated GC (Bamberger et al., 
P4 MPA NET
PR 100 298 134
GR 11 58 1.4
MR 1000 3.1 2.7
PR Agonist Agonist Agonist
GR Partial Agonist Partial Agonist  -
MR Antagonist  -  -
Relative 
Binding   
Affinity
Efficacy
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1999) but has a much higher GR transactivation efficacy than either NET or P4 
(Avenant et al., 2010b). NET-A is ineffective at GR transactivation, but has been 
reported to repress transcription from the IL-8 promoter, as do agonistic GC’s. As a 
result of its high GR efficacy, MPA is likely to have more GC like side effects than 
NET-A and P4 (Africander, 2010; Draper et al., 2006; Ishida and Heersche, 2002). 
MPA increases GR activity, resulting in repression of some immune related genes by 
mediating transrepression via the GR. Repressed genes include IL-1; IL-2; IL-6 and 
IL-8 (Africander et al., 2011a; Bamberger et al., 1999; Brunelli et al., 1996; Hapgood 
et al., 2004; Koubovec et al., 2004; Koubovec et al., 2005; Kurebayashi et al., 2003; 
Malarkey et al., 1997; Wakatsuki et al., 2002). A loss of bone mineral density or 
osteoporosis is widely reported in MPA users and most likely arises from its anti-
oestrogenic and GR agonist properties (Ishida and Heersche, 2002; Ishida et al., 
2008; Kaunitz, 2002; Scholes et al., 2002). 
 
 
1.4.2.3. Progestin contraception and HIV-1 
 
The concentrations of E2 and P4 during the menstrual cycle have been shown to 
influence HIV-1 pathogenesis (Asin et al., 2008; Cu-Uvin et al., 2000; Greenblatt et 
al., 2000), with high P4 levels increasing disease progression and risk of infection or 
HIV-1 acquisition (Hel et al., 2010). Oestrogens are inflammatory and enhance 
endothelial cell function, thereby protecting the vagina against viral infection (Smith 
et al., 2004) whereas P4 is anti-oestrous and anti-proliferative (Parr et al., 1994; 
Smith et al., 2000). P4 increases the genetic diversity of the HIV-1 populations and is 
linked to an increase in secondary infections such as Chlamydia and Lactobacillus 
spp. (Baeten et al., 2005; Jacobson et al., 2000; Lavreys et al., 2004b; MacLean, 
2005). 
 
Trials in Rhesus Macaque monkeys have indicated MPA administration to increase 
risk of Simian Immunodeficiency Virus (SIV) infection and cause higher viral loads 
(Abel et al., 2004; Marx et al., 1996; Veazey et al., 2003). This is possibly due to the 
anti-oestrogenic effects of MPA and P4 (Smith et al., 2004). Subcutaneous injection 
also caused marked vaginal mucosal epithelium thinning, resulting in increased 
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susceptibility to SIV vaginal challenge (Genesca et al., 2010; Hild-Petito et al., 1998; 
Marx et al., 1996) and caused immunosuppression in Macaques (Trunova et al., 
2006). 
 
Progesterone-only based contraception may increase the risk of HIV-1 disease 
transmission in certain groups of people (Hel et al., 2010; Marx et al., 1996; 
Morrison, 2007; Morrison et al., 2007; Morrison et al., 2012). HIV-1 positive MPA 
users have been found to have higher viral loads, a greater genetic diversity of viral 
variants and more cell associated viral DNA in the cervo-vaginal environment 
(shedding) than infected women not using MPA (Kreiss et al., 1994; Lavreys et al., 
2004a; Mostad et al., 2000; Royce et al., 1997). The extent of viral shedding has 
been shown to correlate with hormonal contraception (Clemetson et al., 1993; 
Mostad et al., 1997; Mostad et al., 2000; Richardson et al., 2007; Wang et al., 
2004a). MPA may increase susceptibility to cervo-vaginal viral and bacterial 
infections (Hapgood et al., 2004; MacLean, 2005; Trunova et al., 2006; Wang et al., 
2004a), through altering immune function and vaginal physiology and suppression of 
the humoral and cell-mediated immune responses (Gillgrass et al., 2003; Kaushic et 
al., 2003; Sonnex, 1998). MPA may also increase HIV-1 transmissibility through 
increasing recruitment of inflammatory HIV-1 target cells to the genital tract (Ghanem 
et al., 2005; Martin et al., 1998; Prakash et al., 2002). 
 
The vaginal and cervical lining is a formidable barrier to invading pathogens, with 
epithelial cells expressing high levels of cytokines and chemokines to ensure 
constant immune surveillance and a thick mucosal layer to hinder pathogen mobility 
(Fichorova et al., 2001a; Fichorova et al., 2001b; Miller and Shattock, 2003). 
Progestin contraceptives may decrease the barrier protection of the endometrium 
(Sorensen et al., 2002; Torgrimson et al., 2011), thereby increasing the risk of HIV-1 
infection. MPA may increase the risk of HIV-1 infectivity by antagonising the 
proliferative and protective effects of oestrogen and reducing the barrier protection of 
the vaginal epithelium and reducing the protective effect normally exerted by normal 
vaginal flora, Lactobacillus spp. (Bahamondes et al., 2000; Mauck et al., 1999; Miller 
et al., 2000). Intra-vaginal progestin administration also increases the presence of 
Langerhans cells in the epithelial layers of the vagina (Huber and Gruber, 2001; 
Wieser et al., 2001) and MPA has been found to increase the number of 
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intraepithelial leukocytes, specifically of Langerhans cells, CD8+ T-lymphocytes and 
dendritic cells, all of which are HIV-1 target cells (Freed, 2004; Ildgruben et al., 2003; 
Miller, 1998a; Miller, 1998b; Turville et al., 2001). The direct effect of MPA on vaginal 
endometrium is controversial, as it is unclear whether MPA usage reduces (Miller et 
al., 2000), has no effect (Bahamondes et al., 2000; Hild-Petito et al., 1998; Mauck et 
al., 1999), or increases (Ildgruben et al., 2003) the endometrial thickness. Increased 
HIV-1 pathogenesis in MPA users is likely due to changes to cervical and vaginal 
physiology and the number and types of HIV-1 target cells at the cervical mucosa 
(Mauck et al., 1999).  
 
Conflicting reports exist, with some suggesting no correlation between HIV-1 
acquisition and hormonal contraception (Allen et al., 1991; Bulterys et al., 1994; 
Kapiga et al., 1994; Kiddugavu et al., 2003; Kleinschmidt et al., 2007; Mati et al., 
1995; Morrison et al., 2007; Morrison et al., 2011; Myer et al., 2007; Siraprapasiri et 
al., 1991), whilst others have found its use to increase HIV-1 acquisition, albeit for 
specific sub-populations (Baeten et al., 2005; Blish and Baeten, 2011; Heffron et al., 
2012; Jain, 2012; Lavreys et al., 2004a; Leclerc et al., 2008; Martin et al., 1998; 
Morrison et al., 2005; Morrison et al., 2010; Morrison et al., 2012; Rehle et al., 1992). 
Similarly, no consensus has been reached as to whether MPA has no effect on 
(Cejtin et al., 2003; Morrison et al., 2009; Richardson et al., 2007), or increases viral 
levels and accelerates the loss of CD4+ T-cells in HIV-1 positive women (Stringer et 
al., 2007). 
 
Much evidence also indicates a role for the GR in HIV-1 pathogenesis (reviewed in 
Hapgood and Tomasicchio, 2010) and as progestins may be anti-inflammatory 
themselves or when acting via this receptor (Bamberger et al., 1999; Brunelli et al., 
1996; Koubovec et al., 2004; Koubovec et al., 2005; Kurebayashi et al., 2003; 
Malarkey et al., 1997; Parr et al., 1994; Wakatsuki et al., 2002), it may be that 
injectable contraceptives render users more susceptible to HIV-1 acquisition through 
modulating immune responses via the GR. 
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1.5. The GR and HIV-1 pathogenesis 
 
Many reports in the literature indicate that GR activity and function becomes 
enhanced with HIV-1 infection, leading to GC hypersensitivity and many HIV-1 
positive patients often display chronic over-activation or dysregulation of the HPA 
axis causing excess production of GC’s (Kino and Chrousos, 2001; Kino and 
Chrousos, 2002; Kino et al., 2003a; Kino et al., 2003b; Norbiato et al., 1997a; 
Norbiato et al., 1997b; Norbiato et al., 1997c; Norbiato et al., 1998; Wang et al., 
1998a). It is entirely possible that enhanced GR function is mediated in part through 
the actions of Viral Protein R (Vpr), a small virion associated, accessory protein 
reported before as a GR co-activator (Fakruddin and Laurence, 2005; Kino et al., 
1999; Kino et al., 2002a; Kino et al., 2002b; Mirani et al., 2002; Muthumani et al., 
2006; Thotala et al., 2004). This may be a viral strategy to utilise the 
immunosuppressive properties of the receptor to ensure pathogenic success and 
continued transmission (reviewed in Hapgood and Tomasicchio, 2010). 
 
Altered function of the HPA axis has been reported previously in HIV-1 positive 
subjects (Dluhy, 1990; Kino and Chrousos, 2007; Sellmeyer and Grunfeld, 1996). 
HIV-1 disease progression is marked by a reduction in the innate and T-helper cell 
driven immunities, muscle wasting and myopathy, and a switch from the Th1 (IL-12; 
IFN-γ and TNF-α) to Th2  (IL-4; IL-10 and IL-13) cytokine profiles (Clerici et al., 
1997a; Clerici et al., 1997b; Clerici and Shearer, 1997; Pantaleo et al., 1993; Wang 
et al., 1998b; Yun et al., 2004) consistent with effects an overactive GR would have 
(Elenkov and Chrousos, 2006; Mirani et al., 2002; Norbiato et al., 1997b). IL-12 is a 
T-cell stimulating factor secreted from leukocytes and a regulator of Th1 immunity 
(Ma and Montaner, 2000; Ma et al., 2000). GC’s suppress expression of both the 
p40 and p70 subunits of this gene (Visser et al., 1998). The decrease in IL-12 levels 
is also a key marker of HIV-1 induced immunosuppression and the progression to 
AIDS (Smed-Sorensen et al., 2004; Tcherepanova et al., 2009) and has been 
reported to be a GR target during HIV-1 infection (Mirani et al., 2002). 
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1.5.1. Vpr 
 
HIV-1 encodes six accessory proteins: Tat, Rev, Vpu, Vif, Nef, and Vpr (Gramberg et 
al., 2009). Vpr is a small, 96 aa 14 kDa protein with a diverse array of functions and 
a high degree of sequence conservation amongst primate lentiviruses, although in 
SIV and HIV-2 the functions are split between Vpr and a similar accessory gene, 
Vpx, as a result of a gene duplication (Tristem et al., 1992). In HIV-1 positive 
individuals Vpr is packaged directly into HIV-1 virions (Bachand et al., 1999), and 
has been found to occur unassociated with other proteins in serum and has the 
ability to passively diffuse across cell membranes (Balasubramanyam et al., 2007; 
Levy et al., 1995; Tungaturthi et al., 2003; Xiao et al., 2008). This allows Vpr the 
ability to exert pathogenic effects in infected and uninfected cells alike, in a variety of 
tissues and organs (Coeytaux et al., 2003; Godet et al., 2010; Sherman et al., 2002). 
 
Vpr consists of three α-helices folded around a hydrophobic core (Figure 1.9). The 
first two helices are arranged in a helix-turn-helix motif (Morellet et al., 2003; Wecker 
and Roques, 1999) with the third helix offering a stretch of hydrophobic residues 
resembling a leucine zipper motif (Bourbigot et al., 2005; Schuler et al., 1999; Wang 
et al., 1996b), which may also contribute to oligomerisation (Schuler et al., 1999; 
Venkatachari et al., 2010; Zhao et al., 1994b) and interact with host proteins (Zhao et 
al., 1994a).  
 
Vpr is associated with many pathogenic functions, including cell-cycle arrest at the 
G2/M interface (Di Marzio et al., 1995; He et al., 1995), the induction of apoptosis 
(Patel et al., 2000; Snyder et al., 2010), nuclear import of the viral preintegration 
complex (Haffar et al., 2000), increasing the fidelity of reverse transcription (Fenard 
et al., 2009), transcriptional regulation of host genes (Fakruddin and Laurence, 2004; 
Fakruddin and Laurence, 2005; Janket et al., 2004; Tcherepanova et al., 2009) and 
transactivation of the viral long terminal repeat (LTR) (Ayyavoo et al., 1997a; Cohen 
et al., 1990). Vpr is also highly immunosuppressive (Muthumani et al., 2005b) and 
modulates the activity of the pro-inflammatory TF, NFκB (Ayyavoo et al., 1997b) 
resulting in decreased production of the cytokines IL-12 and TNF-α (Tcherepanova 
et al., 2009). A single arginine residue (R90) is highly conserved amongst viral 
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subtypes and has been reported to be important in mediating these 
immunosuppressive properties. Mutation of this residue alleviates IL-12 suppression 
and causes rapid Vpr degradation (Tcherepanova et al., 2009). 
 
 
 
 
Figure 1.9: Three dimensional structure of Vpr showing the positions of the three α-helices 
and the two NRID co-activator motifs. Vpr is a small protein consisting of three amphipathic α-
helices (α1, α2, and α3). Two of these helices contain on one surface LXXLL NRID motifs which may 
cause a direct interaction with the GR, these are indicated as I and II and occur between residues 22-
26 (I) and 64-68 (II) (Graphic: Zhao et al., 2011, with modifications: Morellet et al., 2003; Sherman et 
al., 2000). 
 
 
Evidence from Rhesus Macaque monkey models has illustrated a role for Vpr (in 
conjunction with Vpx) in the progression towards AIDS and death, by using Vpr and 
Vpx knockout SIV viral particles. Vpx is an SIV gene homologous to Vpr, arising from 
a gene duplication event of the common ancestor of Vpr and Vpx (Tristem et al., 
1992). In SIV, Vpx serves the function of nuclear targeting viral protein, and 
replication in non-dividing cells. It is also packaged directly into the virion 
(Mahalingam et al., 2001). Monkeys infected with an SIV mutant lacking both these 
genes (together these are homologous to Vpr in HIV-1) do not progress to AIDS and 
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death (Gibbs et al., 1995; Hirsch et al., 1998), whereas infection with SIV lacking a 
functional copy of Vpr only showed a delayed disease progression and lower rates of 
viral replication although this did result in AIDS and death (Hoch et al., 1995; Lang et 
al., 1993). A Vpx deletion retards the ability of SIV to replicate in primary cells, is 
associated with lower viral burdens, and delays the onset of AIDS, but does not 
prevent death altogether as the double mutant does (Gibbs et al., 1994; Gibbs et al., 
1995). 
 
A long term non-progressor (LTNP) is an HIV-1 infected individual who does not 
progress to AIDS, even in the absence of antiretroviral treatment (Lambotte et al., 
2005). This phenomenon may be linked to a Vpr point mutation, F72L. Vpr 
molecules isolated from a LTNP were found to carry this mutation, and were unable 
to translocate to the nucleus as the wt does (Caly et al., 2008). Studies have 
indicated that patients who display delayed disease progression and 
immunosuppression may carry non-functional copies of Vpr (Jacquot et al., 2009; 
Saksena et al., 1996; Somasundaran et al., 2002; Wang et al., 1996a). 
 
 
1.5.2. GR and Vpr interactions 
 
Vpr and the GR share common functions, including the induction of apoptosis in 
dendritic and T-cells, and chronic immunosuppression (Herold et al., 2006; 
Muthumani et al., 2004). Vpr contains two NRID co-activator motifs, between amino 
acids 22-26 and 64-68, (Figure 1.9) albeit with the former in reverse orientation (Kino 
et al., 1999; Sherman et al., 2000). It is believed that Vpr acts as a GR co-activator, 
in a manner analogous to SRC-2 (Kino et al., 1999; Sherman et al., 2000; Thotala et 
al., 2004). Transfection of Vpr encoding plasmids has been observed to enhance 
ligand-dependent GR-mediated transactivation of the MMTV and TAT-GRE synthetic 
GRE containing reporter genes in 293T, Jurkat, A204, HS729, CEM, HeLa and CV1 
cell lines (Kino et al., 1999; Kino et al., 2002b; Sherman et al., 2000) and of the 
endogenous receptor of activated NFκB ligand (RANKL) gene in PBMC’s (Fakruddin 
and Laurence, 2005). The sodium hydrogen exchanger (NHE1) gene is repressed by 
both GC’s (Muto et al., 2000), and Vpr. Repression by Vpr is reversible by treatment 
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with RU486, but is it unknown whether Vpr enhances GR-mediated transrepression 
(Janket et al., 2007). In support of these studies, Vpr has been found to associate 
directly with the GR in vitro (Kino et al., 1999; Kino et al., 2002a; Sherman et al., 
2000; Thotala et al., 2004). Further studies have implicated the cellular factors 
human Vpr interacting protein (Ramanathan et al., 2002) and poly ADP-ribose 
polymerase-1 (Muthumani et al., 2006) to mediate this interaction in vivo. 
 
Vpr is constitutively nucleophilic (Kamata and Aida, 2000; Thotala et al., 2004; 
Vodicka et al., 1998), through the actions of an atypical two-part NLS (Gallay et al., 
1997; Haffar et al., 2000; Karni et al., 1998). Vpr nuclear import is regulated through 
the importin-α/β pathway (Popov et al., 1998; Vodicka et al., 1998). This is the same 
mechanism which the GR uses to gain nuclear access (Freedman and Yamamoto, 
2004). Vpr mimics importin-β (Vodicka et al., 1998), by associating with importin-α 
(Nitahara-Kasahara et al., 2007; Suzuki et al., 2009). This association increases the 
affinity of importins for classical NLS’s (Popov et al., 1998). Mutations to the Vpr 
LXXLL motifs in helices I and III prevent Vpr nuclear localisation (Thotala et al., 
2004) and association with importin (Kamata and Aida, 2000). 
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Figure 1.10 (A-H): Select models of co-activation and co-repression of the GR by Vpr. On GRE 
containing promoters, transcription does not occur in the absence of GC’s (A). Ligand activation of the 
GR causes transactivation (B). This is enhanced by the presence of a co-activator such as SRC-2 (C) 
or by Vpr (D). In the absence of GC’s NFκB activates transcription (E). When GC’s are present the 
GR tethers to and represses transcription from NFκB (F). The presence of SRC-2 (G), and Vpr (H), 
will enhance the extent of transrepression. 
 
 
Vpr has a high affinity for DNA (Zhang et al., 1998), but due to its small size Vpr 
alone is unlikely to be able to remodel chromatin itself. HAT’s are generally large 
MW, multi subunit, enzyme complexes (Roth et al., 2001) and Vpr does not display 
any conserved enzymatic active site sequences. Rather altered GR transcriptional 
activities in the presence of Vpr are likely to stem from its propensity to bind multiple 
proteins in vitro (reviewed in Kino and Pavlakis, 2004). Numerous TF’s which 
increase GR-mediated transactivation have been shown to associate with Vpr. 
These include p300/CBP (Kino et al., 2002a), MED-28, 14-3-3 proteins (Kino et al., 
2005), and components of the general TFIIB and TFIIH complexes (Agostini et al., 
1996; Agostini et al., 1999; Kino et al., 2002b). Through these interactions it may be 
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that Vpr enhances GR-mediated transcription and immunomodulatory properties 
through recruitment of additional transcriptionally active co-regulators to the GR. 
 
Some lines of evidence suggest that Vpr may exert effects through actions of the GR 
independently of DEX. In the presence of the GR antagonist RU486, Vpr-mediated 
suppression of IL-12 (which occurs via the GR) is inhibited, likely by disrupting an 
interaction between Vpr and the GR (Mirani et al., 2002). Additionally in the absence 
of DEX, the extent of Vpr-mediated transactivation of the LTR is abrogated by 
RU486 (Soudeyns and Wainberg, 1997), in a manner that correlates with the 
concentration of antagonist present (Schafer et al., 2006). Vpr-induced apoptosis of 
T-cells may similarly be prevented by treatment of cell lines with RU486 (Muthumani 
et al., 2005a). As RU486 is known to disrupt LXXLL GR/co-factor interactions 
(Kauppi et al., 2003), the above evidence indicates that Vpr may act as a weak GR 
agonist itself, as has been implied before (Thotala et al., 2004). 
 
The LTR serves as a promoter for viral gene expression and replication and Vpr 
alone induces a moderate level of LTR transactivation (Forget et al., 1998). The GR 
can also transactivate the HIV-1 LTR (Bressler et al., 1993; Kinter et al., 2001; 
Kolesnitchenko and Snart, 1992; Mitra et al., 1995; Vanitharani et al., 2001; Wiegers 
et al., 2008). The -278 to -168 bp region of the LTR contains three GRE like sites 
(Ghosh, 1992; Kolesnitchenko and Snart, 1992; Mitra et al., 1995; Soudeyns et al., 
1993) which is also the region primarily acted upon by Vpr (Vanitharani et al., 2001). 
RU486 stimulation can reduce GR-mediated transactivation of the LTR in cell lines 
and primary macrophages (Schafer et al., 2006; Soudeyns and Wainberg, 1997). 
Vpr is thought to act as an adaptor molecule, linking the ligand bound GR and 
p300/CBP to the GRE like site in the LTR closest to the TSS (Felzien et al., 1998; 
Kino et al., 2002a; Mitra et al., 1995). 
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1.6. Thesis rationale 
 
HIV-1 has claimed the lives of more than 30 million people since 1981. It has a 
particularly high prevalence in Sub-Saharan Africa, if compared to the global rate 
amongst adults: 5.0% compared to 0.8%, equating to 68% of all HIV-1 positive 
people in this region. South Africa is at the epicentre of the pandemic with near 5.24 
million HIV-1 positive adults, representing 10.5% of the population; the greatest 
number of infected people in any country (UNAIDS, 2011).  
 
One of the HIV-1 accessory genes, Vpr, is highly immunosuppressive and in many 
ways mimics actions of GC’s (Tcherepanova et al., 2009; Tungaturthi et al., 2003), 
and may enhance GR-mediated transrepression (Mirani et al., 2002; Muthumani et 
al., 2006) or transactivation (Fakruddin and Laurence, 2005). Indeed in this manner 
Vpr has widely been reported as a GR co-activator (reviewed in Hapgood and 
Tomasicchio, 2010). Although much still needs to be resolved, it appears that Vpr 
actions are reversible by treatment with RU486, an SR antagonist (Schafer et al., 
2006), although other reports indicate that Vpr modulation of GR activation requires 
ligand to be present (Kino et al., 2002a; Sherman et al., 2000). Vpr and the GR have 
been found to associate in vivo, although it is also unclear if this interaction is ligand-
dependent (Kino et al., 1999; Kino et al., 2002a), or occurs independently of GR 
agonists (Sherman et al., 2000; Thotala et al., 2004). 
 
Progesterone regulates female reproduction and the maintenance of pregnancy 
(Graham and Clarke, 1997; Spencer and Bazer, 2002) and exerts its effects primarily 
through the PR (Rivera et al., 1999). Due to structural similarities between members 
of the SR superfamily, progesterone may also act via the AR, MR, and notably the 
GR (Africander et al., 2011a; Africander et al., 2011b; Africander, 2010; Bentel et al., 
1999; Ghatge et al., 2005; Koubovec et al., 2005; Moore et al., 2012; Philibert et al., 
1999; Winneker et al., 2003). Endogenous female sex hormones affect replication of 
HIV-1 in certain cell types (Asin et al., 2008) and the stage of the menstrual cycle 
has a substantial effect on viral replication rates (Greenblatt et al., 2000). Synthetic 
P4 mimicking steroids are commonly used as contraceptives and similarly exert their 
effects via the PR. Depo-Provera® and Noristerate® are two synthetic progestins 
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widely used as contraceptives in South Africa. Depo-Provera® contains the active 
compound Medroxyprogesterone Acetate (MPA) and Norestirate® is administered 
as the inactive enanthate (NET-EN) form before it is hydrolysed to Norethisterone 
(NET) (Stanczyk and Roy, 1990). As with P4, these hormones may also interact with 
other members of the SR family. MPA is particularly notable in this regard as it has a 
high affinity for the GR and acts as a full agonist (Koubovec et al., 2005). These 
injectable contraceptives are among the most widely used in developing nations 
(Erkkola and Landgren, 2005), and MPA is administered in some form to more than 
20 million women (Affandi, 2002a; Affandi, 2002b). MPA has been available for use 
in South Africa for over 40 years (Westhoff, 2003). Generally MPA is injected every 
three months as a 150 mg aqueous suspension reaching serum concentrations of 
2.6-3.9 nM (Mathrubutham and Fotherby, 1981; Mishell, 1996) whereas NET-EN is 
administered every second month as a 200 mg oily suspension (Garza-Flores et al., 
1991) with a peak serum concentration of 1.5-59 nM (Fotherby, 1983). These 
compounds low cost and minimal user participation make them ideal for use in 
developing countries, particularly in Africa (Erkkola and Landgren, 2005), and nearly 
half of HIV-1 positive women require access to effective contraception (UNAIDS, 
2011).  
 
There is an abundance of literature available supporting the safety of MPA and the 
many non-contraceptive benefits its use involves (reviewed in Westhoff, 2003), 
although an accumulating amount of evidence indicates MPA may enhance risk of 
HIV-1 transmission and shedding (Heffron et al., 2012; Hel et al., 2010; Kleinschmidt 
et al., 2007; Kreiss et al., 1994; Moss et al., 1991; Mostad et al., 1997; Mostad et al., 
2000; Royce et al., 1997; Stringer et al., 2007; Wang et al., 2004a). 
 
Different agonists will differently affect GR function. This study aims to give insight 
into if Vpr will change how different steroids act via the GR and thereby contribute to 
an alteration in GR function. As Vpr is a GR co-activator, this may translate into 
greater changes with strong GR agonists such as MPA than it would for NET-A, due 
to these steroids differing GR efficacies. 
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1.7. Hypothesis, aims, and strategies 
 
To investigate a possible link between hormonal contraceptives, GR-mediated 
transactivation and the HIV-1 accessory gene Vpr the following hypotheses were 
formulated. The central hypothesis was that Vpr would increase ligand-dependent 
GR-mediated transactivation and that different progestins will have different GR-
mediated responses in the presence of Vpr. To investigate this, a number of specific 
hypotheses were developed and experimentally investigated. 
 
 
HYPOTHESIS 1: 
Vpr is a GR co-activator and will ligand-dependently increase GR-
mediated transactivation. This will occur to a greater extent in the 
presence of more efficacious ligands than it will for weaker ligands. 
 
To test this hypothesis, the following aims were investigated: 
  
Aim:  To determine whether Vpr exerts detectable co-activation of the GR under full 
agonist stimulation but not with partial or weak agonists, or antagonists, or in 
the absence of ligand, on GR-mediated transactivation of GRE-containing 
promoter-reporter constructs.. 
 
This will be investigated through use of the TAT-GRE reporter construct in COS1 
cells by overexpressing the hGRα in the presence or absence of HA Vpr. Cells will 
be stimulated with a panel of ligands with different biocharacters and GR 
transactivation efficacies. The resulting level of reporter gene activity will be 
compared between corresponding stimulations to observe if HA Vpr enhances 
ligand-dependent GR-mediated reporter gene transactivation.  
 
Aim: To determine whether Vpr exerts detectable ligand-dependent co-activation of 
the GR for GR-mediated transactivation of GRE containing endogenous 
genes in the same cell line.  
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This will be investigated through quantitative real time PCR in COS1 cells by 
overexpressing the hGRα in the presence or absence of HA Vpr. Cells will be 
stimulated with a panel of ligands with different GR efficacies and the resulting 
mRNA levels compared between corresponding stimulations to observe if HA Vpr 
enhanced transcription of the endogenous genes.  
 
Aim: To determine whether Vpr exerts detectable ligand-dependent co-activation of 
the GR for GR-mediated transactivation of the same endogenous genes in a 
different cell line, which expresses endogenous GR. 
 
This will be investigated through quantitative real time PCR in END1 cells in the 
presence or absence of expressed HA Vpr. Cells will be stimulated with a panel of 
ligands with different GR efficacies and the resulting mRNA levels compared 
between corresponding stimulations to determine if HA Vpr enhanced transcription of 
the endogenous genes.  
 
 
HYPOTHESIS 2: 
Vpr increases both DEX efficacy and potency for GR-mediated 
transactivation 
 
Aim: To determine if the concentration of ligand influences the effect of Vpr on GR 
transcriptional activity. 
 
This will be done by using DEX dose response curves, performed by incubating 
COS1 cells overexpressing the hGRα, with a range of DEX concentrations. This will 
be done in the absence and presence of two different amounts of HA Vpr to observe 
if the level of Vpr protein has an effect on ligand potency and efficacy. The resulting 
DEX dose response curves will then be compared to determine the effects of Vpr on 
DEX potency and efficacy.  
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HYPOTHESIS 3: 
Vpr regulates GR levels and turnover. 
 
Aim: To determine whether ligand-dependent GR turnover is decreased in the 
presence of Vpr, causing higher GR levels and thereby explaining how GR-
mediated transactivation is increased by Vpr. 
 
This will be investigated by overexpressing the hGRα in COS1 cells and stimulating 
cells with the same panel of ligands as used above, in either the presence or 
absence of HA Vpr followed by Western blot analysis of lysates in order to quantify 
the relative hGRα and HA Vpr levels. 
 
 
HYPOTHESIS 4: 
Vpr enhances ligand-dependent GR phos horylation at S203, S211, 
and S226. 
 
Aim: To determine whether Vpr co-activation of the GR is mediated by modulating 
post-translational and ligand-dependent phosphorylation of the GR at serine 
residues 203, 211 and 226. 
 
This will be investigated by overexpressing the hGRα in COS1 cells and stimulating 
cells with the same panel of ligands as used above, in either the presence or 
absence of HA Vpr followed by Western blot analysis of lysates in order to quantify 
the relative extents of S203, S211 or S226 phosphorylation, and if these levels are 
changed in the presence of HA Vpr. 
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HYPOTHESIS 5: 
Vpr increases nuclear localisation of the rGR in the absence and 
presence of ligand. 
 
Aim: To determine whether Vpr increases the nuclear localisation of the GR in the 
presence of a full agonist or without ligand stimulation.  
 
This will be investigated through immunofluorescence in COS1 cells overexpressing 
the rGR in the presence and absence of HA Vpr and stimulated with a saturating 
concentration of DEX or of vehicle alone. The nuclear localisation of the rGR will be 
determined by quantifying the extent of nuclear GR signal as a proportion of total cell 
GR signal (nuclear/whole cell GR signal intensity). This will then indicate how the 
nuclear fraction of GR changes in response to ligand stimulation, the presence of 
Vpr, or both. 
 
 
HYPOTHESIS 6: 
Progestins will differently affect GR function when in the presence 
of Vpr, leading to changes in biocharacter and partial agonist 
activity. 
 
Aim: To determine whether any of the progestins (or other ligands) have different 
GR-mediated responses (biocharacter or partial agonist activity) when in the 
presence of Vpr. 
 
This will be analysed by plotting data as a relative percentage of the maximal 
response, obtained with DEX stimulation thereby indicating the partial agonist activity 
or biocharacter. A post-hoc Fishers least significant differences statistical test will 
determine if any GC or progestin causes a significantly different response via the GR 
if compared to the response it exerted in the absence of HA Vpr. This will indicate if 
the biocharacter of any of the tested ligands changes in the presence of HA Vpr.  
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2. MATERIALS & METHODS 
 
2.1. Cell lines 
 
COS1 African Green Monkey Kidney Fibroblast cells were purchased from the 
American Type Culture Collection. These were cultured in high glucose (1 g/ml) 
Dulbecco’s Modified Eagles Medium (DMEM, Sigma-Aldrich, South Africa) 
supplemented with 10% (v/v) Foetal Calf Serum (FCS, Sigma-Aldrich, South Africa) 
and 1% v/v Penicillin/Streptomycin (100 IU/ml Penicillin and 100 μg/ml Streptomycin, 
Gibco BRL Life Technologies, UK) (DMEM-10). Cells were passaged twice weekly at 
a 1/15 dilution using 0.25% Trypsin/0.1% EDTA in calcium- and magnesium-free 
PBS (Highveld Biologicals, South Africa) for 3 minutes at 37°C and pelleted by 
centrifugation. 
 
E6E7 human endocervical cells (END1) expressing high amounts of endogenous 
GR, were also purchased from ATCC and were cultured in keratinocyte serum free 
medium (KSF, Sigma Aldrich, South Africa) supplemented with 50 μg/ml bovine 
pituitary extract (BPE, Sigma Aldrich, South Africa) and 1% v/v Penicillin/ 
Streptomycin. END1 cells were passaged once weekly to a 1/4 dilution using 5 ml 
0.25% Trypsin/0.1% EDTA in calcium- and magnesium-free PBS for 10 minutes at 
37°C before addition of 5 ml DMEM-10 to prevent further trypsinisation and pelleted 
by centrifugation. Medium was aspirated and cells rinsed with at 37°C with PBS 
before addition of fresh medium once weekly.  
 
Both cell lines were maintained at 37°C in a water jacket incubator (5% CO2, 90% 
humidity) in 75 cm2 tissue culture flaks (Greiner Bio-one, South Africa) and regularly 
tested for Mycoplasma contamination through Hoechst staining (Battaglia et al., 
1980) with only Mycoplasma-negative cell lines being used in experimentation.  
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2.2. Test compounds and antibodies 
 
Dexamethasone (DEX), Medroxyprogesterone Acetate (MPA), Norethisterone 
Acetate (NET-A), Progesterone (P4), Cortisol (CORT) and Mifepristone (RU486) 
were purchased from Sigma-Aldrich, South Africa and dissolved in absolute ethanol. 
Ethanol (EtOH) was used as a vehicle and compounds were always delivered in 
such a way that the same volume (1.0 μl/ml) was always delivered to cells. Cells 
were stimulated with 100 nM DEX, 100 nM MPA, 10 μM NET-A, 1 μM P4, 100 nM 
Cort, 100 nM DEX/1 μM RU486 or a 0.1% v/v dilution of vehicle alone (EtOH) for 24 
hours. These ligand concentrations were calculated to result in GR saturation, based 
on the KD’s and were used for all experiments, unless otherwise indicated (Kontula 
et al., 1983; Ronacher et al., 2009). 
 
The α-phospho serine 203, 211 and 226 (P-S203, P-S211 and P-S226 respectively) 
hGRα-specific antibodies were a generous gift from Dr M.J. Garabedian (New York 
University, School of Medicine, USA). The polyclonal mammalian GR (H-300; sc-
8992) antibody was purchased from Santa Cruz Biotechnology (USA). The GAPDH 
antibody (SC) was used as a loading control and purchased from Santa Cruz 
Biotechnology (USA). The α-HA tag (12CA5) antibody was purchased from Roche 
(South Africa). The secondary α-mouse (sc-2005) and α-rabbit (sc-2313) HRP 
conjugated antibodies were both purchased from Santa Cruz Biotechnology (USA). 
The α-HA antibody used for immunofluorescence (Y11, sc-805) was purchased from 
Santo Cruz Biotechnology (USA). The α-mouse GR antibody (BuGR22) was 
purchased from Cell Signalling (USA). The fluorescent anti-rabbit immunoglobulin-G 
(IgG) AlexaFluor488 (A21206) antibody was purchased from Invitrogen and α-mouse 
IgG Cy3 antibody (715-166-150) was purchased from Jackson Immuno Research 
(USA).  
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2.3. Plasmids 
 
The pCMV4-3HA-Vpr plasmid (HA Vpr) expresses an HA tagged variant of Vpr 
protein obtained from the HIV-1 type B NL4-3 clone and is under control of a 
constitutive CMV promoter in the CMV4 vector plasmid. It was obtained from Dr 
Warner Greene (University of California, San Francisco) and has been described 
previously (Sherman et al., 2000). The p-hGRα (DR) (hGRα) plasmid was a kind gift 
from Prof. David Ray (Manchester University), which constitutively expresses the full 
length and untagged human GRα isoform under control of the CMV promoter cloned 
into the pcDNA3 vector, and has been described before (Ray et al., 1999). The 
pcDNA3.1+ (empty vector) plasmid contains a CMV promoter in the pcDNA vector 
with no inserted downstream DNA sequence. This was used to control for equal 
amounts of transfected DNA and was purchased from Invitrogen (UK). The pTAT-
GRE-E1b-Luc (TAT-GRE) luciferase reporter gene plasmid is controlled by the 
inducible E1b promoter and contains two GRE’s from the rat Tyrosine Amino 
Transferase gene, and was a gift from Dr G. Jestner (Erasmus University of 
Rotterdam, Netherlands) and has been described previously (Sui et al., 1999). The 
rat GR encoding plasmid, pSVL-rGR (rGR), expresses the full length wt rGR under 
control of a constitutive late SV40 promoter cloned into the pSVL vector plasmid and 
was a kind gift from Dr Stoney Simons Jr. (National Institute of Health, USA) and has 
been described previously (Cho et al., 2005).  
 
Plasmids were transformed into Escherichia coli DH5α strain by standard heat shock 
method (Sambrook et al., 1989). Briefly, 10 ng of the desired plasmid and 100 μl of 
competent cells in Luria broth (1% (w/v) tryptone; 0.5% (w/v) yeast extract; 0.5% 
(w/v) NaCl) were incubated on ice for 30 minutes before heat-shock at 42°C for 2 
minutes and placed back on ice for a further 2 minutes. Cells were recovered by the 
addition of 900 μl of SOC medium (2% (w/v) tryptone, 0.5% (w/v) yeast extract, 
0.05% (w/v) NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM Glucose) and incubated at 
37°C for 1 hour. Cells were plated onto Luria agar plates (Luria broth with 1.5% (w/v) 
agar) containing 100 μg/ml ampicillin (Sigma-Aldrich, South Africa) and incubated 
overnight at 37°C. For plasmid purification a single colony was picked and inoculated 
into 100 ml LB containing 100 μg/ml ampicillin and incubated while shaking overnight 
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at 37°C. Plasmid DNA was isolated and purified using a Promega Pureyield Plasmid 
Midi-prep kit (Promega Corp., USA) according to the manufacturer’s instructions. 
Plasmid integrity and purity were analysed by restriction enzyme digestion followed 
by 0.8% agarose gel electrophoresis at 65 V containing 10.0 μg/ml Ethidium 
Bromide. 
 
2.4. Reporter assays 
 
COS1 cells were plated into 10 cm dishes at 2.0x105 cells per dish 24 hours prior to 
bulk transfection using the DEAE dextran method as previously described (Luthman 
and Magnusson, 1983) with a few changes. A transfection mix was prepared in 
serum free (SF) DMEM containing 2.5% FCS with 100 μM chloroquinediphosphate 
equilibrated to 37°C. Cells were transfected with 3 600 ng TAT-GRE, 1 600 ng 
hGRα, and 3 600 μg HA Vpr or empty vector with 100 μg/ml DEAE-Dextran. Media 
was aspirated and 2.5 ml of transfection mix was added to cells for 1 hour at 37°C. 
Medium was aspirated and replaced with 2.5 ml 10% (v/v) DMSO in PBS for 3 
minutes at room temperature. Cells were then washed with PBS and grown in 
DMEM-10 for a day prior to re-plating at a density of 1.4x105 cells/ml in 24 well 
experimental plates (Greiner Bio-one, South Africa). This equated to roughly 112 ng 
hGRα and 250 ng HA Vpr per ml DMEM-10. After 24 hours of incubation, cells were 
stimulated with the test compounds in SF-DMEM at the indicated concentrations.  
 
This method of bulk transfection was found to cause a high measure of error and 
subsequent reporter assays (as indicated in figure legends) were plated and 
transfected directly using FuGENE6 transfection reagent (F6, Roche Applied 
Science, South Africa) according to the manufacturer’s instructions. Briefly cells were 
plated directly into 24 well plates at a density of 1.0x105 cells/ml and grown for 24 
hours in DMEM-10 prior to transfection. F6 was added to 100 μl of SF-DMEM in a 
ratio of 2 μl F6 to 1 μg DNA and left at room temperature for 5 minutes before the 
addition of hGRα and HA Vpr to final concentrations of 175 ng hGRα per well and 50 
or 175 ng HA Vpr per well as indicated (this equates to 350 ng hGRα and 100 or 350 
ng HA Vpr per ml). This was left at room temperature for 30 minutes before addition 
directly to cells in culture medium. One day later cells were washed in PBS and 
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stimulated with a range of DEX concentrations or EtOH as indicated for 24 hours 
according to experimental requirements. 
 
After stimulation cells were washed twice with ice cold PBS and harvested with 50 μl 
reporter lysis buffer (Promega Corp., USA). The luciferase assay (Luciferase Assay 
System, Promega, USA), was carried out with 10 μl of lysate and 50 μl luciferase 
substrate in white 96 well plates in a Modulus Microplate reader (Turner Biosystems, 
USA). Luciferase units were normalised to total protein concentration, as measured 
by Bradford’s Assay (Bio-Rad, South Africa) and expressed relative to control 
values. The Bradford assay consisted of adding 250 μl of Bradford reagent to 2 μl of 
protein samples of unknown concentration (measured in duplicate) from each of the 
24 wells on the experimental plate. The absorbance of the mixture at 595 nm was 
measured by spectrophotometer, and using a set of bovine serum albumin protein 
standards (2 mg/ml BSA, Pierce, South Africa) diluted in reporter lysis buffer and 
thus of known concentration, the concentration of unknown samples was calculated 
(Bradford, 1976).  
 
 
2.5. SDS-PAGE and Western blot 
 
For sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), 
COS1 cells were seeded in DMEM-10 directly into 12 well plates at a density of 
1.0x105 cells/ml. Twe ty four hours later cell were transfected with 350 ng hGRα, 
and 350 ng HA Vpr or empty vector per ml (per well) unless otherwise indicated in 
figure legends using F6 according to the manufacturer’s instructions. One day later 
cells were washed in PBS and stimulated in SF-DMEM with test compounds or 
vehicle (EtOH) as indicated in figure legends for 1, 4 or 24 hours according to 
experimental requirements. Where END1 cells were used in Western blotting, cells 
were seeded at 4x104 cells per well in a 12 well plate and did not require hGRα 
transfection but were similarly transfected with 1 000 ng of either HA Vpr or empty 
vector 24 hours before stimulation in KSF-SF medium for four hours with saturating 
concentrations of ligand.  
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Samples were harvested in 50 μl 2x SDS sample buffer (diluted from 5x SDS sample 
buffer: 100 mM TRIS-Cl pH 6.8; 5% (w/v) SDS; 20% (v/v) glycerol; 2% (v/v) β-
mercaptoethanol; 0.1% (w/v) Bromophenol-blue). Equal amounts (9 μl) of sample 
were boiled (100°C) for 5 minutes and resolved by 10% SDS-polyacrylamide gel in 
running buffer (25 mM TRIS-Cl pH 8.4; 250 mM glycine and 0.1% (w/v) SDS) using a 
Bio-Rad Mini Protean-II electrophoresis cell chamber at 75 V for 30 minutes followed 
by 120 V for 1½ hours (Maniatis et al., 1975).  
 
Proteins were transferred from the gel onto a HyBond-ECL nitrocellulose membrane 
(AEC-Amersham, South Africa) at 180 mA in transfer buffer (25 mM TRIS, 250 mM 
glycine and 20% (v/v) MeOH) for 1 hour using the Mini Protean-II blotting apparatus 
(Bio-Rad, South Africa). Membranes were blocked in 4% (w/v) ECL advance 
blocking powder (AEC-Amersham South Africa) prepared in TRIS buffered saline 
tween (TBST; 50mM TRIS-Cl pH 7.5, 150 mM NaCl and 0.1% (v/v) Tween-20) for 1 
hour at room temperature and incubated with primary antibodies (Table 2.1) 
prepared in blocking solution at 4°C overnight. The following day membranes were 
washed once for 15 minutes and three times for 5 minutes, in TBST at room 
temperature before incubation with Horseradish Peroxidase (HRP) conjugated 
secondary antibodies in 5% (w/v) non-fat milk powder in TBST for an hour at room 
temperature. Blots were washed as above followed by rinsing with TBS and 
developed using Pierce Western blotting detection re-agents (Pierce, South Africa) 
and Hyperfilm MO high performance autoradiography film  (AEC Amersham, South 
Africa), according to the manufacturer’s instructions. Exposed bands on the film were 
scanned and quantified with the AlphaEase FluorChem5500 software (Alpha 
Innotech). After probing, blots were stripped of antibodies at 60°C for 30 minutes in 
stripping buffer (100 mM β-mercaptoethanol, 2% (w/v) SDS and 62.5 mM TRIS-Cl 
pH 6.8) before being re-blocked and re-probed, if necessary.  
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Table 2.1: Dilutions of primary and secondary antibodies used in Western blot analysis 
 
 
 
2.6. Quantitative real time PCR 
 
COS1 and END1 cells were seeded at densities of 1.0x104 or 4.0x104 cells/well 
respectively in 12 well plates, twenty four hours prior to transfection with F6 
according to the manufacturer’s instructions. COS1 cells were transfected with 350 
ng hGRα and 350 ng HA Vpr or empty vector, and END1 cells were transfected with 
1 000 ng HA Vpr or empty vector per ml (per well). After 24 hours of incubation at 
37°C, cells were stimulated in SF-DMEM or KSF (without BPE) respectively, for four 
hours with 100 nM DEX, 100 nM MPA, 10 μM NET-A, 1 μM P4, 100 nM CORT or 
vehicle (EtOH). RNA was isolated using TRIZOL reagent (Sigma-Aldrich, South 
Africa) according to the manufacturer’s instructions and RNA integrity was verified on 
a denaturing 1% agarose gel, containing 10% morpholinopropanesulphonic acid (0.2 
M morpholinopropanesulphonic acid; 0.05 M Sodium Acetate; 0.01 M EDTA, pH 7.0) 
20% (v/v) formaldehyde and electrophoresed at 65 V for 30 minutes. 
 
RNA was stored at -80°C before 500 ng RNA was reverse transcribed with oligo-dT 
priming using the Transcriptor First Strand cDNA Kit (Roche Applied Science, South 
Africa) according to the manufacturer’s instructions. 
 
 
  
Antibody Dilution Secondary Dilution
GAPDH 1/20 000 α Mouse 1/15 000
GR 1/4 000 α Rabbit 1/5 000
HA 1/1 000 α Mouse 1/2 000
P-S203 1/10 000 α Rabbit 1/5 000
P-S211 1/10 000 α Rabbit 1/5 000
P-S226 1/10 000 α Rabbit 1/5 000
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Table 2.2: Primers used in real time PCR 
 
 
 
Equal volumes of each cDNA synthesis reaction were used as a template for 
quantitative real-time PCR, using primers for IκBα, MKP-1 and GAPDH as control 
(Table 2.2) as well as the SensiMix dT kit (Quantace, UK) and a Corbett real time 
PCR machine, according to the manufacturer’s instruction. The cycling parameters 
consisted of an initial 10 minute denaturation at 95°C, followed by 30-35 cycles of 10 
sec at 95°C, 15 sec annealing and 10 sec elongation at 72°C and a final 10 minute 
extension at 72°C. 
 
Melt curve analysis and 1% agarose resolving gel electrophoresis were performed to 
confirm the correct product had been amplified. Relative transcript levels were 
calculated and normalised to GAPDH abundance using the Pfaffl equation (Pfaffl, 
2001). 
 
                    
    
                    
                        
 
 
 
Where ES is the primer efficiency of the target/sample gene, ER is the efficiency of 
the reference gene and Ct is the cycle number at the threshold crossing. 
 
 
2.7. Immunofluorescent microscopy 
 
COS1 cells were seeded at a density of 4.0x105 cells per well in DMEM-10 in 6 well 
tissue culture plates (containing sterile glass coverslips which had been washed 
 GAPDH FWD TGA ACG GGA AGC TCA CTG G
GAPDH REV TCC ACC ACC CTG TTG CTG TA
IκBα FWD ACT CGT TCC TGC ACT TGG CC
IκBα REV TGC TCA CAG GCA AGG TGT AG
MKP-1 FWD AGT ACC CCA CTC TAC GAT CAG G
MKP-1 REV TGA TGG AGT CTA TGA AGT CAA TGG 250 Rauhala et al ., 2005
307 Ishibashi et al ., 2003
238 Emmerich et al ., 1999
Primer Product (bp) ReferenceSequence (5'-3')
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twice in 3.2% HCl for 30 minutes) twenty four hours before changing medium to 
charcoal stripped DMEM-10 and transfection. Cells were transfected with 1.0 μg of 
the rGR plasmid and 1.5 μg HA Vpr per well where appropriate (750 ng rGR and 500 
ng HA Vpr per ml) using F6, according to manufacturer’s instructions (Roche). 
Twenty four hours later cells were stimulated for an hour in SF-DMEM with 100 nM 
DEX or vehicle (EtOH). 
 
After stimulation the cells were washed twice with ice-cold PBS, permeablised with 
methanol (MeOH) for 10 minutes at -20°C, before three washes with PBS at room 
temperature and blocked with 5% (w/v) BSA (Roche Diagnostics, South Africa) 
prepared in PBS, for 1 hour at room temperature. After blocking, cells were 
incubated with primary antibodies (Table 2.3) (diluted in 5% BSA) for 1 hour in a 
humidified environment at room temperature, and subsequently washed three times 
with 1% BSA/PBS containing 0.05% triton X-100 (Sigma Aldrich, South Africa). Cells 
were then stained with fluorophore-conjugated secondary antibodies (prepared in 
5% BSA) in a humidified environment in the dark for an hour at room temperature 
and washed as indicated above.  
 
 
Table 2.3 Dilutions of primary and conjugate fluorophores used in immunofluorescence 
 
 
 
 
Cells were stained in 100 μg/ml Hoechst (Sigma Aldrich, South Africa) for 5 minutes 
at room temperature and mounted using Mowiol (475904, Calbiochem, USA). Slides 
were allowed to set overnight and stored at 4°C in the dark until visualisation. 
Imaging of the slides was performed with a Zeiss Axiovert 200M LSM 510 Meta NLO 
Confocal Microscope using the 40X water immersion objective lens. A multi-track 
scanning configuration using the 488 nm (HeNe gas laser), 561 nm (solid state laser) 
and 633 nm Argon laser to photo-excite and visualise the fluorophores was used. At 
Primary Antibody Dilution Fluorophore Dilution
mouse GR BuGR22 1/250 Cy3 1/1 000
HA Y11 1/200 Alexa488 1/250
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least three different fields of view from three independent experiments were collected 
and analysed using LSM image analysis software. 
 
The pSVL-rGR plasmid (rGR) was used here because the 12CA5 (Roche) primary 
HA antibody bound non-specifically to the mitochondria. This was rectified through 
using a different HA primary antibody (Y11 Santa Cruz) which required a rabbit 
secondary antibody. As the human GRα antibody (p300, Santa Cruz) is also 
generated in rabbits, a different GR expressing plasmid had to be used. The rGR 
was most favourable as it was generated in mice, and could be used in conjunction 
with the only other available fluorophore, Cy3, which is conjugated to a mouse 
secondary antibody. The BuGR22 rGR antibody resulted in non-specific nuclear red 
spots in COS1 cells (Figure 5.2). Although this may have led to interference with the 
quantification process and cast doubt over the certainty of the receptor subcellular 
distribution, it was assumed it would be of equal intensity across all conditions. 
 
2.8. Statistical and graphical analysis 
 
All results were plotted using Graph Pad Prism version 5 (Graph Pad Software Inc.) 
and statistical analysis performed with STATISTICA version 10 (Statsoft Inc.). A two-
way ANOVA test was used to determine whether in general the whole -Vpr group 
was significantly different to the whole +Vpr group (A). A Fishers Least Significant 
Differences post-hoc test was then used to compare all columns to each another. 
Selected columns were paired to note the effect of ligand stimulation vs. vehicle in 
cells lacking Vpr and similarly the effect of ligand stimulation vs. vehicle in cells 
expressing Vpr, or similarly each ligand’s partial agonist activity, expressed as a 
percentage of DEX (B). In cells expressing Vpr, stimulations were matched and 
compared to the corresponding stimulation in the absence of Vpr (C) (e.g. -Vpr EtOH 
vs. +Vpr EtOH and -Vpr DEX vs. +Vpr DEX etc.). The level of significance was 
indicated as *, **, or *** to indicate p<0.05, p<0.01, or p<0.001 respectively. 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
54 
 
E
tO
H
D
E
X
M
P
A
N
e
tA P
4
C
o
rt
D
E
X
+
R
U
4
8
6
E
tO
H
D
E
X
M
P
A
N
e
tA P
4
C
o
rt
D
E
X
+
R
U
4
8
6
0
-Vpr +Vpr
 
E
tO
H
D
E
X
M
P
A
N
e
tA P
4
C
o
rt
D
E
X
+
R
U
4
8
6
E
tO
H
D
E
X
M
P
A
N
e
tA P
4
C
o
rt
D
E
X
+
R
U
4
8
6
0
-Vpr +Vpr
E
tO
H
D
E
X
M
P
A
N
e
tA P
4
C
o
rt
D
E
X
+
R
U
4
8
6
E
tO
H
D
E
X
M
P
A
N
e
tA P
4
C
o
rt
D
E
X
+
R
U
4
8
6
0
100
-Vpr +Vpr  
 
E
tO
H
D
E
X
M
P
A
N
e
tA P
4
C
o
rt
D
E
X
+
R
U
4
8
6
E
tO
H
D
E
X
M
P
A
N
e
tA P
4
C
o
rt
D
E
X
+
R
U
4
8
6
0
-Vpr +Vpr
 
 
Figure 2.1 (A-C): Indications of statistical analysis. (A) A two way Analysis of Variance (ANOVA) 
test, comparing groups of ligand stimulations to test if Vpr caused a significant change in the group as 
a whole. (B) Fishers least significance differences post-hoc test, bars were compared to their 
corresponding condition’s vehicle only control (left) or to maximal DEX activity, indicating the partial 
agonist activity (right). (C) Fishers least significance differences post-hoc test, ligand stimulations 
were compared between the group expressing Vpr and group lacking Vpr. 
 
A 
B 
C 
1--------11 1-1 ------I 
:f.L ..... ......... P.T .... .. 
• ~ ~l l 
1--------11 1-1 ------I 1-------11 11-------1 
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3. RESULTS 
 
3.1. Vpr increases GR-mediated transactivation of the 
TAT-GRE reporter gene 
 
Previous reports in the literature have indicated that Vpr acts as a GR co-activator, 
increasing GR-mediated transactivation of both endogenous genes and synthetic 
promoter-reporter constructs in the presence of the GR agonist DEX (Fakruddin and 
Laurence, 2005; Kino et al., 1999; Kino et al., 2002a; Sherman et al., 2000). In order 
to determine whether Vpr can act as a GR co-activator and increase transactivation 
in the presence of different GC and progestin ligands, COS1 cells were transiently 
transfected with a synthetic reporter (TAT-GRE) construct, as well as the hGRα in 
the presence and absence of HA Vpr, before stimulation with GC’s and progestins.  
 
Results show that in the absence of Vpr, DEX induced a statistically significant level 
of reporter gene activity, roughly 26 fold higher than basal. Significant induction was 
also observed with CORT, MPA, and P4, approximately 20, 17, and 5 fold 
respectively as compared to unstimulated cells. Stimulation with NET-A did not 
significantly increase reporter gene activity. Co-stimulation with DEX and RU486 did 
not significantly increase reporter gene activity above control, indicating that RU486 
antagonised the significant induction by DEX. In the presence of Vpr, a significantly 
higher level of reporter gene activity (Amax) was observed in general when comparing 
the +Vpr group to the -Vpr group (Figure 3.1A). Similar to the results obtained in the 
absence of Vpr; DEX, CORT, MPA, and P4 were able to significantly induce 
transcription above basal in the presence of Vpr (Figure 3.1A). Furthermore, when 
comparing the level of transactivation observed with MPA, P4, and NET-A 
stimulation in the absence of Vpr with the corresponding stimulations in the presence 
of Vpr, a significant increase was observed (coloured bars), indicating that Vpr acted 
like a co-activator under these ligand stimulations. Although Vpr dramatically 
increased reporter gene activity induced by DEX and CORT (26 to 57 and 20 to 45 
fold above basal respectively), both conditions had a high degree of error and these 
differences were not statistically significant (Figure 3.1A). 
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Figure 3.1 (A-E): Vpr increases GR-mediated transactivation of a TAT-GRE promoter-reporter 
plasmid (Continued). 
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Figure 3.1 (A-E): Vpr increases GR-mediated transactivation of a TAT-GRE promoter-reporter 
plasmid. COS1 cells were transfected in 10 cm dishes with hGRα, TAT-GRE and either HA Vpr or 
empty vector 24 hours prior to re-plating in 24 well plates. After re-plating the relative concentrations 
of GR and Vpr were 112 and 250 ng/ml respectively. After 24 hours incubation, cells were stimulated 
with ligands at the concentrations indicated in materials and methods for a further 24 hours. Samples 
were harvested in reporter lysis buffer before luciferase quantification in a Luminex luminometer with 
the Promega luciferase assay and normalisation to total protein as determined by Bradford protein 
assay. Data were either plotted as (A) a fold increase above vehicle in the absence of Vpr, which was 
set as equal to 1, (B) relative to each DEX response set as 100%, showing the partial agonist activity, 
or (C) as the fold increase of each stimulation above its respective basal, set as equal to 1. Figures D 
and E respectively show the difference (absolute increase) and fold induction (relative increase) in 
reporter gene activity mediated by Vpr from Figure 3.1A. Graphs show pooled data from 4 biological 
repeats each performed in triplicate. A Fishers least significant differences post-hoc test was used to 
determine if ligand stimulation caused a significant increase by comparing each stimulation to its 
respective vehicle (A and C), or if any ligand caused a significantly different efficacy to DEX (B). 
Additionally this test was used to compare ligand stimulations in the absence and presence of Vpr 
(coloured bars above histograms). A two way ANOVA was used to compare the groups containing or 
lacking Vpr as a whole. Statistical analysis was marked *, ** or *** to indicate significance levels of 
P<0.05, P<0.01 or P<0.001 respectively.  
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Interestingly Vpr significantly increased reporter gene transactivation under co-
stimulation with DEX and RU486, as well as the basal level of reporter gene activity, 
in the absence of ligand (Figure 3.1A). This suggests that Vpr may transactivate the 
TAT-GRE reporter gene in the presence of antagonist or absence of GC’s, an 
observation inconsistent with previous reports (Kino et al., 1999; Kino et al., 2002a). 
 
Setting maximal reporter gene activity (DEX) as 100% more clearly represents the 
partial agonist activity of other ligands and allows a clear representation of their 
relative biocharacters. The rank-order of transactivation efficacies in the absence of 
Vpr (Figure 3.1B) was similar to an earlier report (Ronacher et al., 2009) which had 
showed that DEX≥CORT>MPA>P4>NET-A, although in the published report NET-A 
did not show any transactivation agonist activity, whereas in Figuer 3.1B NET-A did 
increase reporter gene transactivation via the GR. NET-A, P4, and RU486/DEX all 
had significantly lower efficacies than DEX, with partial agonist activities of 13, 31, 
and 26% respectively. CORT and MPA had partial agonist activities of 76% and 60% 
respectively, which were not significantly different to DEX. This was an expected 
trend as CORT is a full agonist and MPA may act as a partial or full agonist. Vpr did 
not significantly change the biocharacter of any ligand or significantly increase 
percentage partial agonist activity of a ligand relative to its DEX response (Figure 
3.1B). Therefore, Vpr did not affect any ligands biocharacter, and the rank-order of 
efficacy for GR-mediated transactivation was unchanged in the presence of Vpr. This 
indicates that the relative fold increase in transactivation mediated by Vpr for each of 
the tested ligands and vehicle alone is roughly equal. Vpr slightly increased the basal 
level of reporter gene activity independently of ligand (Figure 3.1A), but does not 
cause the basal level of reporter gene activity to increase when compared to the 
maximal response (Figure 3.1B). It is possible that the increased GR-mediated 
transactivation in the presence of ligands and Vpr may be simply be due to the 
effects Vpr alone mediates on TAT-GRE transactivation in addition to ligand-
dependent GR-mediated transactivation, as opposed to Vpr acting as a GR co-
activator. 
 
In order to determine if the effect Vpr exerts on ligand-dependent GR-mediated 
transactivation is simply additive between the effects Vpr ligand-independently exerts 
and ligand-dependent GR-mediated transactivation, or is greater than the increase 
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that each of these alone mediate, data were plotted with both vehicle conditions set 
to 1 and reporter gene activity shown as a fold increase (Figure 3.1C). If Vpr was 
acting independently of, or in an additive manner with ligand stimulation, this would 
be indicated in Figure 3.1C as roughly equal fold inductions in the presence or 
absence of Vpr with each ligand stimulation, and if Vpr were acting as a ligand-
dependent co-activator, the fold induction of each ligand relative to its own basal 
control would be higher in the presence of Vpr. Neither of these is true as in the 
presence of Vpr the fold increase above basal for all ligand stimulations excepting 
NET-A, were significantly lower than the fold increase above basal in the absence of 
Vpr. It appears that Vpr did increase the maximal level of ligand-dependent, GR-
mediated transactivation, but in a manner that was less than additive with ligand 
stimulation, and that Vpr exerted more of an effect on the unliganded GR than it did 
on the ligand bound GR (Figure 3.1C). 
 
Data from Figure 3.1A was plotted alternatively to better give an indication of the 
extent by which Vpr increases reporter gene activity. Plotting the absolute 
differences in reporter gene activity, calculated by subtracting the luciferase/total 
protein values obtained in the absence of Vpr from the values obtained in the 
presence of Vpr reveals the absolute level by which Vpr increases reporter gene 
activity for each ligand. Vpr increased the absolute level of reporter gene activity to a 
greater extent when in the presence of strong agonists than it did in the presence of 
partial agonists (Figure 3.1D). Plotting the ratio by which reporter gene activity is 
enhanced by Vpr (+Vpr / -Vpr luciferase/total protein values) revealed that Vpr-
mediated a similar increase in reporter gene activity for each of the tested ligand 
stimulations, which ranged between a 3 and 6 fold increase (Figure 3.1E). Taken 
together, Vpr increases the absolute level of transactivation with all the GR ligands 
and progestins, but does not change the relative order of efficacies for GR-mediated 
transactivation of any of the ligands. 
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3.2. Vpr-mediated increases in GR driven TAT-GRE 
transactivation are dependent on DEX concentration 
 
The relationship between Vpr and ligand-dependent GR-mediated transactivation is 
not clear. Vpr may have increased reporter gene transactivation independently of GC 
stimulation (Figure 3.1A) or, as reported in literature (Kino et al., 1999; Sherman et 
al., 2000) requires ligand to be present for transcriptional effects to be observed. To 
determine if the concentration of ligand influences the effect of Vpr on GR 
transcriptional activity, a dose response curve using a range of DEX concentrations; 
from 10-13 to 10-6 M (Figure 3.2A) and two different transfected amounts (50 or 175 
ng per well) of HA Vpr was performed. Two different amounts of Vpr were 
transfected to additionally observe if the amount of Vpr influenced the relationship 
between Vpr, DEX concentration, and reporter gene transactivation. 
 
A standard sigmoidal dose response curve was observed with DEX stimulation of the 
GR (Figure 3.2A). This curve was then compared to dose response curves in which 
Vpr was present so that it could be elucidated which concentrations of DEX, if any, 
were required for Vpr to show an observable effect on GRE transactivation. All data 
were plotted as raw, relative light units / total protein instead of being shown as 
relative to any particular measure, as five different aspects of transactivation were 
investigated and this allowed all the data to be interpreted together. 
 
In the absence of Vpr, stimulation with DEX resulted in transactivation of the reporter 
gene in a sigmoidal dose-response manner, consistent with previous reports in 
literature (Ronacher et al., 2009). Very low levels of reporter gene transactivation 
were observed without ligand. Concentrations of DEX in excess of 10-11 M were 
required to induce an observable level of reporter gene activity (Figure 3.2A). The 
response increases exponentially with ligand concentration to 10-9 M before reaching 
a plateau or Amax, at 6.3x105 relative light units per unit protein at 10-7 M DEX 
(Figures 3.2A and D). Higher DEX concentrations did not further transactivation of 
the reporter gene with the same GR quantity, as the receptor is saturated. 
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Figure 3.2 (A-G): Vpr increases the relative efficacy of DEX via the GR without affecting the 
potency on a TAT-GRE reporter (Continued). 
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Figure 3.2 (A-G): Vpr increases the relative efficacy of DEX via the GR without affecting the 
potency on a TAT-GRE reporter. COS1 cells were seeded directly into 24 well plates and grown for 
24 hours prior to FuGene transfection with hGRα, TAT-GRE and 0, 50, or 175 ng HA Vpr or 
corresponding amounts of empty vector DNA as indicated. This equated to 350 ng/ml hGRα, and 100 
or 350 ng/ml HA Vpr. 24 hours later cells were stimulated with DEX at concentrations indicated for 24 
hours prior to harvesting, luciferase quantification, and total protein determination by Bradford’s 
assay. Graphs show three pooled results each performed in triplicate plotted as a variable log 
[agonist] vs. response curve. A two-way ANOVA (continuous variables) and Fishers least significant 
differences post-hoc test was used for statistical analysis and marked *, ** or *** to indicate 
significance of P<0.05, P<0.01 or P<0.001, respectively. Significant differences are all shown 
compared to 0 ng HA Vpr; indicating the effects of Vpr on GR-mediated reporter gene transactivation 
across a range of DEX concentrations (A), how Vpr affects DEX potency (B), The effect of Vpr on the 
Hill slope (C), how Vpr effects maximal DEX efficacy (D), and how Vpr effects the basal level of 
reporter gene activity (E). Additionally data were analysed with fixed log [agonist] vs. response slopes 
(F) and the EC50’s also shown (G). 
F 
G 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
63 
 
All three dose response curves at DEX concentrations lower than 10-10 M are 
indistinguishable from each other. At higher DEX concentrations Vpr was observed 
to greatly increase reporter gene activity above the level that DEX alone exerts. Vpr 
increases GR-mediated transactivation dependently on DEX concentration, with 
greater levels of reporter gene activity induced by Vpr being observed at higher DEX 
concentrations (Figure 3.2A). A greater amount of Vpr also caused a greater 
increase in reporter gene activity, indicating a relationship between the amount of 
Vpr present and the level of ligand-dependent GR-mediated reporter gene 
transactivation. Vpr increases the efficacy of DEX, increasing the Amax above the 
level which DEX alone induces for transactivation of the TAT-GRE reporter gene.  
 
Comparing the EC50 values obtained in the absence and presence of Vpr showed 
that Vpr did not significantly change DEX potency. In the absence of Vpr the EC50 
was 0.5 nM. In the presence of 50 and 175 ng transfected Vpr the EC50’s were 0.3 
and 0.7 nM respectively. Both were similar to the EC50 of DEX in the absence of Vpr 
and neither of these values is a statistically significant difference, indicating Vpr does 
not change DEX potency (Figure 3.2B). A co-activator that increases ligand efficacy 
might have been expected to decrease, rather than increase the EC50 values.  
 
The Hill slope is a measure of the co-operative binding of ligand to a macro-
molecule. This was not significantly changed in the presence of Vpr. If Vpr were 
acting as a GR ligand and increasing receptor dimerisation and steroid binding 
affinity this would have increased the Hill slope. The Hill co-efficient for the GR alone 
was 0.5. As this value is less than 1 it indicates that DEX binding was negatively co-
operative and that DEX binding reduces GR affinity for further ligand binding. In the 
presence of both amounts of Vpr the Hill slopes were slightly increased (0.9 for 50 
ng and 0.7 for 175 ng), but still less than 1, indicating DEX/GR binding is negatively 
co-operative in the presence of Vpr (Figure 3.2C). These are insignificant increases, 
and it was assumed that Vpr did not affect the co-operation of DEX/GR binding.  
 
If Vpr does increase the Hill co-efficient or affect the EC50 value of DEX, the changes 
it mediates are lower than the level of error and thus not observable in an assay of 
this type. 
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Showing reporter gene activity obtained at saturating (10-6 M) ligand concentrations 
indicates the effects of Vpr on DEX efficacy. Neither amount of Vpr significantly 
increased the Amax, although both had mean values higher than the absence of Vpr, 
and the greater amount of Vpr resulted in a greater extent of transactivation of the 
reporter than the lower amount did (Figure 3.2D). This indicated that the 
transactivation of the reporter gene by Vpr in conjunction with DEX is dependent on 
the amount of Vpr present. It is difficult to determine if Vpr increases the 
Amax significantly without further experimental repeats being done as these observed 
increases are also below the level of experimental error. 
 
The effect of Vpr in the absence of ligand is too small to be directly observed on the 
dose response curve. However, plotting reporter gene activity obtained with vehicle 
alone, shows there is a slight but significant increase from the basal level of reporter 
gene activity resulting from transfection of Vpr (Figure 3.2E). Both amounts of Vpr 
induced similar increases, which were less than 0.01% of the magnitude mediated 
by 1 μM DEX stimulation.  
 
Although Vpr did mediate a significant increase in reporter gene activity in the 
absence of ligand (Figure 3.2E), a larger Vpr-mediated increase in reporter gene 
activity was observed at greater ligand concentrations, arguing against Vpr acting 
independently of DEX stimulation of the GR. This indicates that Vpr acts in a manner 
that is related to DEX concentration and DEX mediated increases in reporter gene 
activity, and thus also acts in combination with the GR.  
 
Plotting the same data with fixed, as opposed to variable slopes (Figure 3.2F) did not 
alter the relative positions of the Amax relative to each other, nor did it show an 
observable increase in the basal level of reporter gene activity. Using fixed slope 
curves (Hill co-efficient = 1) to calculate the EC50 values does not show Vpr to have 
an effect of changing the EC50 above the level of error or statistical power of the 
experiment (Figure 3.2G). 
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3.3. Vpr increases GR turnover 
 
Having investigated the effects that Vpr exerts on GR-induced reporter gene 
transactivation, non-transcriptional markers of GR activation were studied. Several 
parameters that indicate GR activation, including GR turnover, phosphorylation, and 
nuclear localisation were investigated. This was done to try and understand the 
mechanism by which Vpr increased GR-mediated reporter gene transactivation. 
Firstly, to determine how turnover was affected by Vpr, GR levels were quantified 
after 24 hours of ligand stimulation, either in the absence or presence of Vpr.  
 
In the absence of Vpr, 24 hours of stimulation with DEX caused a significant 
reduction in GR levels (Figures 3.3A lanes 2 vs. 1 and 3.3B). Turnover under DEX 
stimulation was expected owing to the full agonist nature of this steroid and the short 
GR half-life it causes (44 hours). MPA, NET-A, P4 and CORT did not increase 
turnover (Figure 3.3A, lanes 3, 4, 5, and 6 vs. 1) and showed GR levels not 
statistically different to that of the vehicle (Figure 3.3B). This was unexpected in the 
case of CORT, and to a lesser degree MPA, as these are full agonists and as such 
would be expected to cause ubiquitination and the subsequent degradation of the 
GR. Additionally both of these steroids decrease the GR half life to 12 and 17 hours 
respectively, both of which are less than the time point investigated in this study (24 
hours) (Avenant et al., 2010b). GR levels in the presence of MPA, NET-A, P4 and 
CORT were slightly but insignificantly higher than the level of vehicle alone (Figure 
3.3B).  
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Figure 3.3 (A-C): Vpr decreases GR levels. COS1 cells were seeded directly into a 12 well TC plate 
and incubated at 37°C for 24 hours prior to transfection with HA Vpr or empty vector (350 ng/ml) and 
hGRα (350 ng/ml) using FuGene. Cells were stimulated with ligand at the concentrations indicated in 
materials and methods for 24 hours before harvesting in a 2x SDS sample buffer and resolved on 
10% PAGE before transfer to nitrocellulose membrane probed for the presence of GR, GAPDH, and 
the HA tag. Protein bands were scanned and quantified with Alpha-ease FC software, and total GR 
integrated density value (IDV) was normalised to the intensity of the GAPDH IDV. A representative 
Western blot is shown (A) and histograms (B and C) show pooled data from three biological repeats. 
A Fishers least significant differences post-hoc test was used to determine if ligand stimulation 
caused a significant increase by comparing each stimulation to its respective vehicle (B), or if ligand 
stimulations in the absence and presence of Vpr were different (coloured bars above histograms). A 
two way ANOVA was used to compare the groups containing or lacking Vpr as a whole. Statistical 
analysis was marked *, ** or *** to indicate significance levels of P<0.05, P<0.01 or P<0.001, 
respectively. 
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In the presence of Vpr, a significantly greater extent of turnover was observed with 
NET-A, P4, and CORT stimulations when compared to the corresponding 
stimulations in the absence of Vpr (Figure 3.3B, coloured bars). A slight degree of 
DEX-dependent turnover was observed, but not statistically significant (Figure 3.3A, 
lanes 8 vs. 7 and Figure 3.3B), and was found to be similar to the level of GR 
stimulated with DEX in the absence Vpr (Figure 3.3B). Vpr caused a slight reduction 
in unliganded GR levels, but this was not significant (Figure 3.3B). Considering the 
transfection conditions as a whole, Vpr caused an overall significant reduction in GR 
levels (Figures 3.3B, right vs. left). This indicates that the overall increased reporter 
gene activity in the presence of Vpr (Figure 3.1A) cannot be explained simply by 
increased GR levels or stability. 
 
Vpr levels were unchanged by ligand stimulation (Figure 3.3C), indicating that Vpr is 
not degraded in the proteasome in conjunction with the GR and that ligand 
stimulation of the GR does not affect expression of Vpr. 
 
 
3.4. Vpr does not affect ligand-dependent serine 203, 211, 
or 226 GR phosphor lation 
 
Phosphorylation of serine residues 203, 211 and 226 has previously been shown to 
increase in response to ligand stimulation (Avenant et al., 2010b; Weigel and Moore, 
2007). The effect Vpr has on phosphorylation of these residues is not yet known. It 
was hypothesised that Vpr may increase ligand-dependent GR phosphorylation at 
S203, S211 and S226. Additionally phosphorylation of one or more of these residues 
is required for co-activator recruitment (Avenant et al., 2010a) which could explain 
how GR-mediated transactivation is increased in the presence of Vpr (Figures 3.1A 
and 3.2A). In order to determine how Vpr affects GR phosphorylation, COS1 cells 
transiently transfected with hGRα and HA Vpr or empty vector were stimulated with 
different ligands for an hour and a Western blot was performed with GR phospho-
specific antibodies for phosphorylated serine residues 203, 211, or 226. Blots were 
stripped and re-probed for normalisation of phosphorylation to total GR levels. 
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Figure 3.4 (A-F): Vpr does not affect the phosphorylation of the GR at S203, S211, or S226 in 
the absence or presence of ligands. COS1 cells were plated directly into 12 well plates and grown 
for 24 hours prior to transfection with 350 ng hGRα and either 350 ng HA Vpr or empty vector using 
FuGene. Cells were stimulated for an hour using concentrations of ligand as indicated in materials 
and methods before harvesting in 2x SDS sample buffer and resolved on 10% PAGE and transferred 
to a nitrocellulose membrane. Membranes were probed for the presence of GR, GAPDH, HA tag, and 
phosphorylated GR serine residue 203 (A and B), anti phosphorylated GR serine residue 211 (C and 
D), or phosphorylated GR serine residue 226 (E and F). Protein bands were scanned and quantified 
with Alpha-ease FC software, and phospho-GR IDV was normalised to the intensity of the total GR 
IDV. Representative Western blots are shown (A, C, E) and histograms (B, D, F) show pooled data 
from at least two biological repeats. A Fishers least significant differences post-hoc test was used to 
determine if ligand stimulation caused a significant increase by comparing each stimulation to its 
respective vehicle, or if ligand stimulations in the absence and presence of Vpr were different (bars 
above histograms). A two way ANOVA was used to compare the groups containing or lacking Vpr as 
a whole. Statistical analysis was marked *, ** or *** to indicate significance levels of P<0.05, P<0.01 
or P<0.001, respectively. 
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In the absence of Vpr, ligand stimulation did not significantly change the extent of 
GR S203 phosphorylation in COS1 cells after an hour of stimulation (Figures 3.4A, 
lanes 1-6 and 3.4B) although DEX and CORT did show a small but insignificant 
increase above basal. Vpr had no effect on the phosphorylation status of GR S203, 
either in the absence or presence of any ligand (Figure 3.4B).  
 
All tested ligands excepting NET-A, the weakest ligand in terms of GR 
transactivation efficacy tested here, significantly increased the extent of S211 
phosphorylation in the absence of Vpr when compared to basal. DEX induced 
phosphorylation above basal to the greatest extent, followed by CORT, MPA, and P4 
respectively (Figure 3.4D). The rank-order of ligand induced phosphorylation of this 
residue was not inconsistent with the rank-order of ligand induced reporter gene 
transactivation efficacy from a previous report (Ronacher et al., 2009). In the 
presence of Vpr, S211 phosphorylation was also ligand-dependent, with the tested 
ligands displaying a very similar biocharacter in the presence of Vpr as they did in its 
absence (Figure 3.4D). Vpr did not change the basal level of S211 phosphorylation, 
or significantly increase the extent of ligand-induced S211 phosphorylation (Figure 
3.4D).  
 
GR S226 phosphorylation was increased significantly in response to ligand 
stimulation (Figure 3.4E lanes 2, 3, 4, 5, and 6 vs. 1). DEX induced a 2.5 fold 
increase, while CORT, MPA, P4, and NET-A all significantly increased 
phosphorylation, by 2.1, 1.9, 1.7, and 1.5 fold, respectively (Figure 3.4F). Ligand-
dependent phosphorylation of S226 was found to be highly reproducible, and as with 
phosphorylation of S211, the rank-order of ligand induced phosphorylation of this 
residue was also not inconsistent with the established rank-order of ligand induced 
reporter gene transactivation efficacy (Ronacher et al., 2009). Transfection of Vpr 
exerted no overall significant effect on S226 phosphorylation (Figure 3.4F, right vs. 
left), although Vpr did induce a small and statistically significant increase in S226 
phosphorylation in the absence of ligand (Figure 3.4E lanes 7 vs. 1 and Figure 3.4F). 
Ligand-dependent S226 phosphorylation was not affected by transfection of Vpr, as 
all ligand stimulations showed similar levels of S226 phosphorylation when 
compared to their corresponding stimulations in the absence of Vpr (Figure 3.4F). 
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3.5. Vpr does not result in ligand-independent GR 
phosphorylation at S226 
 
The previous result showed that Vpr increased S226 phosphorylation in the absence 
of ligand (Figure 3.4F). To further investigate this, five different concentrations of the 
HA Vpr construct were transfected in the absence of ligand and the relative extent of 
phosphorylated S226 was compared to a control not transfected with Vpr (0 ng). It 
was hypothesised that the extent of S226 phosphorylation would correlate with 
amount of Vpr present.  
 
The same amount of DNA transfected per well in Figure 3.4 (350 ng per well), had 
no effect on S226 phosphorylation. Indeed, in the absence of ligand, no amount of 
transfected Vpr significantly increased S226 phosphorylation above the basal level, 
and no trend correlating the amount of transfected Vpr with S226 phosphorylation 
was observed (Figure 3.5B). No transfected amount of Vpr affected expression of 
the GR (Figure 3.5C) and as expected, expression levels of Vpr protein significantly 
increased with increasing amounts of transfected Vpr expression vector (Figure 
3.5D). 
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Figure 3.5 (A-D): Vpr does not increase GR phosphorylation at S226 in the absence of ligand. 
COS1 cells seeded directly into 12 well plates were grown for 24 hours prior to transfection with 350 
ng hGRα and the indicated amount of either the HA Vpr or empty vector per well using FuGene. 
Twenty four hours after transfection cells were serum starved without ligand for an hour. Cells were 
harvested in a 2x SDS buffer and resolved on 10% PAGE before transfer to nitrocellulose membrane. 
Protein bands were scanned and quantified with Alpha-ease FC software. A Western blot, 
representative of two biological repeats is shown (A). Histograms show the average of two biological 
repeats. A two-way ANOVA using continuous variables test was used to indicate the significance of 
the correlation between the amount of transfected HA Vpr and phosphorylation of S226 (B), total GR 
levels (C), or Vpr protein levels (D). Histograms were marked *, ** or *** to indicate significance of 
P<0.05, P<0.01 or P<0.001, respectively. 
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3.6. Vpr does not increase rGR nuclear translocation  
 
Prior to the induction of transcription, the GR needs to access the nucleus and 
associate with responsive promoters. The effects Vpr may have on GR nuclear 
translocation were investigated through fluorescent microscopy. It was hypothesised 
that Vpr would cause an increase in the nuclear proportion of the GR in both the 
presence and absence of DEX stimulation thereby increasing transactivation of the 
TAT-GRE reporter gene as observed in Figures 3.1A and 3.2A. 
 
The presence of extra-nuclear DNA in all conditions (Figure 3.6A I-VI) was thought to 
be contamination from Mycoplasma spp. an intracellular pathogen which reveals a 
similar staining pattern if cells are contaminated. The cytoplasmic DNA spots were 
found not to be due to contamination but rather due to excess plasmid DNA. This 
was determined by a transfection negative control showing no cytoplasmic DNA, 
whereas cells that had been transfected showed a Hoechst stain in this manner 
(Figure 5.2). High amounts of DNA needed to be transfected in order for sufficient 
protein expression to allow visualisation under immunofluorescence, and accordingly 
COS1 cells were transfected with 750 ng rGR and 500 ng HA Vpr per ml culture 
medium which was in excess of the concentrations used in the previous assays.   
 
In the absence of ligand the GR resides predominantly in the cytoplasm. The 
nucleus is not entirely vacant of Cy3 signal, indicating a small quantity of unliganded 
GR is present in the ucleus (Figure 3.6A I), in agreement with previous literature 
(Hache et al., 1999; Savory et al., 1999). GR nuclear localisation was calculated by 
expressing Cy3 fluorescent signal in the nucleus as a fraction of the total cell Cy3 
fluorescent signal (nuclear/whole cell GR signal). This was then plotted as a relative 
fold induction above the unstimulated basal not expressing Vpr, as a measure to 
indicate the increase in nuclear translocation that DEX and/or Vpr mediate (Figure 
3.6B). Stimulation of COS1 cells with 100 nM DEX for an hour causes the Cy3 
fluorescent signal to be located nearly entirely in the nucleus (Figure 3.6A II). Areas 
of intense Hoechst stain represent densely packaged chromatin. The liganded GR is 
vacant from such areas (Figure 3.6A II, yellow arrows). DEX stimulation causes a 
significant 3.2 fold increase in rGR nuclear translocation (Figure 3.6B). 
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Figure 3.6 (A-B): HA Vpr does not affect the extent of rGR nuclear translocation. COS1 cells 
were seeded at a density of 4x104 cells/ml directly into a 6 well plate on sterile glass cover slips. After 
24 hours the medium was changed to charcoal stripped DMEM-10 and cells were either transfected 
with 1 μg of the rat-GR (rGR) only, 1.5 μg HA Vpr only, or both 1 μg rGR and 1.5 μg HA Vpr as 
indicated per well using FuGene. After an additional 24 hours, cells were stimulated in SF DMEM for 
an hour with 100 nM DEX or vehicle (EtOH). Cells were fixed and permeablised with methanol before 
addition of the primary α-mouse GR and α-HA (Vpr) antibodies. After an hour cells were washed and 
stained (according the manner described in the materials and methods). The Cy3 secondary antibody 
emits a red signal, indicating the location of the GR, and the Alexa488 conjugated fluorophore emits a 
green signal, indicating the subcellular location of the HA tag (Vpr), and the Hoechst dye stains DNA 
light blue. Yellow arrows indicate areas of densely stained chromatin which lack GR and/or Vpr 
fluorescent signal. Three biological repeats were done, each with at least three different fields of view 
being studied on each slide with a representative image shown (A). Slides were viewed with a Zeiss 
LSM510 Meta confocal microscope using the 40x objective lens, and quantified for fluorescent 
intensity using the LSM image analyser software. The histogram shows the pooled average of GR 
nuclear localisation. This was measured by quantifying the Cy3 fluorescent intensities, and plotted as 
a ratio of nuclear/whole cell intensity (B). A two-way ANOVA and Fishers least significant differences 
post-hoc test was used for statistical analysis and marked *, ** or *** to indicate P<0.05, P<0.01 or 
P<0.001, respectively when comparing DEX stimulation to the basal for each condition.  
 
 
Vpr has been extensively reported to be a constitutively nucleophilic protein (Agostini 
et al., 2002; Thotala et al., 2004). In agreement with this, when Vpr was transfected 
into COS1 cells without the rGR, it was found to be completely nuclear and the 
presence or absence of DEX had no effect on the subcellular localisation of Vpr 
(Figures 3.6A III and IV). This indicates that Vpr nuclear translocation is not 
dependent on DEX stimulation or the presence of the receptor. In a manner similar 
to the liganded GR being vacant from areas of heterochromatin, Vpr was not found 
B 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
75 
 
at areas of intense Hoechst stain, indicating that Vpr likely resides at euchromatic 
DNA regions (Figure 3.6A III, yellow arrows). 
 
In the absence of DEX, it appears that Vpr may have a small effect in the subcellular 
distribution of the rGR. Unstimulated cells expressing both Vpr and the rGR were 
frequently shown to have a higher GR nuclear signal (Figure 3.6A V) than 
unstimulated cells expressing the rGR only (Figure 3.6A I). Inside the nucleus, the 
unliganded GR and Vpr are both vacant from the same sub-nuclear regions (Figure 
3.6A V, yellow arrows). However, quantification of nuclear and total cell GR signal 
intensity using LSM image analyser software revealed that Vpr had no significant 
effect on the nuclear/cytoplasmic distribution of the unliganded rGR (Figure 3.6B).  
The discrepancy between the representative images and the fluorescent 
quantification data may be explained by one of two phenomena. Firstly, the data in 
Figure 3.6B is an average of all quantified slides, and whilst it did appear that Vpr 
frequently caused increased nuclear translocation of the GR (Figure 3.6A V), this 
may not accurately represent the situation in every single quantified slide, as the 
image in Figure 3.6A V represented a frequent occurrence that was apparent to an 
observer. However, it is possible that the trend could not be accurately measured 
using this type of fluorescent quantification. Secondly, the presence of non-specific 
nuclear red spots (Appendix 5.2) may have interfered with the quantification process, 
rendering the quantification of nuclear GR fluorescence inaccurate, and 
consequentially the data in Figure 3.6B not to be a true reflection of the GR 
subcellular distribution. 
 
Vpr also did not affect the extent of nuclear localisation of the DEX-activated rGR 
(Figure 3.6A VI). As DEX stimulation causes almost total GR nuclear translocation, 
any increase in liganded rGR nuclear import through Vpr would be difficult to 
separate from the nuclear import caused by ligand activation alone.  
 
Taken together, Vpr did not increase the nuclear proportion of the rGR in the 
absence of ligand or in the presence of DEX (Figure 3.6B). Reciprocally, the 
subcellular localisation of Vpr is unaffected by the presence of the receptor whether 
inactive (Figure 3.6A V) or ligand bound (Figure 3.6A VI). 
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3.7. Vpr does not enhance GR-mediated regulation of 
endogenous MKP-1 mRNA 
 
MKP-1 was chosen as a suitable endogenous target gene to study the effects of 
ligand stimulation and Vpr as it has previously been shown to be regulated by the 
GR and is maximally expressed after short term GC stimulations (1-8 hours) (Shipp 
et al., 2010; Wu et al., 2005). The expression of MKP-1 mRNA was studied in both 
COS1, and human END cells which express endogenous GRα. As END cells 
express endogenous GR they are a more physiologically relevant system to study 
the effects of Vpr on GR signalling. END cells also express the MR, AR, and ER but 
not the PR-B (Verhoog, 2010).  
In COS1 cells MKP-1 mRNA expression was significantly increased approximately 
2.7 fold in the presence of DEX and nearly 2.0 fold in response to CORT stimulation 
in the absence of Vpr. MPA, NET-A and P4 did not significantly increase MKP-1 
mRNA abundance (Figure 3.7A). However in the presence of Vpr, only DEX and P4 
resulted in a significant increase in MKP-1 mRNA expression above vehicle. When 
comparing corresponding stimulations in the presence and absence of Vpr, no ligand 
showed any significant difference in MKP-1 mRNA levels. Furthermore, as a whole, 
the +Vpr group is not significantly different to the -Vpr group (Figure 3.7A).  
 
In the absence of Vpr the tested ligands all display similar partial agonist activities 
which are significantly lower than the DEX response. In the presence of Vpr, P4 has 
a partial agonist activity that is not significantly different to that of DEX, indicating Vpr 
has mediated a change to its biocharacter (Figure 3.7B). 
 
Variances in expression of MKP-1 mRNA with ligand stimulation cannot be attributed 
to variances in GR expression levels. Although the Western blot is only indicative of 
one biological repeat, the intensity of the GR signal with DEX stimulation appears to 
be only slightly reduced below basal indicating turnover after four hours (Figure 
3.7C). Other than DEX, no form of stimulation increased turnover and the expression 
of Vpr had no ligand-dependent or -independent effect on GR levels in COS1 cells at 
this time point. 
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Figure 3.7 (A-F): Vpr has no effect on MKP-1 mRNA abundance in the presence of different 
GC’s and progestins. COS1 (A-C) and END (D-F) cells seeded in 12 well plates were grown for 24 
hours before transfection with HA Vpr or empty vector, and hGRα (COS1 only). Cells were stimulated 
for four hours at the concentrations shown in materials and methods. Total RNA was isolated, reverse 
transcribed into cDNA, and MKP-1 mRNA abundance was measured by real-time PCR and quantified 
relative to GAPDH (A, B, D, E). Graphs show pooled data of at least two biological repeats. For 
Western blotting (C, F) cells were harvested in 2x SDS sample buffer before 10% PAGE. A two-way 
ANOVA and Fishers Least Significant Differences post-hoc test was used for statistical analysis and 
marked *, ** or *** to indicate P<0.05, P<0.01 or P<0.001, respectively. Statistics show significance as 
compared to each EtOH (A and D) or DEX (B and E) and between corresponding stimulations in the 
presence and absence of Vpr. 
 
 
In END cells, stimulation with DEX, MPA, CORT and P4 significantly increased 
MKP-1 mRNA abundance 5.0, 2.9, 2.7, and 1.7 fold respectively, whereas NET-A 
did not (Figure 3.7D). In the presence of Vpr DEX, CORT and MPA stimulations 
significantly increased MKP-1 mRNA expression above vehicle, but none of the 
ligands exhibited a significantly different effect compared to their corresponding 
stimulation in the absence of Vpr and the +Vpr group was not significantly different 
from the -Vpr group. Vpr did appear to increase the level of MKP-1 mRNA in the 
absence of ligand by 1.5 fold although this was insignificant (Figure 3.7D). 
 
In the absence of Vpr, the relative trend of transactivation efficacies with 
DEX>MPA≥CORT>P4>NET-A was found to be in accordance with an earlier report 
(Ronacher et al., 2009), and what was observed in Figure 3.1. Vpr did not 
significantly change the partial agonist activity of any ligands, but the absolute basal 
level of MKP-1 expression, relative to DEX was observed to be significantly 
increased by the presence of Vpr (Figure 3.7E). 
 
Although the Western blot is only representative of one biological repeat, it appears 
that ligand stimulation did not cause an observable level of GR turnover or regulate 
Vpr expression, and Vpr had no effect on GR levels in END cells under these 
conditions (Figure 3.7F). 
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3.8. Vpr does not enhance GR-mediated regulation of 
endogenous IκBα mRNA 
 
Due to inconsistent results obtained with the reporter constructs, where Vpr 
increased GR-mediated transactivation, and for MKP-1 mRNA expression, where 
Vpr did not increase GR-mediated transactivation, the ability of the Vpr to increase 
GR-mediated transactivation on another endogenous GRE-containing gene was also 
investigated. IκBα represents a suitable candidate gene for study as it has a role in 
inhibition of pro-inflammatory signalling, which may be favourable for HIV-1 
replication and the promoter architecture, as with MKP-1, consists of at least two 
consensus GRE’s which are responsible for upregulation in response to ligand 
activation of the GR (Reddy et al., 2009). 
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Figure 3.8 (A-B): Vpr has no effect on IκBα mRNA abundance in the presence of different GC’s 
and progestins but does increase the partial agonist activity for some ligands relative to DEX. 
The same END cDNA samples used for MKP-1 real time analysis was also analysed for expression of 
the IκBα gene. END cells in 12 well plates were transfected with the HA Vpr empty vector 24 hours 
before ligand stimulation at the concentrations shown in materials and methods for four hours. Total 
RNA was isolated, reverse transcribed into cDNA, and IκBα abundance was measured by real-time 
PCR, before quantification relative to GAPDH. This is indicative of three biological repeats. A Western 
blot indicative of one biological repeat is shown in Figure 3.7F. A two-way ANOVA and Fishers Least 
Significant Differences post-hoc test was used for statistical analysis and marked *, ** or *** to 
indicate P<0.05, P<0.01 or P<0.001, respectively. Statistics show significance compared to each 
EtOH (A) or DEX (B) and between corresponding stimulations in the presence and absence of Vpr.  
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In the absence of Vpr, IκBα mRNA expression in END cells was significantly 
upregulated by DEX and MPA, 2.8 and 1.8 fold, respectively (Figure 3.8A). 
Stimulations with CORT, NET-A and P4 did not significantly increase IκBα 
expression. The presence of Vpr did not significantly increase IκBα mRNA 
expression for any tested ligand stimulation.  
 
Interestingly, under DEX stimulation, the abundance of IκBα mRNA appeared to be 
lower in the presence of Vpr than it was in the absence of Vpr (Figure 3.8B). 
However, this difference is not statistically significant. When plotted relative to their 
corresponding DEX stimulation, CORT and P4 were found to have a significantly 
higher partial agonist activity when in the presence of Vpr. Moreover, in the presence 
of Vpr, the biocharacter of all ligands was found not to differ significantly from DEX, 
whereas these same ligands partial agonist activities were significantly lower than 
DEX in the absence of Vpr. It was found that in general, the presence of Vpr caused 
the whole group of ligands to attain a higher relative biocharacter. The relative trend 
of transactivation efficacies was found to differ from what was observed previously, 
as in the absence of Vpr CORT did not act as a full GR agonist (Figure 3.8B). 
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4. DISCUSSION AND CONCLUSIONS 
 
Six different hypotheses were presented at the beginning of this study, each of which 
had an aim and strategies for investigation. For each of the hypotheses, the Figures 
showing results relevant to that hypothesis, and the relevant section in the 
discussion is included in Table 4.1 below. 
 
 
Table 4.1: Hypotheses, results and relevant sections in discussion 
 
 
 
SECTION PAGE
1
2
4.3 95
3
4
5
6
n/a
Nuclear translocation
Phosphorylation
Vpr regulates GR levels and turnover
Vpr enhances ligand-dependant GR phosphorylation 
at S203, S211, and S226
Turnover
Vpr increases nuclear localisation of the rGR in the 
absence and presence of ligand
Progestins will differently affect GR function when in 
the presence of Vpr, leading to changes in 
biocharacter and partial agonist activity
RESULTS
not hypothesised Figures 3.1A, 3.2D, 3.3B, 3.4F, 3.7A, 3.7D
Figures 3.1B, 3.3, 3.4, 3.7B, 3.7E, 3.8B
Figure 3.6
Figures 3.4, 3.5
Figure 3.3
Figure 3.2
Vpr increases ligand efficacy for transactivation of the TAT-GRE reporter gene, but not of endogenous 
MKP-1 and IκBα mRNA
Vpr effects resemble those of a weak, non-classical GR activator
HYPOTHESIS
Vpr is a GR co-activator and will ligand-dependently 
increase GR-mediated transactivation. This will occur 
to a greater extent in the presence of more efficacious 
ligands than it will for weaker ligands
Vpr increases both DEX efficacy and potency for GR-
mediated transactivation
Vpr mediates a much larger increase in MPA efficacy than it does for NET-A, and changes 
biocharacter in a ligand- and gene-specific manner
3.1A, 3.1D, 3.2A, 3.7A, 3.7D, 3.8A
4.1
4.2
4.3.1
4.3.2
Vpr increases GR turnover but does not change serine 203, 211, or 226 phosphorylation or nuclear 
translocation of the rGR
Vpr increases GR-mediated reporter gene transactivation dependently on DEX concentration but does 
not affect the DEX EC50
4.4
4.5
82
90
96
99
101
103
107
4.3.3
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4.1. Vpr increases ligand efficacy for transactivation of 
the TAT-GRE reporter gene, but not of endogenous 
MKP-1 and IκBα mRNA 
 
Previous reports in the literature have described Vpr as a GR co-activator (Agostini 
et al., 1999), with the ability to enhance DEX-mediated GRE driven reporter gene 
activity from the MMTV promoter and other synthetic GRE containing promoter-
reporter constructs in CEM, Jurkat, A204, HS27, (Kino et al., 1999; Kino et al., 
2002a; Kino et al., 2002b), HEK293, and CV-1 cells (Sherman et al., 2000). In this 
present study it was hypothesised that Vpr would act ligand-dependently (Table 4.1), 
and increase reporter gene transactivation to a greater extent in the presence of 
agonists than partial agonists. 
 
To investigate the hypothesis, reporter gene analysis with transiently expressed 
hGRα and HA Vpr was performed in COS1 cells. Vpr was observed to significantly 
increase the efficacy or maximal reporter gene activity (Amax) after a 24 hour 
stimulation with the ligands MPA, NET-A, P4 and DEX/RU486. A statistically 
significant increase to the efficacy of DEX or CORT was not observed in the 
presence of Vpr, most likely owing to the high degree of error observed with these 
ligand stimulations (Figure 3.1A). Interestingly, Vpr also mediated a small but 
statistically significant increase in reporter gene activity in the absence of ligand. 
RU486 has been observed by others to abrogate Vpr co-activation of the DEX 
activated GR in 293T and A204 cells (Kino et al., 1999; Sherman et al., 2000). In this 
present study, RU486 was found to abrogate DEX induction of the TAT-GRE 
reporter gene in both the absence and presence of Vpr, although a higher level of 
reporter gene activity was observed when in the presence of Vpr (Figure 3.1A). If the 
absolute increases in reporter gene activity mediated by Vpr are compared across 
ligand stimulations, it becomes clear that Vpr did not increase GR-mediated reporter 
gene transactivation equally for each ligand simulation. Rather, Vpr appears to 
mediate greater increases in the absolute level of reporter gene activity when the GR 
is stimulated with efficacious agonists than when it is stimulated with partial agonists. 
However these were not significant differences compared to each other (Figure 
3.1D). The relative fold induction by which Vpr increases GR-mediated reporter gene 
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transactivation, however appears similar in the absence and presence of all ligand 
stimulations (Figure 3.1E). In support of the original hypothesis, Vpr did significantly 
increase GR-mediated transactivation of the TAT-GRE reporter gene in the presence 
of ligands, and this appeared to be to a greater extent when in the presence of full 
agonists. It thus appears that Vpr enhanced ligand efficacy for transactivation of the 
reporter gene. Hypersensitivity to GC’s has been reported before in AIDS patients 
(Kino and Chrousos, 2001), and hence the observation of Vpr increasing GR ligand 
efficacies in this present study suggests a mechanism whereby this could occur. 
 
COS1 cells generally have very low GR expression (de Lange et al., 1997; Verhoog, 
2010) making the use of transiently transfected hGRα and the TAT-GRE reporter 
gene very practical in terms of measuring the specific effect of transfected Vpr on 
GR-mediated transactivation without significant interference from other SR’s. The 
TAT-GRE promoter contains two full length consensus GRE’s (Table 4.2), which 
ensures a high level of transcription driven from this promoter. For these reasons 
promoter-reporter assays in COS1 cells are a useful tool for investigating GR-
specific transcriptional affects, but are conversely not a physiologically relevant 
model. In addition to COS1 cells, END cells were also used for endogenous gene 
PCR as they express endogenous GR, negating the need for transfection of a GR 
expression vector. END cells also express the AR, MR, and ER, and are highly 
responsive to steroids (Verhoog, 2010). These cells are human in origin and derived 
from the endocervical epithelial cells of the female genital tract, a region which 
provides a barrier to sexually transmitted diseases making them a physiologically 
relevant system in which to study the effects of HIV-1 Vpr (Fichorova et al., 2002; 
Kaushic et al., 2010; Wira et al., 2005). 
 
In the present study, two candidate endogenous genes were selected to study the 
effect of Vpr on GR-mediated transactivation by real time PCR, primarily based on 
their responsiveness to GC stimulation through GRE’s in the promoter regions 
(Table 4.2), and secondarily on their likely relevance to HIV-1 infection through 
reported effects on immune function. These were MKP-1, a nuclear phosphatase 
which prevents MAPK signal transduction (Furst et al., 2007), and IκBα, a gene 
which inhibits NFκB by sequestration of the RelA subunit in the cytoplasm (Auphan 
et al., 1995). Based on the above promoter-reporter results, Vpr was also expected 
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to increase GR-mediated transactivation of both the MKP-1 and IκBα genes owing to 
their reported responsiveness to GC stimulation and the presence of putative GRE’s 
in their promoters (Table 4.2). 
 
 
Table 4.2: GRE-sequences from selected gene promoters relevant to this study 
 
 
 
 
GC induction of MKP-1 expression has been shown by others to be greatest 
between one and two hours of ligand stimulation in a variety of cell types, through 
five GRE like sites (Table 4.2) (Furst et al., 2007; Lasa et al., 2002; Shipp et al., 
2010; Tchen et al., 2010; Wu et al., 2005). In this present study, in both COS1 and 
END cells the abundance of MKP-1 mRNA was up regulated after four hours of 
ligand stimulation in a ligand-dependent manner, but expression was not significantly 
increased by Vpr (Figures 3.7A and 3.7D). IκBα expression has been previously 
shown to be upregulated by GC stimulation in a tissue specific manner (Han et al., 
1999; May and Ghosh, 1997; Scheinman et al., 1995) through several putative GRE 
half sites (Deroo and Archer, 2001) and two full length GREs (Table 4.2) (Reddy et 
al., 2009) and is greatest after four hours of ligand stimulation in A1-2 cells (Deroo 
and Archer, 2001). In the present study, after four hours of ligand stimulation in END 
cells it was found that although GC’s increased expression, Vpr did not significantly 
Gene name Number of GRE's Reference
Consensus n/a AGA ACA nnn TGT TCT Strähle et al., 1987
TGT ACA gga TGT TCT
GGA CTT gtt TGT TCT
GTT ACA aac TGT TCT
GGT ATC aaa TGT TCT
ACG TCT tag TGT TCT
ATT TTC tag TGT TCT
RANKL 1 TTT CCC gac TGT TCT Kitazawa et al.,  1999
TGG CCA ccc TGC GTC
GGA ACA ttc TGC CGT
TGG ACA gcg GAG CCT
GGG CCA ttg TGG CGC
CGC TCA ctg TGT ATA
GGA CGA agc CAT TCT
GGA ACC caa TGT TCT
CAA ACA ccg TGT TCA
CTG CAG ctt TGT TCT
GILZ 3 Wang et al.,  2004
2IκBα Heck et al.,  1997         Reddy et al.,  2009unknown
4MMTV-LTR
MKP-1 5 Shipp et al.,  2010  
TAT 2
Ham et al.,  1988
Grange et al.,  1991 
Sequence
GR transactivated genes containing GRE's
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affect the absolute level of IκBα mRNA transcripts for any of the tested ligands 
(Figure 3.8A). IκBα expression in COS1 cells could not be analysed as the available 
human primers did not anneal to cDNA from COS1 cells (data not shown). Published 
primers specific for IκBα from monkey cell lines could not be found online and the 
monkey genomic sequences are not available on the databases. Based on the 
effects Vpr had on IκBα expression in END cells, it was thought that designing new 
primers for use in COS1 cells would be a futile effort. 
 
Vpr has been observed to enhance GR-mediated mRNA and protein expression of 
the Receptor of Activated NFκB Ligand (RANKL) gene, which contains one GRE in 
the promoter (Table 4.2), in both PBMC and Jurkat cells (Fakruddin and Laurence, 
2005).Expression of the GRE containing Glucocorticoid Induced Leucine Zipper 
(GILZ) gene (Table 4.2) has previously been shown in both A549 and U2OS cells to 
respond to ligand stimulation of the GR with the same relative rank-order of GR 
transactivation efficacies that the tested ligands induced for TAT-GRE transactivation 
in published reports (Hadley et al., 2011; Ronacher et al., 2009). However, Vpr was 
not found to enhance GR-mediated transactivation of the GILZ gene in COS1 cells 
(Avenant et al., 2012, unpublished data). Besides the effect Vpr exerts on the GR at 
some GRE-containing promoters, Vpr also reduces induction of the synthetic NFκB 
driven promoter-reporter gene without DEX being present (Muthumani et al., 2006). 
Previous work in our laboratory has found Vpr to abrogate NFκB and AP-1 induction 
by TNF-α but not to enhance DEX-mediated suppression of these reporter genes 
(Avenant et al., 2012, unpublished data). Vpr has however been reported by others 
to enhance ligand-dependent, GR-mediated transrepression of the NFκB and AP-1 
regulated endogenous IL-12 gene (Mirani et al., 2002). The effects of Vpr on GR-
mediated transrepression were not investigated here, as it was beyond the scope of 
this project to study transrepression, and this present study was confined to 
transactivation only. These effects of Vpr on GR-mediated expression of the 
endogenous RANKL and IL-12 genes are consistent with Vpr acting as a GR co-
activator. However, unpublished data from our laboratory, as well as the limited 
published data for endogenous GR regulated genes, suggests that whether Vpr acts 
as a GR co-activator on all endogenous genes is controversial and requires further 
investigation. The effects of Vpr on global gene expression have been analysed 
through a microarray, where numerous genes regulated by Vpr were identified. This 
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study did not indicate whether the GR is also involved with expression of these 
genes (Janket et al., 2004), but did indicate that transactivation of Heat Shock 
Protein Factor 1 gene (HSF1) is increased 14-fold in the presence of Vpr (Janket et 
al., 2004). This is notable as HSF1 is a component of the GR chaperone complex 
and a major contributor to stress-induced activation of the GR (Li et al., 2000a), 
suggesting another indirect mechanism whereby Vpr could affect GR function. 
 
The differences in the results obtained on the reporter gene compared to the 
endogenous genes in the present study are interesting and intriguing and require 
some explanation. Discrepancies in GR-mediated transactivation between synthetic 
reporter and endogenous genes with similar promoter elements have been reported 
before. For example, the MMTV-Luc reporter gene and endogenous IκBα promoters 
share common GRE response elements, yet the endogenous IκBα promoter 
responded to both R5020 (a synthetic PR agonist) and GC stimulation, whereas a 
stably integrated MMTV promoter was only responsive to GC stimulation in T47D 
cells (Deroo and Archer, 2002). This was found to be a result of the “closed” 
chromatin structure of the stably integrated reporter gene, and the open/permissive 
nature of the chromatin around the endogenous IκBα promoter (Deroo and Archer, 
2001; Deroo and Archer, 2002). However, this example is not analogous to the 
comparison in the present study, which involves a transiently transfected reporter 
plasmid versus an endogenous gene, the promoters of which will differ markedly in 
their chromatin structure.  
 
The structure of chromatin appears to dictate the nature of the GR interaction with a 
promoter and the resulting transcriptional outcome (John et al., 2008). The reporter 
gene plasmid used in this study was transiently expressed in COS1 cells and as a 
result is not packaged into a native chromatin state. Thus the most likely explanation 
for the inconsistency in the observed reporter and endogenous gene results is that 
Vpr cannot access the GR and endogenous GRE-regulated gene promoters in the 
context of native chromatin, whereas it may do so for transiently transfected 
synthetic genes. Chromatin structure determines how the GR associates with DNA 
(John et al., 2011), and a GRE sequence confers specific conformational changes to 
the GR AF-2 domain (Meijsing et al., 2009) which is responsible for the GR 
association with transcriptional co-regulators (Kauppi et al., 2003). It is possible that 
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at the endogenous promoter, the GR occurs in a transcription initiation complex 
(TIC) with other transcription factors that is different to the TIC found at the promoter-
reporter gene. It is plausible that the TIC found at the promoter-reporter gene favours 
a Vpr interaction with the GR, whereas the GR-TIC complex at the endogenous gene 
did not, owing to either an alternate GR conformation or the blocking of co-factor 
interacting sites by other co-regulatory proteins. These results do not exclude the 
possibility that the effects of Vpr are highly promoter specific and that Vpr can 
regulate some, but not all GRE-containing endogenous genes. The GRE sequences 
of GR-regulated genes which have been reported in the literature to be affected by 
the presence of Vpr (RANKL, MMTV-LTR, and TAT-GRE) contain the TGT TCT half 
site whereas the two endogenous genes investigated in this study do not (Table 4.2). 
Further investigation will need to determine if this specific DNA sequence is a marker 
for Vpr enhancement of GR-mediated transactivation.  
 
It is important to note that in the reporter gene assay in COS1 cells (Figure 3.1) 
different amounts of the GR (112 ng/ml) and Vpr (250 ng/ml) expression vectors 
were transfected when compared to the real time PCR assay (Figure 3.7), and all 
subsequent experiments in COS1 cells in which 350 ng/ml of either Vpr and/or the 
GR expression vectors were transfected unless otherwise indicated. COS1 cells 
were plated at the same densities so that the amount of medium was proportional to 
the amount of cells. END cells did not require GR transfection, but did require much 
higher levels of Vpr transfection (1 000 ng/ml) in order to detect similar levels Vpr 
expression as in the COS1 cell line (Figure 3.7). This may have been due to poorer 
transfection efficiency of this cell line. The discrepancy in the amounts of transfected 
DNA between the reporter assay and real time experiments was a consequence of 
the bulk DEAE-Dextran transfection, and re-plating method used in Figure 3.1 to 
correct for transfection efficiency. This bulk transfection and re-plating method was 
found to cause a much higher degree of experimental variability and error, and less 
reproducibility than a direct FuGene6 transfection. As a result, subsequent assays 
after Figure 3.1 were transfected directly with FuGene6. The commonly used β-
Galactosidase assay for transfection efficiency could not be used however as the 
two available β-Galactosidase encoding plasmids were found to have expression 
regulated by either Vpr or steroids respectively, making it impossible to correct for 
variances in transfection efficiency. Without correcting for transfection efficiency it is 
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impossible to know if co-transfection of the Vpr expression vector affected the 
transfection efficiency of other plasmids. The relative concentrations of GR, Vpr, 
other components of the transcriptional machinery and GRE promoter sequences 
may determine the outcome of the effect of Vpr on GR-mediated transactivation. As 
different amounts and ratios of the GR and Vpr expression vectors were transfected 
in Figures 3.1, 3.7, and 3.8, these factors vary substantially when comparing results 
of reporter gene experiments with overexpressed GR in COS1 cells to those of 
endogenous genes regulated by either overexpressed GR in COS1 or the 
endogenous GR in END cells.  This confounds a direct comparison of these obtained 
results by making a direct comparison between the above reporter gene assay and 
real time PCR results difficult. Thus, comparison of the results obtained via 
overexpressed GR in COS1 cells for the reporter gene versus the endogenous MKP-
1 gene suggest that these differing results may not be due to the gene promoter 
alone, but also could have been an artefactual observation owing to the differing 
methods of transfection and relative GR/Vpr ratios, both of which are confounding 
factors when drawing a conclusion based on a comparison of these results. 
 
It was thus difficult to conclude whether the original hypothesis that Vpr is a classical 
GR co-activator is true (Table 4.1). Taken together, Vpr significantly increased the 
efficacy of some ligands at the TAT-GRE promoter-reporter plasmid, which is 
consistent with a role of Vpr as a GR co-activator, but had no effect on the mRNA 
abundance of the two tested endogenous genes. The discrepancy between these 
results could be due to a whole host of confounding factors. Furthermore, showing 
Vpr to have no effect on two endogenous genes does not indicate that Vpr has no 
effect on all GRE regulated endogenous genes nor disprove the co-activator model 
for Vpr. Insights gained from this present study indicate that before conclusive 
statements can be made regarding Vpr-mediated co-activation of the GR, many 
further studies and strategies would need to be investigated, especially regarding a 
direct interaction between Vpr and the GR in whole cells and the identification of at 
least one endogenous gene which Vpr enhances GR mediated transcription of.  
 
A co-activator should associate directly with the GR on the promoter through, for 
example LXXLL motifs and serve to increase recruitment of additional proteins to 
enhance agonist-mediated effects on transcription. The presence of LXXLL motifs is 
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common to both Vpr and the p160 steroid receptor co-activators (SRC), and Vpr has 
been reported to immunoprecipitate in vitro with the DEX bound GR (Kino et al., 
1999; Kino et al., 2002a), although other reports indicate that this may not be ligand-
dependent (Sherman et al., 2000; Thotala et al., 2004). Mutation of either of the two 
Vpr LXXLL motifs reportedly abolishes Vpr immunoprecipitation with the GR 
(Sherman et al., 2000). Alternatively, Vpr may interact with the GR through an 
intermediate protein in vivo (Muthumani et al., 2006; Ramanathan et al., 2002). 
However, no evidence for a direct, in vivo association between Vpr and the GR has 
yet been shown. Similar to an SRC, Vpr has been reported to immunoprecipitate 
with numerous transcription factors (Kino et al., 2002a; Kino and Pavlakis, 2004). 
The association of SRC-2 (alternatively GRIP-1 or TIF2) with the GR is blocked by 
stimulation with RU486 (Kauppi et al., 2003). However, in the present study RU486 
treatment did not prevent Vpr from mediating an increase in DEX-mediated reporter 
gene transactivation (Figure 3.1A and 3.1D), suggesting Vpr not to act exactly as the 
co-activator SRC-2 does via the GR. RU486 stimulation in the absence of DEX has 
been found to reduce both Vpr/GR-mediated transactivation of the HIV-1 LTR 
(Schafer et al., 2006), and to prevent Vpr/GR-mediated transrepression of the NHE1 
gene (Janket et al., 2007) suggesting Vpr itself to act more like a GR agonist than a 
ligand-dependent co-activator. This is supported by the observation in this current 
study where Vpr induced a significant increase in reporter gene transactivation in the 
absence of ligand (Figure 3.1A). 
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4.2. Vpr increases GR-mediated reporter gene 
transactivation dependently on DEX concentration 
but does not affect the DEX EC50 
 
Classical GR co-activators, such as members of the p160 SRC family have been 
reported to ligand-dependently increase efficacy (Amax), decrease EC50 (a measure  
of potency), and change the partial agonist activity of certain ligands for both 
transiently expressed reporter and endogenous gene expression (He and Simons, 
2007; Hong et al., 1997; Lee and Simons, 2010; Luo and Simons, 2009; Onate et al., 
1995; Ronacher et al., 2009; Sun et al., 2008; Szapary et al., 1999). SRC’s increase 
the Amax by associating with numerous TF’s and histone acetyltransferases (HAT) 
which cause nucleosomal re-arrangement in the region of the promoter and result in 
increased transcriptional rates (Li et al., 2003). 
 
In order to gain insight into the possible co-activator role of Vpr via the GR, the 
relationship between ligand concentration and Vpr mediated increases in GR-driven 
reporter gene transactivation was investigated through DEX dose response curves. 
Two different amounts of Vpr expression vector were transfected as it was expected 
that higher concentrations of Vpr protein would result in greater reporter gene 
transactivation, as was observed previously in the presence of 100 nM DEX at the 
TAT-GRE reporter gene (Sherman et al., 2000). Non-saturating concentrations of 
ligand indicate how Vpr affects EC50, and the saturating concentration indicates the 
effects on Amax. Owing to the well-documented effects of SRC-2 on GR-mediated 
transactivation, and the resemblance of some Vpr mechanisms to SRC-2, it was 
thought that in addition to the already observed effect Vpr has on increasing ligand 
efficacy, Vpr would also increase the potency of DEX (Table 4.1).  
 
In the absence of ligand, both amounts of Vpr expression vector induced a similar, 
very low but statistically significant induction of the reporter gene. This was less than 
0.01% of the effect induced by 1 μM DEX, making the physiological relevance 
unclear. At DEX concentrations less than 10-10 M, dose response curves in the 
presence of Vpr were indistinguishable from that in the absence of Vpr. At higher 
DEX concentrations reporter gene activity is increased by Vpr in a manner that is 
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greater than additive between ligand stimulation and the level of reporter gene 
activity that Vpr caused in the absence of ligand. Vpr did not increase reporter gene 
activity equally across all concentrations of DEX, but rather increased reporter gene 
transactivation to greater extents in the presence of higher DEX concentrations. 
Additionally increased reporter gene activity was observed with the greater amount 
of transfected Vpr expression vector if compared to the lower amount (Figure 3.2A). 
As DEX is a highly specific GR agonist, this illustrates a relationship between Vpr 
and DEX stimulation of the GR and excludes the possibility that Vpr acts entirely 
independently of DEX-mediated GR transactivation (Figure 4.1A). Vpr did not 
significantly decrease the EC50 as it had been expected to. The EC50 of DEX in the 
absence of Vpr was 0.5 nM. Transfection of 50 ng of Vpr expression vector 
insignificantly decreased this, in the direction expected, to 0.3 nM. However, 
transfection of the higher amount (175 ng) caused an insignificant increase, rather 
than decrease in the DEX EC50, to 0.7 nM, thereby suggesting that Vpr did not 
change the affinity of DEX for the GR. Transfection of Vpr also did not significantly 
change the Hill slope, which is a measure of the degree of co-operative ligand 
binding. Previous work by collaborators has shown that at high GR concentrations, 
positive co-operation occurs, suggesting that ligand binding to one GR monomer 
increases ligand binding to the other GR monomer within a GR dimer, whilst at low 
GR concentrations there is no such co-operativity, with a Hill slope of 1 (Robertson, 
2011). As Vpr resulted in no change in the Hill slope in the present study, the results 
suggest that Vpr did not change the degree of co-operation of ligand binding to the 
GR. Interestingly, in the absence of Vpr, the Hill slope was less than 1, suggesting 
negative co-operativity, a finding not observed in the previous study (Robertson, 
2011). This should however be investigated further, as it indicates that under these 
conditions that ligand binding to one GR monomer hampers ligand binding to the 
other GR monomer within a GR dimer. When drawing conclusions from these data, it 
should be noted that it is possible that Vpr mediated a small change to the EC50 and 
Hill slope that was undetectable above the level of error and biological variability in 
this experiment. More accurate values for the EC50 and Hill slopes may be obtained 
using more concentrations of DEX in the range of the steep slope on the dose 
response curve, in addition to performing more repeat experiments (increasing the n-
value), preferably in a cell line expressing endogenous GR. 
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The finding that Vpr increased the Amax for the DEX dose response curves is 
consistent with the result in Figure 3.1 as well as several reports in the literature. In 
293T cells Vpr enhanced DEX-mediated TAT-GRE reporter gene transactivation 
above the level of the GR alone, dependently on ligand concentration, similar to the 
classical co-activator SRC-2, albeit to a lower extent (Sherman et al., 2000). Similar 
results were observed in A204 cells where Vpr enhanced a GR-mediated DEX dose 
response of the MMTV promoter-reporter gene (Kino et al., 1999). The EC50’s were 
not however determined in either published study. 
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Figure 4.1 (A-D): Models representing different possible outcomes for increasing ligand-
dependent transactivation. A steroidal dose response curve is shown in black, with different 
possible outcomes for increased transactivation shown in colour. (A) GR independent activation 
would increase efficacy by an equal magnitude independently of steroid concentration without 
affecting EC50, (B) classical co-activation (frequently observed with SRC-2) simultaneously increases 
efficacy and decreases EC50. (C) Some co-activators may increase ligand potency but have no effect 
on efficacy, (D) whilst others may increase the Amax without affecting the EC50. 
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When assessing what insights can be obtained from the dose response curves 
regarding Vpr mechanism of action and its possible function as a GR co-activator, a 
comparison with data obtained by others with established GR co-activators is helpful. 
SRC-2 co-activation of the GR was found to be dependent on ligand concentration 
(Hong et al., 1997; Onate et al., 1995; Voegel et al., 1996) and the extent of SRC-2 
recruitment to the GR was found to be dependent on ligand efficacy (Ronacher et al., 
2009). Vpr does mediate more of an increase in GR-mediated reporter gene activity 
in the presence of agonists than it does for partial agonists (Figure 3.1D), and 
induces more of an increase in reporter gene activity at higher DEX concentrations 
(Figure 3.2A). This suggests that Vpr, like SRC-2, serves to enhance ligand induced 
GR-mediated transactivation rather than mediate a ligand independent general 
increase in GR-mediated transactivation. The effects of Vpr are thus dependent on 
the degree of GR activation, and will be greater in the presence of efficacious 
steroids and high concentrations of ligand. 
 
The established co-activator SRC-2 simultaneously increases ligand potency and 
efficacy (Figure 4.1B), in what is termed classical co-activation (Hong et al., 1997; 
Onate et al., 1995; Szapary et al., 1999). However, mutational analysis has revealed 
that modulation of the EC50 and Amax are in fact separable effects, mediated through 
different regions of the GR (Awasthi and Simons, 2012). Select mutations in the GR 
LBD which affect the interaction with SRC’s can selectively modulate one of these 
parameters without affecting the other, indicating that the EC50 and Amax may be 
modulated by co-factors independently (Lee and Simons, 2010; Luo and Simons, 
2009; Russcher et al., 2005; Tao et al., 2008; Vottero et al., 2002). The exact effects 
of a GR co-activator appear to be highly variable according to context, and no firm 
rule about the relationship between Amax and EC50 exists. Rather, there are some 
reports in which a co-activator only affects EC50 and not Amax (Figure 4.1C), while 
others report that a co-activator may affect only the Amax and not EC50 (Figure 4.1D) 
(as reviewed in Ong et al., 2010). Overexpression of SRC-1 in Astrocytes and SRC-
2 in MSC80 cells has been reported to not affect the Amax of a GRE containing 
reporter gene (Grenier et al., 2006) and SRC-1 has been reported to only increase 
ligand potency via the GR, but not the Amax (Szapary et al., 1999). In contrast, SRC-2 
knockdown has been shown to have no effect on DEX EC50 for expression of the 
endogenous GILZ and CD163 genes, but did reduce the Amax (Luo and Simons, 
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2009). TSA, VPA and Ubc9 have also been reported to ligand-dependently increase 
the Amax of a synthetic reporter gene, without affecting the EC50 (Kaul et al., 2002; 
Kim et al., 2006; Lee and Simons, 2010), similar to the effects obtained with Vpr in 
this present study.  
 
Although it had been expected that Vpr would decrease the DEX EC50, an analysis 
of the literature revealed that under certain conditions co-activators may increase the 
Amax without rendering a ligand more potent. Data from Figure 3.2 is thus not 
inconsistent with a role of Vpr as a GR co-activator, but alone is insufficient as proof 
thereof. Published results show there is a high degree of variability regarding the 
effects a co-activator may exert on GR-mediated transactivation. SRC-2 is a 
constituent member of the p160 SRC family, and around 350 further co-regulators 
have been identified (York and O'Malley, 2010). As Vpr is not a human gene, it may 
not perfectly mirror all functions of SRC-2, but does increase GR-mediated 
transactivation of a reporter gene, similar to the effects of a co-activator. This may be 
through a similar mechanism or in a manner distinct from classical co-activation. 
Data obtained from Figures 3.1 and 3.2 could not determine the mechanism by 
which Vpr enhanced reporter-gene activity. 
 
The SRC-1 and SRC-3 members of the p160 family have intrinsic HAT activity, 
whilst it is controversial as to whether SRC-2 harbours a HAT function (Leo and 
Chen, 2000; Marmorstein, 2001). Due to its small size it is unlikely that Vpr itself may 
have HAT activity, as HAT’s are generally large multi-subunit enzyme complexes 
(Roth et al., 2001), and Vpr does not display any recognised chromatin remodelling 
motifs (Neuwald and Landsman, 1997; Yuan and Giordano, 2002). Although 
sequence alignment between SRC-2 and Vpr proteins does not yield any conserved 
domains apart from the Leucine rich domains, it is possible that the mechanism by 
which Vpr increases reporter gene transactivation is similar to the mechanism by 
which SRC-2 does. SRC’s increase GR driven transcription by recruiting further co-
regulators and HAT’s to the promoter (Horwitz et al., 1996; Onate et al., 1995; 
Voegel et al., 1996). SRC-2 recruits further co-regulators to the TIC to increase 
transcription. The homo- and hetero- oligomerisation properties of Vpr (Kino and 
Pavlakis, 2004) may also result in increased recruitment of HAT’s or other chromatin 
remodelling proteins to the TIC. One such TF this has already been reported for is 
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p300, which is responsible in part for enhanced GR activity in the presence of Vpr 
(Felzien et al., 1998; Kino et al., 2002a). 
 
Several factors and some data indicate that Vpr differs in its mechanism of action 
compared to SRC-2. Vpr was able to increase GR-mediated transactivation in the 
presence of RU486 (Figure 3.1A), which is thought to block SRC-2 association with 
the GR, and thereby prevent SRC-2 induced transcriptional effects (Bledsoe et al., 
2002; Kauppi et al., 2003), however, the presence of DEX in this experiment may 
have contributed to the greater level of reporter gene transactivation observed, and 
the concentration of RU486 may not have been sufficient to prevent co-activator 
association. Vpr did not mediate a change in DEX potency (Figure 3.3B), as SRC-2 
does, nor did it increase the relative extent of partial agonist activity of any ligand. 
 
In conclusion, many lines of evidence indicate that the effects of Vpr closely 
resemble those of SRC-2. In contrast, other evidence both from this study and 
reported by others indicates that Vpr may act in a manner that is very similar to, but 
actually discrete from classical co-activation by p160 SRC’s. The results from this 
present study indicate the need for alternate strategies before the role of Vpr as a 
GR co-activator can be proven. The increase mediated by Vpr to the reporter gene 
Amax is insufficient to classify Vpr as a GR co-activator. Indeed, any reporter gene 
analysis cannot be relied upon as the sole indicator of Vpr co-activation of the GR. 
Rather an endogenous gene regulated in a similar mechanism would need to be 
identified and co-occupancy of the GR and Vpr at a promoter would be required 
before such a statement could be made. 
 
 
4.3. Vpr increases GR turnover but does not change 
serine 203, 211, or 226 phosphorylation or nuclear 
translocation of the rGR 
 
To determine if Vpr changes GR-mediated reporter gene transactivation by a 
mechanism that is discrete from classical co-activation, which predominantly 
increases protein-protein interactions at the promoter, three steps involved with the 
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activation of the GR were investigated. Since ligand efficacy was enhanced in the 
presence of Vpr, it was hypothesised that Vpr could have: changed the abundance 
of the GR itself, caused selective hyperphosphorylation of key GR serine residues, 
or increased the extent of GR nuclear translocation.  
 
 
4.3.1. Turnover 
 
Ligand binding destabilises the GR by causing poly-ubiquitination, which enhances 
GR affinity for the proteasome (Kinyamu et al., 2005). The greatest extent of ligand-
dependent GR degradation occurs with the most efficacious ligands (Avenant et al., 
2010b). Decreasing GR levels after ligand activation serves as a mechanism to 
prevent excessive GR signalling (Wallace and Cidlowski, 2001). Thus decreased GR 
levels reflect increased transactivation efficacy. In an apparent paradox, proteasomal 
inhibition prevents GR degradation, thereby increasing GR levels. This also has the 
effect of increasing GR mediated transcription (Deroo et al., 2002; Wallace and 
Cidlowski, 2001). Vpr could have stabilised the GR against degradation thereby 
increasing GR levels prior to stimulation, or could have either acted like a ligand itself 
or increased ligand efficacy, which would have had the effect of reducing GR levels. 
Both mechanisms can plausibly explain how Vpr resulted in an increase in reporter 
gene transactivation. 
 
The current study showed that stimulation of the GR with DEX for 24 hours 
significantly decreased GR levels, while stimulation with CORT, MPA, P4, or NET-A 
did not (Figure 3.3B). This may have been expected with the weaker agonists NET-A 
and P4, as these have low GR efficacies, but was not expected with CORT or MPA 
stimulations, two ligands which significantly induced reporter gene transactivation. It 
has been previously shown that the half-life of the unliganded GR in this cell line is 
44 hours. This is reduced to 10 hours upon stimulation with DEX, 12 hours with 
CORT, 17 hours with MPA, 28 hours with P4, and 37 hours with NET-A. Stimulation 
of the GR with each of these ligands has been found to significantly decrease GR 
levels after 24 hours (Avenant et al., 2010b). Both the unliganded and liganded GR 
are continually turned over, although the liganded GR is degraded much faster than 
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the unliganded GR (Avenant et al., 2010b). The experimental design in the present 
study and those of the published report differ as de novo protein synthesis had been 
prevented in the published report, allowing determination of the GR half-life, whereas 
the present study effectively measured GR turnover, which includes both de novo 
GR synthesis and degradation. Thus the observation of no change in GR levels for 
stimulations with all ligands except DEX could plausibly be explained by a rate of GR 
expression which is as fast or faster than GR degradation and that a change in 
ligand-dependent GR turnover may have been masked by new GR protein 
synthesis. 
 
Use of a two-way ANOVA test allowed a comparison of the two whole groups (-Vpr 
and +Vpr) by excluding ligand stimulation as a variable. COS1 cells transfected with 
the GR and Vpr were found to have significantly lower GR levels than cells 
transfected with the GR and an empty vector plasmid. DEX dependent GR turnover 
was equal in the absence and presence of Vpr, and the levels of GR stimulated with 
MPA were not significantly different in the absence and presence of Vpr. However, 
significantly lower GR levels in the presence of Vpr were observed with CORT, P4, 
and NET-A if compared to the corresponding stimulations in the absence of Vpr. Vpr 
also decreased levels of the GR stimulated with vehicle alone, suggesting that it may 
exert some measure of activation to the unliganded GR. However, this difference 
was not found to be statistically significant (Figure 3.3B).  
 
Increased turnover of the GR mediated through the actions of Vpr has not been 
reported before, but does suggest that the increased reporter gene activity induced 
by Vpr in the present study cannot be explained simply by higher levels of GR 
protein. Vpr enhanced the efficacy of the tested ligands and as previously reported, 
ligands with greater efficacies cause greater levels of GR degradation (Avenant et 
al., 2010b). It is thus possible that the lower levels of GR observed in the presence of 
Vpr reflect enhanced efficacy, although it should be noted that the extent of turnover 
did not correlate with the ligands transactivation efficacies. Vpr itself may have acted 
as a weak, non-classical GR activator thereby causing enhanced GR degradation in 
a manner similar to how a ligand would. It is also possible that Vpr increases GR 
ubiquitination and affinity for the proteasome (Kinyamu et al., 2005), thereby 
lowering GR levels. The cell cycle arresting abilities of Vpr are dependent on an 
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interaction with DCAF/VprBP. These proteins form a direct linkage with DDB1, a 
core subunit of the Cul4 ubiquitin ligase (Le Rouzic et al., 2007). The recruitment of 
an ubiquitin ligase to the GR/Vpr complex may have resulted in increased GR 
ubiquitination and subsequently more rapid degradation. 
 
Vpr has been found to immunoprecipitate with the GR in the presence of DEX (Kino 
et al., 1999; Kino et al., 2002a), although such an interaction has not been observed 
from studies in our lab (Avenant et al., 2012, unpublished data). In this current study, 
in the presence of Vpr, all ligand stimulations were found not be significantly different 
to stimulation with vehicle alone, although DEX stimulation did cause a slight 
reduction in GR levels in the presence of Vpr (Figure 3.3B) and no ligand stimulation, 
inclusive of DEX had any effect on Vpr levels (Figure 3.3C). This therefore suggests 
that Vpr is not degraded alongside the DEX activated GR. Thus if a complex 
containing both these proteins exists in vivo, it is likely to be dissociated prior to GR 
degradation or Vpr may be resistant to proteasomal degradation. 
 
To ensure that each condition within an experiment was transfected with an equal 
quantity of DNA and thus treated with an equal volume of transfection reagent, a 
quantity of empty vector DNA equal to the quantity of Vpr expression vector was 
transfected into cells that were required not to express Vpr. As discussed in section 
4.1 above, transfection efficiency was unable to be determined, and accordingly it 
was impossible to determine if transfection of Vpr decreased transfection of the GR 
expression vector, which would have also resulted in decreased GR levels. 
Alternatively, the cytotoxic (Gummuluru and Emerman, 1999) and apoptotic (Snyder 
and Ross, 2009; Snyder et al., 2010) effects of Vpr may have also contributed to 
lower GR plasmid expression, increased proteolytic activity, or caused cell lysis and 
a consequential loss of the expressed proteins into the culture medium. Apoptosis 
and cell death alone are unlikely causes however, as the GAPDH loading control 
was not found to be lower in the presence of Vpr (Figure 3.3A). 
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4.3.2. Phosphorylation 
 
The relative phosphorylation status of three key GR serine (S) residues; 203, 211, 
and 226 has been reported to change with GR nuclear import and export (Dean et 
al., 2001; Itoh et al., 2002), affect co-factor association (Avenant et al., 2010a; Chen 
et al., 2008) and reflect ligand efficacy for transactivation of reporter genes (Avenant 
et al., 2010b). All three residues are ligand-dependently hyperphosphorylated after 
an hour of stimulation (Blind and Garabedian, 2008; Chen et al., 2008; Ismaili and 
Garabedian, 2004; Wang et al., 2007). Ligand transactivation efficacy also reflects 
the extent of SRC-2 association with the GR (Ronacher et al., 2009), which is 
dependent on the GR being phosphorylated at one or more of these residues 
(Avenant et al., 2010a). Changes in phosphorylation status were thus thought of as a 
likely target mechanism for Vpr mediated modulation of GR signalling. If Vpr is 
causing an increase in GR ligand efficacy, it could be expected to also enhance 
phosphorylation of these serine residues in the same manner that ligands do (Table 
4.1). If, however Vpr resulted in GR activation via a non-classical mechanism, i.e. 
other than through the ligand-binding domain as for classical GR ligands, Vpr could 
increase basal S226 phosphorylation, as has been reported for GnRH at the 
corresponding residue on the mouse GR (Kotitschke et al., 2009) or TNF-α on the 
human GR (Verhoog et al., 2011). 
 
Ligand-dependent S203 hyperphosphorylation was not observed in this study 
(Figure 3.4B), in agreement with previous reports indicating S203 phosphorylation is 
only weakly increased upon DEX stimulation in U2OS and A549 cells (Wang et al., 
2002). The basal level of S203 phosphorylation is reportedly much higher than that 
of S211 (Ismaili and Garabedian, 2004; Wang et al., 2002), causing the ligand-
induced fold increases above basal to appear lower. Consistent with this, in the 
present study in the absence of Vpr, DEX stimulation insignificantly increased S203 
phosphorylation only 1.2 fold above basal, and a high level of basal S203 
phosphorylation was present (Figure 3.4A). This causes the relative fold increases 
induced by ligand to appear lower when compared to basal. No ligand significantly 
increased S203 phosphorylation above stimulation with vehicle alone, and Vpr had 
no effect on S203 phosphorylation, either in the absence or presence of any of the 
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tested ligands (Figure 3.4B). Others have shown that phosphorylation of S203 alone 
slightly impairs S211 phosphorylation (Wang et al., 2002), and causes the GR to 
attain a peri-nuclear distribution, but not gain nuclear access (Wang et al., 2002). 
The GR phosphorylated at S203 has not been found associated with the TAT-GRE 
promoter (Blind and Garabedian, 2008), and thus it was not entirely surprising that 
Vpr exerted minimal observable effect on S203 phosphorylation. 
 
Hyperphosphorylation of S211 reflects higher levels of GR-mediated transactivation 
(Avenant et al., 2010b), and the P-S211/P-S226 ratio is linked to increased GR-
mediated transactivation (Chen et al., 2008). It was therefore hypothesised that Vpr 
would enhance ligand-dependent S211 phosphorylation. Significant phosphorylation 
of both residues S211 (Figure 3.4D) and S226 (Figure 3.4F) was found to occur after 
an hour of ligand stimulation, in agreement with previous findings indicating that 
these residues may be simultaneously phosphorylated (Wang et al., 2007). The 
established rank-order of GR reporter gene transactivation efficacies from an earlier 
report was DEX≥CORT>MPA>P4>NET-A (Ronacher et al., 2009). Ligands result in 
different levels of S211 and S226 hyperphosphorylation correlating with their 
transactivation efficacies in this same rank-order (Avenant et al., 2010b). The relative 
extents of S211 and S226 phosphorylation obtained in the current study were not 
inconsistent with this rank-order (Figure 3.4). However, Vpr had no significant effect 
on ligand-dependent phosphorylation at either of the tested residues (Figures 3.4D 
and 3.4F), which was not expected. 
 
Phosphorylation of S226 alone decreases GR efficacy for transactivation of the TAT-
GRE reporter gene in COS1 cells (Avenant et al., 2010b). Phosphorylated S226 
leads to a decrease in phosphorylation of S211, consistent with ligand-dependent 
S226 phosphorylation attenuating GR function (Chen et al., 2008; Krstic et al., 1997; 
Wang et al., 2007). S226 has been reported by others to be partially phosphorylated 
in the absence of ligand, and to become hyperphosphorylated upon ligand 
stimulation. However, ligand-dependent S226 hyperphosphorylation does not occur 
to the same extent as S211 hyperphosphorylation does in rat hepatoma cells (Blind 
and Garabedian, 2008). Although Vpr had no effect on ligand-dependent S226 
phosphorylation in this present study, it did cause a statistically significant increase 
in S226 phosphorylation in the absence of ligand (Figure 3.4F), consistent with 
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previous reports regarding the effects of the non-classical GR activators, GnRH and 
TNF-α (Kotitschke et al., 2009; Verhoog et al., 2011).  
 
The effect of Vpr on ligand-independent S226 phosphorylation was tested further by 
transfecting differing amounts of the Vpr expression vector with the expectation that 
higher amounts of Vpr would reflect as increased extents of ligand-independent 
S226 phosphorylation. However, no tested concentration of Vpr expression vector, 
including the concentration previously shown to increase S226 phosphorylation (350 
ng/ml), had any effect (Figure 3.5). These two conflicting results therefore make a 
conclusion regarding the effect of Vpr on ligand-independent S226 phosphorylation 
difficult to reach based on the available data from this present study. Further 
experimentation would be required before a conclusive statement may be made 
regarding the effects of Vpr on ligand-independent S226 phosphorylation. 
 
This report is the first investigating the effect of ligand selective phosphorylation of 
GR residue S203, and the effects of Vpr on S203, S211, and S226 GR 
phosphorylation. 
 
 
4.3.3. Nuclear Translocation 
 
It was hypothesised that Vpr would increase nuclear translocation of the GR in the 
presence and absence of DEX owing to its nucleophilic nature and the shared 
nuclear import pathway (Freedman and Yamamoto, 2004; Refaeli et al., 1995). This 
may be the mechanism whereby Vpr increases GR-mediated transactivation of the 
reporter gene in both the absence and presence of ligand (Table 4.1). 
 
Using immunofluorescence analysis and confocal microscopy, the subcellular 
distribution of the rGR and Vpr in the absence and presence of DEX was 
investigated in COS1 cells (Figure 3.6A and B). The rGR was predominantly 
cytoplasmic, but not entirely vacant from the nucleus in the absence of ligand, in 
agreement with previous literature reports indicating that the unliganded GR is 
constantly shuttled between the nucleus and cytoplasm (Hache et al., 1999; Madan 
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and DeFranco, 1993; Savory et al., 1999). Stimulation of the receptor with DEX for 
an hour caused the rGR to translocate almost entirely to the nucleus, which equates 
to a roughly three-fold increase in the nuclear/whole cell proportion of the rGR. This 
is also consistent with literature which indicates that almost entire rGR nuclear 
translocation occurs upon ligand stimulation (Baumann et al., 1999; Htun et al., 
1996). In both A549 and U2OS cells, the extent of GR nuclear translocation 
correlates with ligand efficacy (Hadley et al., 2011). Vpr was found to be both 
constitutively and entirely nuclear, independent of DEX stimulation or the presence 
of the rGR. This is in agreement with earlier studies showing Vpr to be nucleophilic 
(Mahalingam et al., 1997; Sherman et al., 2001; Suzuki et al., 2009) and to have a 
general affinity for nucleic acids (Kichler et al., 2000; Zhang et al., 1998). Co-
expression of the rGR with Vpr does not cause a statistically significant change in 
the subcellular distribution of the unliganded or DEX-activated rGR if compared to 
results obtained in the absence of Vpr (Figure 3.6B). Because DEX caused near 
total nuclear translocation of the GR, it was difficult to observe how Vpr might have 
increased this. 
 
Areas of intense Hoechst stain indicate highly condensed chromatin, which is likely 
to be transcriptionally inactive (yellow arrows). This staining pattern indicates that the 
liganded GR is vacant from such areas (Figure 3.6A II) as is Vpr (Figure 3.6A III) and 
that inside the nucleus Vpr and the GR display a similar distribution (Figure 3.6A V). 
Visual inspection of these images prior to quantification indicated that in the 
presence of Vpr, the unliganded GR had higher nuclear signal intensity than it did in 
the cytoplasm (Figure 3.6A V). In addition, there was a greater proportion of the 
unliganded rGR in the nucleus in the presence of Vpr (Figure 3.6A V) if compared to 
the absence of Vpr (Figure 3.6A II). Quantification of the fluorescent intensities with 
LSM image analyser software determined that the nuclear proportion of the 
unliganded rGR was not significantly increased by Vpr (Figure 3.6B). However, 
increased nuclear localisation may have been masked by the high level of non-
specific nuclear rGR staining by the primary GR antibody (Figure 5.2).  
 
Vpr may have mediated a small increase in rGR nuclear translocation in the absence 
of ligand that was too small below the background level to be established as 
statistically significant. Such an observation of Vpr increasing nuclear import of the 
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unliganded GR would have supported previous observations from this present study 
which indicate Vpr to increase transactivation via the unliganded GR, as a weak, 
non-classical GR activator may (Figures 3.1A and 3.2D). The experimental design 
was unable to conclude if Vpr did increase DEX-mediated GR nuclear translocation, 
as the saturating DEX concentration used caused nearly entire GR nuclear 
translocation (Figures 3.6A II and VI). Fluorescent quantification of the slides 
determined that the nuclear proportion of the rGR was not significantly affected by 
Vpr in the presence of 100 nM DEX (Figure 3.6B). 
 
 
4.4. Vpr mediates a much larger increase in MPA efficacy 
than it does for NET-A, and changes biocharacter in a 
ligand- and gene-specific manner 
 
Agonists and partial agonists have different relative binding affinities for the GR 
which correlates well with potency, and to a lesser extent efficacy (Ronacher et al., 
2009). These differences cause transcriptional responses that vary according to the 
nature of the bound steroid, in a cell type and promoter specific manner (Africander 
et al., 2011b; Hapgood et al., 2004; Ishida et al., 2008; Ronacher et al., 2009). It was 
hypothesised that Vpr would alter the biocharacter of the GR partial agonists, in 
addition to generally mediating an increase for the reporter gene transactivation 
efficacies of the tested steroids (Table 4.1). The five ligands tested (DEX, MPA, 
NET-A, P4 and CORT) and the antagonist (RU486) have different GR transactivation 
efficacies, and accordingly exhibit different levels of reporter gene transactivation 
when acting via the GR. Reports in the literature have established the rank-order of 
these ligands as DEX≥CORT>MPA>P4>NET-A for reporter gene transactivation 
efficacy in COS1 cells (Ronacher et al., 2009) and HEK293 cells (Koubovec et al., 
2005). DEX and CORT are full GR agonists, and result in greatest induction of the 
TAT-GRE reporter gene via the GR. MPA and P4 are partial agonists, although 
under high enough GR concentrations MPA may act as a full agonist (Zhao et al., 
2003), and NET-A has a very low GR binding affinity and efficacy and is not  
reported as a GR agonist for transactivation (Koubovec et al., 2005; Schindler et al., 
2003; Schoonen et al., 2000; Sitruk-Ware, 2004). 
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The partial agonist activity is a measure of the transactivation that a ligand induces 
relative to that of a full agonist, which in this present study is DEX. Co-activators 
which enhance the Amax have been reported before to also affect the partial agonist 
activity of non-agonist steroids (Lee and Simons, 2010; Luo and Simons, 2009; Sun 
et al., 2008). The effects of Vpr on ligand biocharacter were also investigated as 
many confounding factors, other than Vpr alone may have mediated a change to 
ligand efficacy and the absolute increases in GR-mediated transcription. 
 
Plotting the reporter gene activity induced by each of the tested ligands relative to 
DEX revealed that Vpr did not cause any ligand to attain a significantly higher 
different biocharacter relative to DEX. No ligand was found to change biocharacter 
from a partial agonist, with a significantly lower partial agonist activity than DEX, to a 
full agonist which is not significantly different to DEX (Figure 3.1B). Although 
statistically significant differences were not observed between the tested ligands, a 
rank-order for reporter gene transactivation efficacy that was consistent with 
previous literature (DEX>CORT>MPA>P4>NET-A) was observed in both the 
absence and presence of Vpr (Figure 3.1B) (Koubovec et al., 2005; Ronacher et al., 
2009). The relative fold increase by which Vpr increased reporter gene activity for 
each ligand was similar (Figure 3.1E), which therefore indicated that whilst Vpr did 
increase ligand transactivation efficacy, it did not alter the relative biocharacter of 
these ligands for induction of the TAT reporter gene. 
 
The effect of Vpr on ligand biocharacter for the induction of the two endogenous 
genes was also investigated. In COS1 cells in the absence of Vpr, the partial agonist 
activity of P4 is significantly lower than that of DEX, as it is acting as a partial 
agonist, whereas in the presence of Vpr the partial agonist activity of P4 was at a 
level of significance comparable with DEX (Figure 3.7B). This suggests that Vpr 
changed the biocharacter of P4 from a partial to a full agonist for expression of MKP-
1 (Figure 3.7B). Additionally, although significance was not established, the relative 
trend of transactivation efficacies in the absence of Vpr was not consistent with that 
observed in the presence of Vpr. 
 
END cells not expressing Vpr appeared to induce expression of MKP-1 mRNA in 
accordance with the observed and published rank-order for relative GR 
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transactivation efficacies of these ligands, although significant differences between 
ligands could not be established given the small differences and large number of 
variables. All ligands were found to act as partial agonists in both the absence and 
presence of Vpr (Figure 3.7E), indicating Vpr to not alter any ligands biocharacter for 
expression of MKP-1 in END cells. Interestingly, a significantly higher basal level of 
MKP-1 expression was observed if the absolute partial agonist activities are 
compared between the corresponding conditions, although the relevance of such an 
observation is disputable. 
 
Transfection of Vpr into END cells significantly increased the partial agonist activities 
of P4 and CORT when expressed as a percentage of the DEX response and 
corresponding stimulations compared in the absence and presence of Vpr (Figure 
3.8B). In the presence of Vpr all ligands were found to have a partial agonist activity 
that was at a level insignificantly different to DEX, whereas in the absence of Vpr all 
ligands were found to have a partial agonist activity significantly lower than DEX 
(Figure 3.8B). It was concluded that Vpr increased the partial agonist activity for all 
ligands for expression of the IκBα gene in END cells, especially the relative 
biocharacter of P4 and CORT relative to DEX, such that the partial agonists behaved 
like agonists. This is an interesting observation as P4 and CORT were the only two 
endogenous steroids used in this present study, and supports the observation 
regarding the effect of Vpr in changing the biocharacter of P4 from a partial agonist 
to a full agonist shown in Figure 3.7B. It is possible that Vpr preferably increases the 
partial agonist activity if the GR is bound to endogenous hormones as opposed to 
synthetic exogenously administered steroids such as MPA and NET-A. This result 
should be interpreted with caution since the relatively high error of the data in the 
presence of Vpr may have masked differences in the maximal responses of the 
ligands in the presence of Vpr as compared to in the absence of Vpr. A clearer result 
should be obtained through more biological repeats, with fewer variables so as to 
give a greater power of statistical analysis, to confirm whether Vpr significantly 
changes the biocharacter of partial agonist to agonists on some endogenous genes.  
 
Steps in the GR pathway other than transcription were also investigated to observe 
any progestin-specific and Vpr-dependent effects. None of the progestins or GC’s 
caused differing levels of S203, S211, or S226 phosphorylation when in the 
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presence of Vpr. Interestingly, stimulations with CORT, P4, and NET-A were all 
found to have significantly lower GR levels in the presence of Vpr whereas DEX and 
MPA did not (Figure 3.3B). 
 
The partial agonist activities of MPA and NET-A relative to DEX were not found to 
differ for transactivation of the reporter gene or either of the endogenous genes in 
the absence and presence of Vpr. It was hypothesised that the progestins MPA and 
NET-A could act differently via the GR when in the presence of Vpr (Table 4.1), but 
this was found not to have occurred as Vpr enhanced reporter gene transactivation 
with both these ligands roughly 4.5 fold (Figure 3.1E). Vpr increased all the tested 
ligands Amax at the TAT-GRE reporter gene in a manner that reflected the ligand 
efficacies. However, the Vpr-mediated increase in reporter gene Amax with MPA (a 
full to strong partial agonist), was much greater than it was for NET-A (a weak partial 
agonist) (Figure 3.1D). This Vpr mediated increase on reporter gene Amax raises 
concerns regarding the use of exogenously administered steroids with high GR 
transactivation efficacies. If endogenous genes are found which respond to Vpr in 
the same manner as the reporter gene does, then use of MPA should be treated with 
caution where exposure to Vpr is concerned. If Vpr is present in conjunction with 
efficacious GC’s, such as MPA, it could lead to an enhanced level of GR-mediated 
responses, than if compared to the presence of a weak agonist such as NET-A. This 
would affect endocrine and immune functions and the contraceptive side effect 
profile. Such an effect is noteworthy regarding bone related disorders, as long-term 
use of MPA has been reported to enhance osteoporosis, likely through its GR 
agonist properties (Greydanus et al., 2001; Ishida and Heersche, 2002; Ishida et al., 
2008; Kaunitz, 2000c; Ott et al., 2001; Scholes et al., 2002). Vpr potentiates GR-
mediated induction of the RANKL gene (Fakruddin and Laurence, 2005) which is 
implicated to play a role in HIV-1 related bone density loss through enhancing bone 
resorption (Fakruddin and Laurence, 2004). It is therefore possible that bone density 
loss during HIV-1 infection, and after long-term use of MPA are mediated by similar 
mechanisms, namely through the GR. Vpr is thus highly relevant to the choice of 
contraception, and NET-A could prove favourable to be used in place of MPA where 
Vpr exposure is concerned. NET-A would exert less GC like effects than MPA, and 
thus Vpr would most likely not dramatically enhance GC like side effects of this 
contraceptive. 
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4.5. Vpr effects resemble those of a weak, non-classical 
GR activator 
 
It was not hypothesised that Vpr would mediate an effect on the GR in the absence 
of ligands (Table 4.1). Rather it was thought that Vpr would only enhance ligand-
dependent stimulation of the GR. However, statistically significant increases in the 
basal level of GR-mediated reporter gene activity in the presence of Vpr were 
observed twice in this present study (Figures 3.1A and 3.2E). This is a novel finding 
and was not reported in previous publications which investigated the effects of Vpr 
on GR-mediated reporter gene transactivation (Kino et al., 1999; Kino et al., 2002a; 
Sherman et al., 2000). However it is possible that these authors may not have 
noticed these effects which may have been masked by their method of 
normalisation. 
 
It was understood that Vpr increased TAT-GRE transactivation through the GR. If 
Vpr were acting independently of the GR altogether, then the additional measure of 
reporter gene activity induced by Vpr would be equal under all conditions and 
concentrations, including the absence of ligand (Figure 4.1A). This was not observed 
as it was found that the Vpr-mediated increases in reporter gene activity were larger 
at higher DEX concentrations (Figure 3.2A) or with more efficacious GR agonists 
(Figure 3.1D). As DEX is a specific GR agonist, this refuted the possibility that Vpr 
increased reporter gene activity independently of the GR. A negative control is 
present in Appendix 5.1 indicating that COS1 cells not transfected with the GR 
expression vector show a negligible level of reporter gene activity, and are not 
responsive to DEX stimulation. Ideally, this negative control should have also been 
included for all of the tested ligands from this study. 
 
In addition to increased reporter gene transactivation, results presented in this study 
suggest that Vpr increased GR turnover in a manner that was both independent of 
which ligand was used for GR stimulation, and occurred in the absence of ligand 
(Figure 3.3B). Under stimulation with vehicle alone, S226 phosphorylation (Figure 
3.4F) and rGR nuclear localisation (Figure 3.6A IV), both appeared to also be 
enhanced by the presence of Vpr. These observations are consistent with Vpr itself 
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acting as a GR ligand, although statistical significance of these changes in the 
individual experiments was not established. This does not however, discount the 
possibility that Vpr does have a significant effect on the unliganded GR, but rather 
only indicates that the experimental design used in this current study was unable to 
detect any possible effects conferred by Vpr as they may have been within the range 
of experimental error. Reducing the number of variables from 12, and increasing the 
number of biological repeats should effectively resolve this issue. It would be highly 
co-incidental that several different assays, each of which was independently 
performed, would all suggest ligand-independent GR activation mediated by Vpr. It is 
possible that Vpr activates the GR in a manner analogous to GnRH (Kotitschke et 
al., 2009) or TNF-α (Verhoog et al., 2011). The mechanism by which GnRH and 
TNF-α activate the GR has not been fully established, but is not thought to involve 
direct binding to the GR. Results thus far suggest that activation is via indirect effects 
of GnRH or TNF-α on kinases via their respective receptors, which then modulate 
GR phosphorylation and nuclear translocation. Another possibility is that Vpr may 
create an intracellular environment more conducive to GR activation and GRE 
transactivation, as has been reported for the LTR, where the cell-cycle arresting 
capabilities of Vpr cause increased GR-mediated transactivation (Gummuluru and 
Emerman, 1999), although such an effect may have been expected to also be 
evident for transactivation of the endogenous genes. 
 
Taken together a putative model may be proposed to explain increases in 
unliganded GR activity in the presence of Vpr. Given that results in the literature 
suggest that Vpr associates with the GR, this suggests that a mechanism of GC 
ligand-independent activation by Vpr is different to that of GnRH and TNF-α. In the 
absence of ligand, nuclear Vpr may associate with the GR (Sherman et al., 2000; 
Thotala et al., 2004) as it shuttles between the cytoplasm and nucleus (Hache et al., 
1999; Madan and DeFranco, 1993; Savory et al., 1999), leading to increased GR 
nuclear retention. Owing to the capability of Vpr to interact with multiple proteins 
(Kino and Pavlakis, 2004) and homo-oligomerise (Schuler et al., 1999; Zhao et al., 
1994b), the GR may associate with multiple Vpr molecules, which in turn associate 
with GR co-activators, including p300 (Felzien et al., 1998; Kino et al., 2002a; Wang 
et al., 1995). As Vpr displays an affinity for nucleic acids (Kichler et al., 2000; Zhang 
et al., 1998), this may cause increased association of the GR/Vpr/co-activator 
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complex with any accessible promoters and marginally increase transcription rates 
(Figure 4.2). It is possible that the GR/DNA association is weak owing to the 
absence of ligand, and that GR binding to DNA would have only occurred at highly 
accessible promoters, such as those not in a condensed chromatin formation. The 
absence of native chromatin on the reporter gene promoter fits well with this 
hypothesis, as it could explain why Vpr mediated an effect for unliganded GR-
mediated transactivation of the promoter-reporter, but not for either of the tested 
endogenous genes. 
 
 
 
 
Figure 4.2: A putative model indicating how Vpr may increase GR-mediated transcription in the 
absence of ligand. The unliganded GR (shown here in pink) shuttling between the nucleus and 
cytoplasm associates with newly translated Vpr in the cytoplasm or already in the nucleus, increasing 
GR nuclear retention. Owing to its propensity to interact with numerous proteins and DNA, Vpr non-
specifically enhances transcription co-factor binding to the GR, and GR association with DNA, leading 
to a small level of transactivation from some accessible GRE containing genes. 
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4.6. Conclusions 
 
Vpr increases the efficacy of all tested ligands for GR-mediated transactivation of the 
TAT-GRE reporter gene, without affecting the potency of DEX, whereas transcription 
of the endogenous genes MKP-1 and IκBα was not affected by the presence of Vpr. 
The extent by which Vpr increases reporter gene activity is dependent on the 
concentration of DEX and is greater in the presence of a higher amount of Vpr. In the 
absence of ligand Vpr also marginally increases reporter gene activity. The ligand-
dependent effects of Vpr on GR-mediated transcription are likely either to be 
promoter specific or dependent on the presence and/or architecture of chromatin at 
the promoter. Additionally, the relative concentrations of promoter-promoter genes, 
GR molecules, Vpr molecules, and other endogenous co-regulators may determine 
ligand-dependent Vpr effects. The mechanism by which Vpr increases ligand-
dependent GR-mediated transactivation was not fully determined, although a 
mechanism similar to that of the classical co-activator SRC-2 is a likely possibility, 
and several other possible mechanisms were excluded. Vpr does not stabilise the 
GR against ligand-dependent degradation, but rather increases GR turnover in the 
presence of several ligands, possibly indicative of a more transcriptionally “capable” 
GR that is responsible for enhanced reporter gene activity, as opposed to simply 
higher GR levels. Vpr does not detectably increase GR phosphorylation or nuclear 
localisation in the presence of ligand, although experimental design may have been 
unable to reveal such differences. Results did show that Vpr is constitutively nuclear, 
and like the rGR, was not found at areas of heterochromatin. In the absence of 
ligand, Vpr significantly increased reporter gene transactivation in some 
experiments, and appeared to enhance GR turnover, S226 phosphorylation, and 
rGR nuclear translocation, indicating Vpr may act as a weak non-classical GR partial 
agonist.  
 
The enhanced ligand-dependent reporter gene efficacy mediated by Vpr raises the 
possibility that Vpr may increase the absolute level of GR signalling with therapeutic 
administration of steroids which have high GR efficacies. Vpr was observed to 
change the biocharacter of P4 relative to DEX for transcription of both tested 
endogenous genes, but in general did not mediate large changes to the partial 
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agonist activity of the tested steroids. Vpr did however; increase GR-mediated 
reporter gene activity in a manner that was dependent on both ligand efficacy and 
concentration. MPA is a steroid, where if exposure to HIV-1 and thus Vpr is likely, 
use should be treated with caution. MPA may lead to excessive GR activity if Vpr is 
present, more so than would NET-A, which has very little GR transactivation efficacy. 
Excessive GR signalling will have numerous endocrine effects, not least of which will 
be immunosuppression, a condition already associated with AIDS.  
  
 
4.7. Future perspectives 
 
Much of the data from this study supports the novel finding that Vpr acts as a non-
steroidal GR activator. However, due to the large number of variables as well as the 
relatively small effects compared to the technical and biological error in the 
experiments, statistical significance was not always obtained. Thus future 
experiments should include some repeat experiments from this present study, but 
with fewer variables and a greater n-value, and using a cell line which expresses 
endogenous GR, such as END cells to confirm this finding. Thereafter, future studies 
building on the work presented in this thesis, should focus on investigating in more 
depth the mechanisms by which Vpr increases ligand-dependent and ligand-
independent GR-mediated transactivation. These are presented below as questions 
and the proposed approach.  
 
1) Does phosphorylation of GR serine residues 203, 211, and/or 226 determine 
whether Vpr can enhance ligand-dependent GR-mediated transactivation? The 
current study showed that Vpr did not enhance ligand-dependent GR 
phosphorylation at these three serine residues, but did not determine if 
phosphorylation of one or more of these residues is required for Vpr to associate 
with, and thus enhance transactivation via the GR, as has been reported for SRC-2  
(Avenant et al., 2010a; Wang et al., 2007). Using GR expression constructs 
harbouring the point mutations S203A, S211A, and S226A will prevent 
phosphorylation of that particular residue. If Vpr is unable to mediate an increase in 
reporter gene activity with a mutant GR this would support the hypothesis that 
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phosphorylation of the particular residue is required for Vpr to enhance GR-mediated 
transactivation. Such an effect could be further confirmed by failure of Vpr to co-
immunoprecipitate with such a GR mutant. GR mutants should be used as single, 
double or triple mutants to allow the specific location and number of mutations which 
prevent the effects of Vpr on the GR to be established. These studies would be 
required to be performed in COS1 cells owing to the very low level of endogenous 
GR, which would otherwise confound results, but should use Vpr peptides or purified 
protein to allow exact control over the amount of Vpr added. The represents a 
physiologically relevant setting as Vpr protein has the ability to occur unassociated in 
serum and passively transverse the cell membrane (Tungaturthi et al., 2003). 
 
2) Does Vpr increase GR S134 and/or S404 phosphorylation in the absence of 
GR ligand? Phosphorylation of GR residue S404 regulates the CBP/p300 
interaction with the GR (Galliher-Beckley et al., 2008), a co-factor which has been 
previously reported to directly associate with Vpr (Kino et al., 2002a), and S134 is 
phosphorylated ligand-independently (Galliher-Beckley et al., 2011). The phospho-
status of these residues should be investigated by Western blotting with 
phosphorylation specific antibodies to determine if S134 and/or S404 
phosphorylation is enhanced by Vpr. In order to gain better control over the levels of 
the GR and Vpr, this experiment should be performed in the physiologically relevant 
END cell line which express endogenous GR, and with the addition of Vpr peptide or 
purified protein as opposed to transient transfection of Vpr expression vector.  
 
3) Does the sequence of the GRE dictate whether Vpr will enhance GR-
mediated transactivation of an endogenous gene, in the absence and presence 
of GR ligands? It appears that the TGT TCT GRE half-site (Table 4.2) is common to 
genes on which Vpr mediates an effect. Using END cells with endogenous GR, and 
adding Vpr peptide or purified protein in the presence and absence of DEX followed 
by microarray analysis, will allow identification of any endogenous genes co-
regulated by both the GR and Vpr.  Microarray analysis has the capacity to analyse 
thousands of different genes for changes in expression at one time. After GR-
regulated genes on which Vpr has an effect have been identified, the promoters of 
these genes can be analysed and the GRE sequence elucidated. This assay will 
have the advantage of identifying novel GR-regulated genes which Vpr may regulate 
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in a manner similar to a co-activator. To confirm the effects of Vpr occur through the 
endogenous GR, siRNA knockdown can also be used to inhibit GR expression, and 
thus observe if changes in gene expression induced by Vpr is concomitantly lost 
when GR levels are decreased, thereby indicating Vpr to act via the GR. 
 
4) Are the effects of Vpr on GR-mediated transactivation cell-type specific in 
the absence and presence of GR ligands? To determine if the effects of Vpr are 
variable across cell type, the effects of Vpr on GR-mediated transactivation should 
be compared in different cells for transactivation of the same gene. This will require a 
gene, at which Vpr enhances GR-mediated transactivation, such as endogenous 
RANKL or the TAT-GRE reporter gene. Using cell types with endogenous GR will 
present variances in GR levels that cannot be controlled for, but will present a more 
physiological setting in which to study the effects of Vpr on gene transcription. END 
and Jurkat cells should also be used owing to their human origin, physiological 
significance for HIV-1 actions, and expression of endogenous GR. Both represent 
cell types in which Vpr may be expected to be found after HIV-1 infection. To control 
for possible variances in Vpr levels that may be caused by transfection into different 
cell types, the cells should be treated with equal amounts of Vpr peptide or purified 
protein. The relative extents of RANKL and TAT-GRE expression could then be 
analysed (by qPCR or luciferase quantification respectively) in the absence and 
presence of DEX, and absence and presence of Vpr to determine if the effects of Vpr 
on GR-mediated transactivation are cell-type specific. 
 
5) Does Vpr associate directly with the GR in vivo? GR and Vpr co-
immunoprecipitation experiments have been done before, but do not indicate 
whether the interaction occurs in vivo, or if it is a direct interaction. A Fluorescence 
Resonance Energy Transfer (FRET) assay could be performed to determine if these 
two proteins interact directly. For matters of consistency, it would be best to use END 
cells with endogenous GR and exogenously added and tagged Vpr protein to allow 
the greatest measure of control in the relative levels of these proteins. Alternatively 
tagged Vpr could be delivered using HIV-1 pseudovirus or engineered HIV-1 
infectious molecular clones. FRET analysis uses photo-excitation to excite an 
electron on a fluorophore tag, which, after falling back to a ground state releases a 
photon that may excite a second, adjacent fluorophore tag which is then detected. 
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As this energy transfer can only occur over very small distances, detection of the 
second fluorophore indicates that the two tagged proteins must be in direct contact 
with each other. This assay also has the advantage of being able to show both an in 
vivo association and the sub-cellular location where such an interaction occurs. If the 
GR and Vpr are found to associate directly, follow up experiments should determine 
if the interaction is ligand-independent or ligand-dependent. If the former, this would 
support the finding that Vpr acts like a GR agonist. If ligands with greater efficacy 
cause a greater extent of Vpr recruitment to the GR and if antagonists reverse Vpr 
association with the GR, this would support the hypothesis of Vpr being a GR-co-
activator.  
 
6) Does Vpr change components of the complexes at the promoter or alter 
chromatin structure in the absence and presence of GR ligands? To further 
investigate such an association, the co-localisation of Vpr and the GR at an 
endogenous promoter should also be investigated. For consistency with the FRET 
analysis, END cells with endogenous GR and a similar method of delivery of Vpr 
should be used.  Vpr is only known to enhance GR mediated transactivation of one 
endogenous gene, RANKL (Fakruddin and Laurence, 2005). Using chromatin-
immunoprecipitation analysis (ChIP), analysis of this gene to isolate promoter bound 
GR molecules will reveal if Vpr is present in the promoter bound GR complex. ChIP-
on-ChIP analysis will also confirm that these two proteins are present in the same 
promoter bound complex. As with FRET analysis above, treatment of cells with DEX 
or RU486 may reveal if the association of Vpr with the GR is ligand-dependent and 
similar to how SRC-2 associates with the GR. The components of GR-promoter 
bound complexes may be compared in the absence and presence of Vpr to 
determine what additional proteins Vpr recruits to the promoter. Vpr may increase 
the relative abundances of the GR, GR associated TF’s, recruit novel co-factors and 
chromatin-modifying proteins to the promoter so as to enhance gene expression. By 
performing ChIP analysis with antibodies specific to modified (specifically acetylated 
or methylated) histones, some insight will be obtained as to whether Vpr is 
responsible for altered chromatin structure at the promoter. DNase I hypersensitive 
site mapping could also prove another strategy to investigate whether Vpr alters 
chromatin structure, making promoters more or less accessible. 
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7) Does Vpr only enhance GR-mediated transactivation in the absence of 
chromatin? This may be determined by comparing the effect of Vpr on the extent of 
GR-induced transcription of the endogenous TAT gene with that of the same 
promoter-reporter plasmid which is not organised into native chromatin, in the same 
cells. If Vpr only increases GR-mediated reporter gene activity, but not 
transactivation of the endogenous TAT gene, this would be consistent with the 
hypothesis that chromatin inhibits the effects of Vpr on the GR, although other 
explanations would be possible. This hypothesis may be tested further through 
DNase I hypersensitive site mapping on endogenous genes where Vpr is known to 
enhance GR-mediated transactivation, such as RANKL, and comparing this to a 
similar GRE containing gene, where Vpr is known not to affect GR-mediated 
transactivation, such as GILZ. Results should determine if hypersensitive chromatin 
is a prerequisite for Vpr to enhance GR-mediated gene expression. Ideally such 
experiments should be done in a cell line which expresses endogenous GR, such as 
END cells, using expressed or exogenously added Vpr protein.  
 
8) Does Vpr increase the potency of MPA and NET-A via the GR? The effects of 
Vpr on a GR dose-response curve under MPA and NET-A stimulations should be 
investigated and compared. Whilst it is established that Vpr increases these ligands’ 
efficacies under certain conditions, it is not known how Vpr may affect their 
potencies, and GR-mediated transactivation at sub-saturating concentrations. If Vpr 
were to increase these ligands’ potencies, MPA would exert more GC like side 
effects at lower concentrations than expected when in the presence of Vpr. 
Accordingly, a GR dose response curve in a cell line which expressed endogenous 
GR, such as END cells should be done. For simplicity this experiment should be 
investigated on a reporter gene, and the GR stimulated with a range of MPA or NET-
A concentrations to give an accurate value of the EC50’s of MPA and NET-A in the 
absence and presence of Vpr. 
 
9) Does Vpr increase MPA-mediated induction of any GR-regulated 
endogenous genes to a greater extent than it does for NET-A? One of the main 
findings of this study was that Vpr enhanced GR-mediated reporter gene activity to a 
greater extent with MPA stimulation than it did with NET-A and P4 stimulation. The 
identification of an endogenous gene regulated in a similar manner would have 
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profound clinical significance for HIV-1 infection and the choice of contraception. 
Using cell lines with endogenous GR which resemble HIV-1 target cells, and cells 
likely to encounter Vpr during HIV-1 infection such as Jurkat and END cells, a GR-
regulated target gene on which Vpr enhances transcription should be identified. This 
should be done through a microarray experiment as discussed above. Upon 
identification of a suitable endogenous gene, GR siRNA knockdown analysis should 
be used to prove the effects of MPA or NET-A on gene expression are mediated by 
the actions of the GR, by investigating transcription rates (as determined by qPCR) 
in the presence of lower amounts of GR. Thereafter, the relative extents of MPA and 
NET-A stimulation of GR-mediated transcription of the endogenous gene should be 
compared in the presence of Vpr to determine if Vpr potentiates MPA driven 
transcription of the gene to a greater extent than it does for NET-A. As such a finding 
would have profound clinical significance, the experiment should be repeated in 
primary cells and tissue extracts with endogenous GR with different methods of Vpr 
delivery, including using virus, as well as physiological relevant concentrations of 
MPA and NET-A, so as to resemble as closely as possible a physiological setting. 
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5. APPENDICES 
 
5.1. Reporter gene control 
 
Transactivation of the TAT-GRE reporter gene requires the presence of the hGRα. A 
representative Western blot indicates that COS1 cells do not express detectable 
levels of the GR (Figure 5.1A). Cells not transfected with the hGRα do not show an 
increase in reporter gene activity with DEX stimulation and transfection of the hGRα 
causes a roughly 100-fold increase in reporter gene activity when DEX is not present 
and near 2 500 fold induction in the presence of DEX (Figure 5.1B).  
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Figure 5.1: COS1 cells do not express a detectable level of hGRα (A) and transfection of the 
hGRα construct is required for observable reporter gene transactivation (B). COS1 cells were 
transfected in 10 cm dishes with TAT-GRE, and either hGRα or empty vector 24 hours prior to re-
plating in 24 well plates. After a further 24 hour incubation, cells were stimulated with 100 nM DEX for 
24 hours. Cells were harvested in a 2x SDS sample buffer and resolved on 10% PAGE before 
transfer to nitrocellulose membrane (A) or harvested in reporter lysis buffer before luciferase 
quantification in a Luminex luminometer with the Promega luciferase assay and normalised to total 
protein as determined by Bradford protein assay. Data was plotted as a fold induction above the 
unstimulated condition in the absence of hGRα (B). The histogram shows pooled data from 3 
individual biological repeats each performed in triplicate. A two-way ANOVA and Fishers least 
significant differences post-hoc test was used for statistical analysis and marked *, ** or *** to indicate 
P<0.05, P<0.01 or P<0.001, respectively with significance shown relative to the corresponding vehicle 
control.  
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5.2. Immunofluorescence controls 
5.2.1. Transfection negative control 
 
Cells were not transfected, but were incubated with primary antibodies, fluorophores, 
and Hoechst stain (Figure 5.2A). The cytoplasm exhibits undetectable staining with 
Hoechst (DNA) stain, revealing that cells are not contaminated with Mycoplasma 
spp., and the cytoplasmic DNA observed previously is likely transfected plasmid 
DNA. The Alexa488 stain exhibits low intensity background without HA Vpr 
transfection and does not preferentially occur in the cytoplasm or nucleus. Without 
rGR transfection, red nuclear spots are visible indicating this not to be an effect of 
the presence of rGR protein, but rather due to non-specific binding of the BuGR22 
antibody to an endogenous nuclear COS1 protein. Cells were not stimulated with 
DEX making it highly unlikely that this is endogenous GR, as the signal is nuclear 
and endogenous GR would be cytoplasmic if not stimulated.  
 
 
5.2.2. Primary antibody negative control 
 
Cells were transfected with both the rGR and HA Vpr expression vectors but were 
not incubated with the α-mouse GR or α-HA antibodies. Thereafter slides were  
stained with the secondary fluorophores (Figure 5.2B). This control was performed 
as it determined the extent of background signal owing to the fluorophores, thereby 
allowing a threshold to be set above which any fluorescent intensity was deemed to 
be specific. This control indicates that the fluorescence observed in Figure 3.6 is a 
result of the fluorophores specifically adhering to the primary antibodies. The 
absence of red and green stain indicates that the primary antibodies are required in 
order for fluorescence to occur. The red spots appear to have been caused by the α-
mouse GR BuGR22 antibody adhering to non-specific nuclear proteins in the COS1 
cells, as the red nuclear spots observed in Figure 5.2A are absent in this control 
which lack the primary antibody. Hoechst staining does detect cytoplasmic DNA in 
these cells, as they had been transfected with both the rGR and HA Vpr expression 
vectors.  
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 Figure 5.2 (A-C): Immunofluorescence controls. (A) Transfection negative control (B) Primary antibody negative control (C) Fluorophore negative control.
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5.2.3. Fluorophore negative control 
 
Cells were transfected with both the rGR and HA Vpr, followed by incubation with 
primary antibodies for an hour (Figure 5.2C). The fluorophore conjugated secondary 
antibodies Cy3 and Alexa488 were not used to stain these slides and accordingly no 
fluorescence is observed in these cells. This control indicates that the fluorescence 
observed in Figure 3.6 is a specific result of the fluorophore conjugated secondary 
antibodies and not an alternate source of fluorescence.  
 
 
5.3. Representative qPCR Ct values, melt curves, and 
agarose gel analysis 
 
In order to optimise primer concentrations for qPCR, a standard PCR was first 
performed on cDNA from COS1 and END cells using the GoTaq-buffer and -Flexi 
DNA polymerase kit according to the manufacturer’s instructions (Promega Corp., 
USA). Once effective primer and MgCl2 concentrations had been optimised, qPCR 
was performed. It was however found that IκBα primers could not anneal at any 
tested concentration of MgCl2 to COS1 cDNA, as assessed by the lack of a 
detectable conventional PCR product. Vpr was not observed to increase the 
abundance of either MKP-1 or IκBα mRNA transcripts relative to basal and no primer 
standard curve was performed. Without a standard curve, a primer efficiency of 2 is 
assumed. The correct primer efficiency allows an accurate determination of absolute 
RNA levels. If the primer efficiency for either of the tested genes were different to 2, 
this would not have affected the relative expression levels, and as such, it was 
deemed unnecessary to perform a PCR standard curve.  
 
As all PCR products were found to be of the expected size (Figures 5.3A and 5.4A 
and Table 5.3), and displayed uniform melt curve analyses (Figure 5.3B and 5.4B) it 
was determined that the assay was valid and that the Ct values represented values 
corresponding to the original amount of cDNA present.  
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Figure 5.3: (A) Representative agarose gel analysis, (B) melt curve analysis, and (C) Ct 
threshold value of qPCR amplified GAPDH and MKP-1 cDNA in COS1 cells.   
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Figure 5.3: (A) Representative agarose gel analysis, (B) melt curve analysis, and (C) Ct 
threshold value of qPCR amplified GAPDH, MKP-1, and IκBα cDNA in END cells.   
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Table 5.1: Result showing qPCR Ct values of GAPDH and MKP-1 in COS1 cells from a single 
representative experiment.  
 
 
 
 
 
Table 5.2: Result showing qPCR Ct values of GAPDH, MKP-1, and IκBα in END cells from a 
single representative experiment.  
 
 
 
 
 
 
 
 
 
 
 
COS1 Name GAPDH Ct MKP-1 Ct
EtOH 12.75 18.98
DEX 12.71 17.36
MPA 12.53 18.20
NET-A 12.67 18.30
P4 12.09 17.54
CORT 12.49 17.42
Vpr/EtOH 12.69 18.43
Vpr/DEX 12.41 17.44
Vpr/MPA 12.56 18.10
Vpr/NET-A 12.07 17.82
Vpr/P4 12.57 17.77
Vpr/CORT 12.11 17.61
NTC 29.00 27.70
END Name GAPDH Ct MKP-1 Ct IκBα Ct
EtOH 11.49 17.87 20.28
DEX 11.90 15.98 19.28
MPA 11.67 16.80 20.13
NET-A 11.52 17.87 20.55
P4 11.61 17.07 20.13
CORT 11.66 16.94 19.99
Vpr/EtOH 12.03 17.54 20.73
Vpr/DEX 12.12 15.53 19.72
Vpr/MPA 11.87 16.69 20.09
Vpr/NET-A 12.28 17.57 20.76
Vpr/P4 11.81 17.24 20.27
Vpr/CORT 11.93 16.41 20.28
NTC n/a 29.79 n/a
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Table 5.3: Quantitative PCR primers 
 
 
 
 GAPDH FWD TGA ACG GGA AGC TCA CTG G 100 19 58
GAPDH REV TCC ACC ACC CTG TTG CTG TA 100 20 55
IκBα FWD ACT CGT TCC TGC ACT TGG CC 250 20 60
IκBα REV TGC TCA CAG GCA AGG TGT AG 250 20 55
MKP-1 FWD AGT ACC CCA CTC TAC GAT CAG G 250 22 55
MKP-1 REV TGA TGG AGT CTA TGA AGT CAA TGG 250 24 4256 250 Rauhala et al ., 2005
56 307 Ishibashi et al ., 2003
60 238 Emmerich et al ., 1999
Primer Theoretical Anneling Temp (°C)
Product 
(bp) Reference
Final Conc. 
(nM)
Length    
(bp) GC %Sequence (5'-3')
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